

# Open Research Online

---

The Open University's repository of research publications and other research outputs

## Neural Stem Cells as Model to Study Neurodegeneration and Novel Therapeutics in Lysosomal Storage Disorders

### Thesis

#### How to cite:

Bouché, Valentina (2013). Neural Stem Cells as Model to Study Neurodegeneration and Novel Therapeutics in Lysosomal Storage Disorders. PhD thesis The Open University.

For guidance on citations see [FAQs](#).

© 2013 The Author



<https://creativecommons.org/licenses/by-nc-nd/4.0/>

Version: Version of Record

Link(s) to article on publisher's website:

<http://dx.doi.org/doi:10.21954/ou.ro.0000f0b6>

---

Copyright and Moral Rights for the articles on this site are retained by the individual authors and/or other copyright owners. For more information on Open Research Online's data [policy](#) on reuse of materials please consult the policies page.


---

[oro.open.ac.uk](http://oro.open.ac.uk)

Doctor of Philosophy, PhD

Valentina Bouché

**Neural stem cells as model to study neurodegeneration  
and novel therapeutics in lysosomal storage disorders**



The Open University



Discipline: Life and Biomolecular Sciences

Affiliated Research Center: TIGEM - Telethon Institute of Genetics and  
Medicine

Thesis submitted in accordance with the requirements of the Open  
University for the degree of "Doctor of Philosophy"

September 2012

DATE OF SUBMISSION : 28 SEPTEMBER 2012

DATE OF AWARD : 18 MARCH 2013

ProQuest Number: 13835924

All rights reserved

INFORMATION TO ALL USERS

The quality of this reproduction is dependent upon the quality of the copy submitted.

In the unlikely event that the author did not send a complete manuscript and there are missing pages, these will be noted. Also, if material had to be removed, a note will indicate the deletion.



ProQuest 13835924

Published by ProQuest LLC (2019). Copyright of the Dissertation is held by the Author.

All rights reserved.

This work is protected against unauthorized copying under Title 17, United States Code  
Microform Edition © ProQuest LLC.

ProQuest LLC.  
789 East Eisenhower Parkway  
P.O. Box 1346  
Ann Arbor, MI 48106 – 1346

*to MAMMA*



**TABLE OF CONTENTS**

ABBREVIATIONS.....1

ABSTRACT.....4

INTRODUCTION.....6

    The lysosome.....6

        Components of lysosomes.....9

        Function of lysosomes.....16

        Lysosomal Storage Diseases.....27

    Neural Stem Cells.....43

        Isolation of adult NSCs.....50

AIM.....54

RESULTS.....56

    Isolation of NSCs from post-natal brain of wild-type and MSD mice.....56

    NSCs uniformly express morphological and molecular features of radial  
glia progenitors.....59

    MSD-NSCs present a progressive loss of self-renewal.....62

    MSD-NSCs are able to differentiate into astrocytes and neurons.....64

    MSD neurons develop neurites and are electrophysiologically active....66

    MSD-NSCs recapitulate the progressive GAG accumulation.....69

    MSD differentiated cells suffer from impaired autophagy.....73

    MSD differentiated cells display the tendency to form aggresomes.....77

    MSD differentiated cells show increased apoptosis.....81

TFEB induces lysosomal biogenesis in NSCs.....	83
TFEB promotes cellular clearance in MSD-NSCs.....	85
TFEB Overexpression Induces Lysosomal Exocytosis.....	88
TFEB Overexpression Enhances Lysosomal Predocking to the PM and Elevates Intracellular Ca <sup>2+</sup> .....	91
TFEB Releases Ca <sup>2+</sup> from Acidic Stores through the Activation of Mucolipin-1.....	94
TFEB induces storage clearance in a mouse model of MSD.....	102
DISCUSSION.....	105
NSCs recapitulate the main hallmarks of MSD pathology.....	105
TFEB-mediated activation of lysosomal exocytosis promotes the clearance of undegraded substrates.....	111
MATERIALS AND METHODS.....	115
Isolation of NSCs and cell culture conditions.....	115
Flow cytometry analysis of nestin.....	116
RT-PCR analysis.....	116
Neurosphere assay.....	117
Cell Differentiation.....	118
Immunofluorescence.....	118
Immunoblotting.....	120
Neurite Outgrowth Assay.....	121
Electrophysiology and patch clamp recording.....	121
Electron Microscopy (EM) and immuno-gold analysis.....	122
Alcian Blue staining.....	123

GAG quantitative assay.....	124
GAG pulse-and-chase analysis.....	124
TUNEL assay.....	124
Transfection and nucleofection.....	125
Staining for Surface LAMP1.....	125
Flow Cytometry analysis of surface LAMP1.....	126
Enzymatic Activities.....	126
Calcium Measurements by Confocal Imaging.....	127
Flow Cytometric Calcium Flux Assay.....	127
REFERENCES.....	129
ACKNOWLEDGEMENTS.....	169

**ABBREVIATIONS**

AAV2/9	adeno-associated virus type 2/9
AD	Alzheimer's disease
ALS	Amyotrophic Lateral Sclerosis
ATG	autophagy-related proteins
BMP	bone morphogenetic proteins
CATD	cathepsin D
CDM6PR	cation-dependent M6PR
CGN	<i>cis</i> -Golgi network
CIM6PR	cation-independent M6PR
CLEAR	Coordinated Lysosomal Expression and Regulation
CLN3	Neuronal Ceroid LipofuscinosIs type 3
CMA	chaperone-mediated autophagy
CMV	cytomegalovirus
CNS	Central Nervous System
ECM	extracellular matrix
EGF	epidermal growth factor
ER	endoplasmic reticulum
ERT	enzyme replacement therapy
FGE	formylglycine-generating enzyme
FGF	fibroblast growth factor
Fz	Frizzled
GAG	glycosaminoglycans
GFAP	glial fibrillary acidic protein
GTPase	guanosine triphosphatases
HD	Huntington's disease
HDAC6	histone deacetylase 6

HEXB	hexosaminidase B
HGSNAT	heparan- $\alpha$ -glucosaminide N-acetyltransferase
HSCs	Hematopoietic Stem Cells
HSPGs	heparan sulfate proteoglycans
LAMP1	lysosome associated membrane protein 1
LAMP2	lysosome associated membrane protein 2
LAMP2A	lysosome-associated membrane protein 2
LC3 or MAP1LC3	microtubule-associated protein 1 (MAP1) light chain 3
LDH	lactate dehydrogenase
LIMP2	lysosome integral membrane protein 2
LMPs	lysosomal membrane proteins
LROs	lysosomal related organelles
LSD	Lysosomal Storage Disorder
M6P	mannose-6-phosphate
M6PR	mannose-6-phosphate receptor
MCOLN1	mucolipin 1
MHC	major histocompatibility complex
MLIV	mucopolidosis type IV
MPSII	mucopolysaccharidosis type II
MPSIIIA	mucopolysaccharidosis type III A
MPSIIIC	mucopolysaccharidosis type III C
MSD	Multiple Sulfatase Deficiency
MTOC	microtubule-organizing centre
mTOR	mammalian target of rapamycin
mTORC1	mTOR complex 1
NCL	neuronal ceroid lipofuscinosis
NEPs	neuroepithelial progenitors
NPC	Niemann-Pick disease

NPC1	Niemann-Pick disease type 1
NSCs	Neural Stem Cells
PD	Parkinson's disease
PM	Plasma Membrane
Ptau	hyperphosphorylated tau
RG	radial-glia
RMS	rostral migratory stream
SGZ	subgranular zone
Shh	sonic hedgehog
SNAP-25	synaptosomal-associated protein 25
SNARE	soluble N-ethylmaleimide-sensitive factor attachment protein receptor
SRT	substrate reduction therapy
SUMF1	sulfatase modifying factor 1
SVZ	subventricular zone
SYT7	synaptotagmin 7
TA	transient amplifying
TFEB	Transcription Factor EB
TGN	<i>trans</i> -Golgi network
TRP	transient receptor potential
TRPML	mucolipins
TTX	tetrodotoxin
Tuj1	class III $\beta$ -tubulin
UBA	ubiquitin-binding domain
v-ATPase	vacuolar H <sup>+</sup> -adenosine triphosphatases
Wnt	wingless-type MMTV integration site family

## ABSTRACT

Neural Stem Cells (NSCs) are self-renewing multipotent populations responsible for the generation of neurons and glial cells of the developing brain and account for the limited regenerative plasticity of the adult brain. In view of their reliable use as cellular model to study neurodegenerative diseases, and as potential donors in cell-based therapeutic approaches, we have isolated and characterized NSCs from a mouse model of a neurodegenerative Lysosomal Storage Disorder (LSD), the Multiple Sulfatase Deficiency (MSD), caused by mutations in the sulfatase modifying factor 1 (SUMF1) gene that encodes the enzyme responsible for sulfatase activation.

Isolated MSD-NSCs are phenotypically similar to wild-type precursors and are able to differentiate into neurons and astrocytes, although they show a progressive loss of their self-renewal capacity. Moreover, differentiated MSD cells recapitulate the main pathological features of the disease, such as progressive cell vacuolization, lysosomal accumulation of glycosaminoglycans (GAGs), altered autophagy with accumulation of poly-ubiquitinated proteins, and increased levels of apoptosis. Interestingly, glia-differentiated MSD cells display the tendency to form aggresomes, perinuclear aggregates of misfolded protein, which is a common feature to many neurodegenerative diseases.

We also showed that the overexpression of the Transcription Factor EB (TFEB), a master-gene that modulate lysosomal function and autophagy, induces lysosomal exocytosis through activation of mucolipin 1 (MCOLN1) and reduces

significantly primary and secondary pathologic storage, ameliorating the phenotype of MSD cells (Medina et al. 2011).

These results validate the use of NSCs isolated from LSD mouse models to study their neurodegenerative phenotype, and envisage their use to explore new therapeutic approaches by the modulation of TFEB expression in LSDs.



## INTRODUCTION

### The lysosome

Lysosomes are cellular organelles present in all cell types, which are primarily involved in degradation and recycling processes (Kornfeld and Mellman 1989). The lysosome was first described by de Duve in 1955 as an acidic organelle containing a set of lysosomal enzymes (De Duve et al. 1955), whose function is the degradation of other cellular components. The first morphological demonstration of lysosomes by electron microscopy of organelles prepared from rat liver was presented by Alex Novikoff in 1956 (Novikoff, Beaufay, and De Duve 1956). Since these early days, much has been learned about lysosomes and related organelles, about their diverse functions, biogenesis and failures in disease.

According to its physiological function at different stages, lysosome can be divided into the primary lysosome, the secondary lysosome and the residual body (Zhang et al 2009). Primary lysosomes are membrane-bound intracellular organelles that contain a variety of hydrolytic enzymes; they fuse with membrane-bound vacuoles that contain material to be digested, forming secondary lysosomes. Once in the lumen of lysosomes, substrates are then degraded via a finely orchestrated network of soluble lysosomal hydrolases (also referred to as acid hydrolases), integral lysosomal membrane proteins (LMPs), lysosomal related organelles (LROs) and other cellular constituents (Saftig and Klumperman 2009).

After digestion occurred, secondary lysosomes become residual bodies, containing only indigestible or slowly digestible materials and within which enzymatic activities have become virtually exhausted (Zhang et al 2009).

Macromolecules are delivered toward lysosomes for degradation from the extracellular space through endocytosis or phagocytosis, as well as from the cytoplasm through autophagy (Doherty and McMahon 2009; Kornfeld 1986; Ravikumar et al. 2009). Due to their crucial function, lysosomes are involved in various cellular processes, such as cholesterol homeostasis (Lange et al. 1998), membrane repair (Reddy et al. 2001), bone and tissue remodelling (Chapman et al. 1994), pathogen defence (Kanai et al. 1970), signal transduction (Mandeville et al. 1996), cell division (Allison and Mallucci 1964), neurotransmission (Holtzman 1977) and cell death (Guicciardi et al. 2004). These complex functions highlight the fact that the lysosome is a central organelle which is much more than just the wastebasket of the cell (Saftig 2006).

## **Components of lysosomes**

As De Duve initially observed, lysosomes are limited by a single phospholipid bilayer. Their shape varies between globular and tubular (Saftig and Klumperman 2009) and their detailed structure differs depending on the cell type. In fact, lysosomes can be morphologically heterogeneous due to differences in their internalized content. This heterogeneity of the lysosomal content appears usually electron-dense but often includes irregularities and membrane sheets (Saftig and Klumperman 2009).

A common characteristic of lysosomal compartments is their acidic interior with a pH of 4.5–5, which is maintained by the vacuolar H<sup>+</sup>-adenosine triphosphatases (v-ATPase), a transmembrane multiprotein complex (Schröder et al. 2010). Preservation of low pH is important for several lysosomal functions, such as cargo release, hydrolase maturation, vesicle maturation, autophagy and neurotransmitter loading into synaptic vesicles (Marshansky and Futai 2008; Mijaljica, Prescott, and Devenish 2011). Additionally, the pH gradient within the endomembrane system is required for intracellular trafficking and its loss can impair mannose-6-phosphate receptor (M6PR) recycling back to the Golgi for reloading of newly synthesized lysosomal hydrolases (Sobota et al. 2009).

Lysosomes contain more than 50 different acid hydrolases, such as proteinases, peptidases, phosphatases, nucleases, glycosidases, sulfatases and lipases, and several activator proteins that are localised mainly in the matrix. These hydrolases are then able to decompose macromolecules and even membranes into their monomeric constituents.

In other studies, it has been shown that cells can also contain lysosome-like organelles, such as melanosomes, lytic granules, major histocompatibility complex (MHC) class II compartments, platelet-dense granules and synaptic-like micro-vesicles (Dell'Angelica 2004). Nevertheless, acid hydrolases and LMPs are essential for the function of lysosomes.

### Acid hydrolases

Each of the 50 known lysosomal acid hydrolases targets specific substrates for degradation, and their collective action is responsible for the total catabolic capacity of the lysosome (Saftig and Klumperman 2009). The breakdown products, such as amino acids, monosaccharides, oligosaccharides and nucleotides, are then transported back to the cytosol by specific transporter proteins residing in the lysosomal membrane (Saftig 2006). In addition to bulk degradation and pre-protein processing, lysosomal hydrolases are also involved in antigen processing, degradation of the extracellular matrix and initiation of apoptosis (Conus and Simon 2008).

Lysosomal targeting of newly synthesized lysosomal proteins can be (1) direct, from the *trans*-Golgi network (TGN) to the endosomal system, or (2) indirect, involving transport to the plasma membrane and subsequent endocytosis (Saftig and Klumperman 2009).

Most newly synthesized lysosomal hydrolases enter the lysosomal compartment directly via the biosynthetic route (Figure 1). They are synthesized in the rough endoplasmic reticulum (ER) and then packaged into vesicles in the

Golgi apparatus. In the TGN, acid hydrolases undergo a critical modification of one or several of their carbohydrates to mannose-6-phosphate (M6P) moieties by the enzyme N-acetylglucosamine (GlcNAc)-phosphotransferase (Hasilik, Waheed, and von Figura 1981; Sleat et al. 2005); then acid hydrolases bind the M6PR that delivers them to endosomes (Kornfeld and Mellman 1989). There are two types of M6PR, 300 kD cation-independent M6PR (CIM6PR; also known as IGF2R) and 46 kD cation-dependent M6PR (CDM6PR), both of which are ubiquitously expressed (Braulke and Bonifacio 2009). As the v-ATPase leads to acidification during the maturation of the endosomal compartment, the hydrolases dissociate from their receptors, which are then recycled back to the trans-Golgi network or to the cell surface (Saftig 2006) (Figure 1).

In the absence of a functional M6PR pathway, newly synthesized lysosomal hydrolases do not acquire M6P tags because of a deficiency in N-acetylglucosamine (GlcNAc)-phosphotransferase activity, also known as I-cell disease or mucopolipidosis type II (Hasilik, Waheed, and von Figura 1981; Waheed et al. 1982; Reitman, Varki, and Kornfeld 1981). Nevertheless, in some I-cell diseased cells, a significant portion of newly synthesized lysosomal hydrolases do reach the lysosome (Waheed et al. 1982; Little et al. 1987; Owada and Neufeld 1982). In this condition, new hydrolases can follow the constitutive secretory pathway to the plasma membrane and after secretion might be taken up by endocytosis.

## Lysosomal Membrane Proteins


Lysosomes are surrounded by a single phospholipid bilayer that serves as a limiting membrane. Such lysosomal membrane has several functions including sequestration of lysosomal enzymes, mediation of fusion events, acidification of the lysosomal lumen and transport of degradation products to the cytoplasm (Saftig 2006). In fact, the lysosomal membrane gathers the aggressive hydrolases to the organelle lumen, thus preventing undesired proteolytic damage to the surroundings; at the same time, it forms an impermeable barrier for the monomeric metabolites originating from the degradation of macromolecules, preventing their leakage in the cytoplasm. Therefore selective transport proteins are required in order to clear these compounds from the lysosomal lumen and facilitate their efflux into the cytosol.

LMPs are highly glycosylated proteins decorating the luminal surface of lysosomal membranes (Koike et al. 2005). The mammalian lysosome contains ~25 LMPs (Lübke, Lobel, and Sleat 2009), although additional LMPs are currently being revealed (Lübke, Lobel, and Sleat 2009; Schröder et al. 2007; Callahan, Bagshaw, and Mahuran 2009). The most abundant LMPs are lysosome associated membrane protein 1 and 2 (LAMP1 and LAMP2), lysosome integral membrane protein 2 (LIMP2, also known as SCARB2) and the tetraspanin CD63 (Saftig and Klumperman 2009). The sorting of most lysosomal membrane proteins depends on short sequence motifs within their cytoplasmic tails, which are necessary and sufficient to target them to lysosomes (Saftig 2006).

Furthermore, lysosomal membranes are characterized by a system of

transporters that play several important roles, such as establishing controlled acidic pH in the lysosome, absorption of the products of digestion, the release of  $\text{Ca}^{2+}$  from the lysosomal lumen that drives the fusion of lysosomes with late endosomes, and transport of the metals bound to endocytosed proteins across the lysosomal membrane into the cytoplasm (Ruivo et al. 2009; Jentsch 2007; Luzio et al. 2005). Among them, lysosomes contain also members of the transient receptor potential (TRP) superfamily; in particular, a key role is played by MCOLN1, an ion channel belonging to the subfamily of mucolipins (TRPMLs), which localizes also to late endosomes membrane. It has been shown that the channel is permeable to multiple ions including  $\text{Ca}^{2+}$ ,  $\text{Fe}^{2+}$ ,  $\text{Na}^+$ ,  $\text{K}^+$ ,  $\text{Zn}^{2+}$  and  $\text{H}^+$  (X.-P. Dong et al. 2008; LaPlante et al. 2002; Raychowdhury et al. 2004) and therefore it appears to be a prominent lysosomal metal transporter. Although the exact function of MCOLN1 remains to be conclusively proven, it is becoming evident that it functions as a lysosomal  $\text{Ca}^{2+}$  release channel. Membrane trafficking deficits (Treusch et al. 2004), as well as impaired fusion of lysosomes with autophagosomes in MCOLN1 deficient cells (Vergarajauregui and Puertollano 2006) support the role of MCOLN1-mediated  $\text{Ca}^{2+}$  release in the  $\text{Ca}^{2+}$ -dependent membrane fusion along the endocytic pathway.

Besides transport proteins, the membrane also contains other enzymes, including the heparan- $\alpha$ -glucosaminide N-acetyltransferase (HGSNAT), which uses cytosolic acetyl coenzyme A for the acetylation of non-reducing terminal  $\alpha$ -glucosaminyll residues of the heparan sulphate degradation intermediates in the lysosomal matrix (Fan et al. 2006; Hrebíček et al. 2006).



**Figure 1. Transport of newly synthesized lysosomal hydrolases to lysosomes.**

Lysosomal hydrolases are synthesized in the endoplasmic reticulum and move to the cis-Golgi network (CGN), where they are covalently modified by the addition of M6P groups. At the TGN, the M6P signal allows the segregation of lysosomal hydrolases from all other types of proteins through selective binding to the M6P receptors. The clathrin-coated vesicles produced bud off from TGN and fuse with late endosomes. At the low pH of the late endosome, the hydrolases dissociate from the M6PRs and the empty receptors are recycled to the Golgi apparatus for further rounds of transport.

Model taken from Coutinho et al. 2012



## Lysosomal Related Organelles

LROs are specialised lysosomes with cell-type specific functions, such as melanosomes in melanocytes, Weibel–Palade bodies in endothelial cells, lamellar bodies in type II pneumocytes, dense bodies in platelets and granules in cytotoxic *T* cells and natural killer cells (Raposo, Marks, and Cutler 2007). LROs usually co-exist with normal lysosomes. They share features of late endosomes/lysosomes but are functionally, morphologically and compositionally distinct; they can also contain cell-type-specific proteins and might require additional cellular machinery for their biogenesis (Bonifacino 2004; Dell’Angelica 2004). Some LROs resemble lysosomes morphologically with electron-dense protein deposits and/or intraluminal membranes, and are accessible to endocytic traffic (Raposo, Marks, and Cutler 2007); other LROs present entirely novel morphological features as a product of their unique cargo, such as the proteinaceous fibrils of melanosomes, the proteinaceous tubules of Weibel-Palade bodies and the lipid swirls within lamellar bodies (Raposo and Marks 2002; Bonifacino 2004).

Together with lysosomes, LROs are involved in various physiological processes, such as cholesterol homeostasis, plasma membrane repair, bone and tissue remodelling, pathogen defence, cell death and cell signalling (Saftig and Klumperman 2009).


## **Function of lysosomes**

Lysosomes are involved in several cellular processes including endocytosis, phagocytosis, autophagy and exocytosis (Figure 2).

### **Endocytosis and Lysosome Formation**

One of the most important functions of lysosomes is the digestion of material taken up from outside the cell through endocytosis. However, this function is directly related also to lysosome formation within the cell. In other words, lysosome biogenesis represents an intersection between the secretory pathway, through which lysosomal proteins are processed, and the endocytic pathway, through which extracellular molecules are taken up at the cell surface. Specifically, lysosomes are formed by the fusion of transport vesicles budded from the TGN with endosomes, but they can also contain molecules taken up by endocytosis and coming from the plasma membrane. Material from outside the cell is taken up in clathrin-coated endocytic vesicles, which bud from the plasma membrane and then fuse with early endosomes. Membrane components are then recycled to the plasma membrane and the early endosomes gradually mature into late endosomes, which are the precursors to lysosomes. In addition, early endosomes receive also endogenous proteins from the TGN, such as M6PRs carrying acid hydrolases (Klumperman et al. 1993; Waguri et al. 2003) to be delivered to the lysosome; in this step, one of the important changes during endosome maturation is the lowering of the internal pH to about 5.5 (Figure 1).

Acid hydrolases are then targeted to lysosomes by mannose-6-phosphate residues, which are recognized by M6PRs in the TGN and packed into clathrin-coated vesicles (Rohrer and Kornfeld 2001). The clathrin coat is then removed and transport vesicles fuse with late endosomes, causing the acidification of the internal pH; this change in the internal pH causes the dissociation of hydrolases from the M6PR. The hydrolases are thus released into the lumen of the endosome, while M6PRs remain in the membrane and are eventually recycled to the Golgi (Figure 2). As late endosomes acquire a full complement of acid hydrolases they mature into lysosomes.



**Figure 2. Lysosomes are involved in several cellular processes and undergo maturation.**

Lysosomes participate in endocytosis, phagocytosis, autophagy and exocytosis. During their biogenesis and maturation they are subjected to a few steps of maturation. Primary lysosomes contain hydrolytic enzymes, they fuse with other endocytic vesicles that contain material to be digested, forming secondary lysosomes; once digestion occurred, secondary lysosomes become residual bodies, containing only indigestible or slowly digestible materials.

Modified from The McGraw-Hill Companies, Inc. 2006

## Autophagy

The lysosome is the end-terminal for substrates coming from the autophagy pathway. Autophagy is a mechanism by which the cell digests its own intracellular components and other organelles, such as mitochondria (Figure 1 and 3). This process secures the cell's supply with macromolecules under conditions of starvation and allows the disposal of unneeded and non-functional organelles (Schröder et al. 2010).

Autophagy also was first observed by de Duve in 1963 (De Duve 1963); he identified membrane-bound vesicles containing endogenous organelles undergoing digestion; various stimuli, including starvation and glucagon administration, stimulate this process.

Autophagy is critical for growth, development and survival and therefore it is highly conserved among eukaryotic organisms, from yeasts to mammals (T Lang et al. 2000; Noda et al. 2000; Young et al. 2006).

There are various types of autophagy, differing in their mechanisms and functions (Klionsky 2005): microautophagy, macroautophagy and chaperone-mediated autophagy (CMA). Microautophagy is the non-selective internalization of small cytosolic portions via lysosomal invaginations. Macroautophagy (hereafter referred to as autophagy) is the selective sequestration of cytoplasm or organelles that are enclosed in the double-membrane structures known as autophagosomes, which subsequently fuses with lysosomes. CMA is the selective targeting of specific cytosolic soluble proteins to the lysosome via molecular chaperones. This latter process involves a direct translocation of the unfolded protein through the

lysosomal membrane by a mechanism not fully clarified, although critically depending on an isoform of the lysosome-associated membrane protein 2 (LAMP2A) as an essential component.

The first step of autophagy appears to be the formation of a cup-shaped structure, also referred to as an isolation membrane or pre-autophagosome, in the cytosol, where it gradually elongates to surround a portion of the cytoplasm and its constituents (Figure 3). Subsequently, the edges of the membrane fuse together to form a vesicle, which represents a double-membrane structure termed autophagosome (Juhasz and Neufeld 2006). Autophagosomes then undergo a maturation process consisting of multiple fusion events with both endosomes and lysosomes (Yoshimori 2004; Komatsu et al. 2006; Hara et al. 2006; Nakagawa et al. 2004; Ogawa et al. 2005; Ravikumar, Duden, and Rubinsztein 2002; Kamimoto et al. 2006; Eskelinen 2005) and their content is digested by lysosomal hydrolases. In fact, upon acquisition of lysosomal proteases and the v-ATPase, the interior of the autophagosome becomes acidified, and cytoplasmic materials are subjected to degradation (Kimura et al. 2007). Autophagosomes at this final stage, after fusion with lysosomes, are called autolysosomes (Figure 3).


Autophagy is regulated by more than 30 autophagy-related proteins (Atg), many of which have been discovered in yeast (Levine and Klionsky 2004). Most of the characterized *ATG* gene products, including Atg3, Atg5, Atg7, Atg10, Atg12, and LC3 (microtubule-associated protein 1 (MAP1) light chain 3), are involved in two ubiquitylation-like post-translational modifications of target proteins, which are the Atg12-conjugation and the LC3-modification (Atg8-lipidation in yeast), which are essential for the dynamic process of autophagosome formation (Kabeya et al.

2000; N Mizushima, Noda, et al. 1998; N Mizushima, Sugita, et al. 1998; Noboru Mizushima, Ohsumi, and Yoshimori 2002; I Tanida et al. 2001; Isei Tanida et al. 2002). Atg12-conjugation is essential for the formation of pre-autophagosomes, whereas LC3-modification is essential for the formation of autophagosomes (Kabeya et al. 2000; N Mizushima et al. 2001). Atg12 is activated by the E1-like enzyme Atg7, transferred to the E2-like enzyme Atg10, and conjugated to Atg5 to form an autophagosomal precursor (N Mizushima, Noda, et al. 1998; N Mizushima, Sugita, et al. 1998; N Mizushima et al. 2001; Noboru Mizushima, Ohsumi, and Yoshimori 2002; Nemoto et al. 2003; I Tanida et al. 2001). LC3 is the mammalian orthologue of yeast Atg8 and its nascent form, ProLC3, is processed: its carboxyl terminal region is cleaved off to become a soluble cytosolic form, LC3-I, exposing a carboxyl terminal glycine residue (Kabeya et al. 2000). LC3-I is then activated by Atg7, transferred to Atg3, a second E2-like enzyme, modified with phosphatidylethanolamine and becomes a membrane-bound form, LC3-II (Tanida et al. 2001; Tanida et al. 2002). LC3-II is localized to both the outer and the inner membrane of pre-autophagosomes and autophagosomes (Kabeya et al. 2000). Following the fusion of autophagosomes with lysosomes, intra-autophagosomal LC3-II is degraded by lysosomal hydrolytic enzymes (Kabeya et al. 2000). The formation of LC3-II is therefore a good marker to monitor the occurrence of autophagosome formation (Kabeya et al. 2000) and thus LC3 is commonly used as an autophagosomal marker.

In mammalian cells, autophagy is regulated by nutrient availability and hormones, and has been suggested to be essential for cellular homeostasis (Kimura et al. 2007). In addition to its homeostatic function, autophagy plays quite

important physiological roles. In fact, although autophagy is strongly induced under conditions of physiological stress, such as starvation, it also occurs at a basal level in normal conditions; for example, constitutive autophagy in nutrient-rich conditions is involved in intracellular protein quality control, in global turnover of cellular components (including organelles) (Komatsu et al. 2006; Hara et al. 2006) and as a defense mechanism against bacterial pathogens (Nakagawa et al. 2004; Ogawa et al. 2005) or the toxic effects of aggregate-prone proteins (Ravikumar, Duden, and Rubinsztein 2002; Kamimoto et al. 2006).





**Figure 3: Schematic diagram of the steps of autophagy.**

Autophagy begins with the formation of the phagophore or isolation membrane (vesicle nucleation step). The concerted action of the autophagy core machinery proteins at the phagophore assembly site is thought to lead to the expansion of the phagophore into an autophagosome (vesicle elongation). The autophagosome can engulf bulk cytoplasm in a non-specific manner, including entire organelles, or target cargos specifically. When the outer membrane of the autophagosome fuses with a lysosome (docking and fusion steps), it forms an autophagolysosome, or autolysosome. Finally, the sequestered material is degraded inside the autophagolysosome (vesicle breakdown and degradation) and recycled.

Model taken from Meléndez and Levine, 2009.

## Exocytosis

Lysosomes are also involved in a secretory pathway known as lysosomal exocytosis (Figure 1). Exocytosis is the removal of cellular cargo by fusion of vesicles with the plasma membrane (PM) (Figure 4). In response to a transient increase of cytosolic  $\text{Ca}^{2+}$ , secretory vesicles move towards the PM, fuse with the membrane, and then expel the luminal contents into the external cellular environment. Initially, lysosomal exocytosis was considered to be limited to specialized secretory cells; in these cells, exocytosis has a housekeeping function responsible for the secretion of hormones, cytokines, and neurotransmitter. However, several studies indicate that this process occurs in all cell types (N W Andrews 2000; Rodríguez et al. 1997; Rodríguez et al. 1999). In fact, it has been demonstrated that in non-secretory cells exocytosis plays an important role in PM repair (Idone et al. 2008), bone resorption (Smit et al., 2000), cycling/recycling proteins to plasma membrane (Catala et al. 2009), pathogen invasion (Imai et al., 2003), neurite outgrowth (Seiler et al. 2008), and cellular clearance (Pawelek and Lerner 1978; Boissy, Zhao, and Gahl 1998). In fact, lysosomes have traditionally been viewed as terminal degradative compartments, but they are the most important exocytic organelle in non-secretory cells, behaving as  $\text{Ca}^{2+}$ -regulated exocytotic vesicles (Rodríguez et al. 1997).

Lysosomal exocytosis is an ATP- and temperature-dependent process, in a way similar to what is known for the classical secretory process (Rodríguez et al. 1997). Lysosomes have exocytic activity, a common feature with synaptic vesicles. In fact, they originate from a common early endosome and they also share

mechanisms of exocytic activation. During the process of the synaptic vesicle release, action potentials of neurons reach the presynaptic terminal and activate several voltage-regulated  $\text{Ca}^{2+}$  channels; this event induces an influx of  $\text{Ca}^{2+}$  into the presynaptic cytoplasm, the fusion of the synaptic vesicle with the PM and, eventually, the release of the neurotransmitter (Nizami et al. 2010). The  $\text{Ca}^{2+}$  sensor synaptotagmin and the soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) synaptobrevin-2 decorate the synaptic vesicles membrane and were found to bind the PM through the corresponding SNAREs, syntaxin-1A and synaptosomal-associated protein 25 (SNAP-25), respectively (Thorsten Lang and Jahn 2008). The influx of  $\text{Ca}^{2+}$  into the cell drives interactions between the vesicular and target SNAREs synaptotagmin 7 (SYT7) and syntaxin 4 (Thorsten Lang and Jahn 2008), thus inducing lysosomal exocytosis.

Moreover, lysosome exocytosis has emerged also as an important mechanism for propagating the  $\text{Ca}^{2+}$  wave in astrocytes to modulate synaptic transmission (Li et al. 2008; Z. Zhang et al. 2007), although on a timescale orders of magnitude slower than synaptic transmission.


Lysosomal exocytosis requires two sequential steps. (Figure 4). In the first  $\text{Ca}^{2+}$ -independent step (Jaiswal, Andrews, and Simon 2002), lysosomes are recruited to the close proximity of the cell surface. In the second step the pool of pre-docked lysosomes fuse with the PM in response to  $\text{Ca}^{2+}$  elevation, thus emptying their content outside the cell (N W Andrews 2000; Jaiswal, Andrews, and Simon 2002; Tucker, Weber, and Chapman 2004).

Taking advantage of exocytosis, lysosomes play a pivotal role in the

degradation of extracellular matrix (ECM) proteins, cell invasion, and cell migration into the ECM (Lakka et al. 2004; Tu et al. 2008).

Exocytosis of lysosomes in response to a transient increase in intracellular  $\text{Ca}^{2+}$  was first observed in eggs of sea urchin, in which, during the fertilization process, thousand of secretory granules are released in response to an increase in intracellular  $\text{Ca}^{2+}$  concentration (Baker and Whitaker 1980). Furthermore, exocytosis, was also observed during cell invasion of *Trypanosoma Cruzi*: binding of the parasite to the cell membrane triggers calcium influx and subsequent fusion of lysosomes with the region of the plasma membrane that surrounds the invading parasite (Norma W Andrews 2002).

Although the main steps of lysosomal exocytosis have been elucidated, little is known about its regulation and how this process is coordinated with lysosomal biogenesis.



**Figure 4: Schematic diagram of the steps of lysosomal exocytosis.**

Exocytosis is the removal of cellular cargo by fusion of vesicles with the plasma membrane (PM). This process requires two sequential steps. (1) In the first  $\text{Ca}^{2+}$ -independent step, lysosomes are recruited to the close proximity of the cell surface. (2) In the second step the pool of pre-docked lysosomes fuse with the PM in response to  $\text{Ca}^{2+}$  elevation, thus emptying their content outside the cell.

Modified from *Microbiology: An Evolving Science*. Joan L. Slonczewski and John W. Foster.

## **Lysosomal Storage Diseases**

In 1932, Pompe made the crucial observation of extensive glycogen accumulation, within membrane-bound vesicles in the heart and skeletal muscles of a 7 months old patient who had died from cardiac complications. Based on these findings, in 1963 Hers and coworkers deduced the link between the deposition of glycogen in Pompe patients and the inherited deficiency of the hitherto unknown lysosomal enzyme alfa-D-glucosidase (Hers 1963), identifying the first lysosomal disorder. The discovery of the involvement of lysosomes in glycogen degradation gave rise to the concept that also other lysosomal storage disorders could be explained by specific enzyme deficiencies (Parkinson-Lawrence et al. 2010).

Nowadays, LSDs are a class of metabolic disorders and comprise a group of more than 50 different genetic diseases (Wilcox 2004). Despite the large number and clinical diversity of lysosomal disorders, these diseases share some common features. First, they are typically inherited as autosomal recessive traits (only two are X-linked); second, they most commonly afflict infants and young children; third, most involve pathology of the brain; and fourth, when brain pathology is present they are untreatable (Jeyakumar et al. 2005). Although each of these conditions is rare, they exhibit a combined prevalence of 1:5,000 births; some of these disorders occur at higher frequency in geographically isolated populations owing to founder effects (Dahl, Hillborg, and Olofsson 1993), or in certain ethnic groups in which consanguineous marriages are common (Ozkara and Topçu 2004).

LSDs are caused by mutations in proteins critical for lysosomal function. They mostly involve the dysfunction of a specific soluble lysosomal hydrolases, which

result in impaired degradation, substrate accumulation and lysosomal storage (Figure 5).

However, lysosomal integral membrane proteins, proteins involved in post-translational modifications, in vesicular trafficking and in the biogenesis of lysosomal proteins have also been shown to cause storage disorder phenotypes. For example, over the last years a number of defects in lysosomal membrane proteins have been recognized as the primary cause of lysosomal diseases (Ruivo et al. 2009). In fact, lysosomal accumulation can also occur if the correctly degraded compound is not properly transported to the cytosol (like in Salla disease and in cystinosis).

Other causes of LSDs are deficiencies in membrane-associated enzymatic activities (like HSGNAT in mucopolysaccharidosis type III C, MPSIIIC) and impairments of ion translocation (like MCOLN1 in mucolipidosis type IV, MLIV). For a significant number of LSDs caused by defects in lysosomal membrane proteins, the pathogenetic events at a molecular level and also the function of the protein under physiological conditions is incompletely understood (Schröder et al. 2010). This applies to neuronal ceroid lipofuscinosis (NCL) variants caused by defects in the membrane proteins CLN3 (Jalanko and Braulke 2009) and CLN7 (Siintola et al. 2007).

However the biochemical nature of the defects resulting in lysosomal storage is very diverse and in many cases the sequence of events leading to lysosomal dysfunction is only incompletely understood (Schröder et al. 2010).

In general, LSDs are typically characterized by enlarged lysosomes that contain partially degraded material as a result of a deficit in either degradation of

specific compounds, such as glycosaminoglycans, lipids, or protein, or in transport across the lysosomal membrane or in endosome-lysosome trafficking. Any disruption of lysosomal function can lead to the accumulation of undegraded substrate(s) in endosomes and lysosomes, eventually compromising cellular function and ultimately resulting in a complex spectrum of clinical manifestations (Hopwood and Brooks 1997).

The accumulation of the primary storage material can cause a chain of secondary disruptions to other biochemical and cellular functions, which leads to the severe pathology observed in LSDs (Parkinson-Lawrence et al. 2010). Once material starts to accumulate, it builds up within lysosomes until the lysosomal burden of the cell reaches some maximum level, at which point storage material starts to accumulate in other parts of the cell (Jeyakumar et al. 2005). The accumulation of undigested molecules can subsequently alter many cellular processes, including lysosomal pH regulation, synaptic release, endocytosis, vesicle maturation, autophagy, exocytosis and  $\text{Ca}^{2+}$  homeostasis (Vitner, Platt, and Futerman 2010; Bellettato and Scarpa 2010; Ballabio and Gieselmann 2009; Bezprozvanny 2009). It is still undefined whether the storage material affects cell function only when it begins to accumulate in extra-lysosomal sites or if problems in cell homeostasis are triggered while the material is still confined to the lysosome (Jeyakumar et al. 2005).

The accumulation of the primary storage material can also have a functional impact on the cell, including the inhibition of other enzymatic processes, causing the accumulation of secondary undegraded substrates and the disruption of lysosomal biogenesis (Parkinson-Lawrence et al. 2010).



Clinically, LSDs are associated with a progressive phenotype involving multiple organs and tissues (Settembre et al. 2008).

Although lysosomal proteins are ubiquitously distributed, the accumulation of undegraded substrate(s) in LSDs patients is normally restricted to those cells, tissues, and organs in which substrate turnover is high (Parkinson-Lawrence et al. 2010). However, the Central Nervous System (CNS) is particularly affected in LSD patients; over two-thirds of LSDs involve CNS dysfunction, like progressive cognitive and motor decline, and these symptoms are often the most debilitating (Schultz et al. 2011). In the CNS, the progressive accumulation of undegraded material induces a series of secondary defects, eventually leading to severe neurodegeneration.

Storage may begin during early embryonic development, and the clinical presentation for LSDs can vary from an early and severe phenotype to late-onset mild disease (Filocamo and Marrone 2011). However, although individuals affected by LSDs can display early symptoms, many are clinically normal at birth and typically meet early developmental milestones, indicating that lysosomal storage does not affect neuronal function and maturation at early developmental stages. In general, this suggests that lysosomal dysfunction *per se* does not impact significantly the complex events of early brain development, such as neural induction, establishment of axis, neuronal differentiation and migration, and synapse formation (Schultz et al. 2011).


Several systems for the classification of LSDs have been proposed. Most simply the diseases are grouped according to the nature of the storage material – either regarding biochemical composition or morphological appearance – in

mucopolysaccharidoses, glycoproteinoses, (sphingo)lipidoses, glycogen storage diseases and neuronal ceroid lipofuscinoses.

Although individual LSDs are rare, as group they are one of the most common genetic disorders in children, affecting 1 out of every 7000-8000 live births.

Many of the phenotypes observed in LSDs can be markedly improved by substrate reduction therapy (SRT), enzyme replacement therapy (ERT) or gene therapy, whose efficacy can be monitored by concomitant resolution of storage material (Eng et al. 2001, 200; Liu et al. 2005). In fact, storage burden in tissue sections or body fluids can be used as a reliable indicator of therapeutic efficacy in emerging treatment strategies for some LSDs (Eng et al. 2001; Schultz et al. 2011).

However, the progressive lysosomal accumulation of undegraded metabolites results in generalized cell and tissue dysfunction, and, therefore, in a multi-systemic pathology (Filocamo and Morrone 2011); thus, such treatments are not yet available or feasible for most LSDs. Therefore, understanding how the affected cellular pathways interconnect and impact the viability of cells is critical for future therapeutic development (Schultz et al. 2011).



**Figure 5. Schematic diagram illustrating the pathogenesis of lysosomal storage diseases.**

A complex substrate is normally degraded by a series of lysosomal enzymes (A, B, and C) into soluble end products. If there is a deficiency or malfunction of one of the enzymes (e.g., B), catabolism is incomplete and insoluble intermediates accumulate in the lysosomes.

*Modified from Kumar: Robbins and Cotran Pathologic Basis of Disease*

## Multiple Sulfatase Deficiency

Among acid hydrolases acting within the lumen of lysosomes, sulfatases are a family of enzymes that share both structural and functional similarities. They are involved in a number of different biological functions as diverse as degradation of complex molecules, production of steroid hormones and cell signalling. In particular, they catalyze the hydrolysis of sulfate ester bonds from a wide variety of substrates, ranging from complex molecules, such as GAGs, to sulfolipids and steroid sulfates. These enzymes can be divided, at least in mammals, into two main categories based on their subcellular localization: those acting at an acidic pH, localized in the lysosomes, and those acting at a neutral pH that are found in the ER, in the Golgi apparatus, and at the cell surface (Hanson, Best, and Wong 2004; Parenti, Meroni, and Ballabio 1997) (Hopwood and Ballabio, 2001).

MSD is an extremely rare autosomal recessive disorder, with an incidence of 1:1,400,000 and characterized by a dramatic impairment of all sulfatase activities. Life expectancy for MSD patients is commonly under 10 years of age.


Almost two decades ago it was demonstrated that sulfatases undergo a unique post-translational modification, which is indispensable for their enzymatic activity (Schmidt et al. 1995). This modification involves a highly conserved cysteine residue (Cys), located within the active site of sulfatases, which is modified into a formylglycine residue (FGly). The gene encoding the enzyme involved in the post-translational modification of sulfatases was identified and found to be mutated in patients with MSD (Cosma et al., 2003; Dierks et al., 2003). The MSD causing gene is called SUMF1 and encodes a formylglycine-generating

enzyme (FGE) (Figure 6). SUMF1 exerts its activity within the ER; however, it can also be secreted and taken up by distant cells and tissues, where it relocalizes in the ER as an active enzyme (Zito et al. 2007). In MSD patients residual sulfatase activities are substantially reduced (Dierks et al. 2003; Cosma et al. 2003), but still detectable at variable levels, indicating that MSD is caused by hypomorphic mutations in SUMF1 gene and that the complete loss of SUMF1 function is likely to be lethal in humans (Cosma et al. 2003). Interestingly, the phenotype of MSD patients combines, with some phenotypical variability, all the clinical symptoms observed in each individual sulfatase deficiency (Bischel, Austin, and Kemeny 1966). As a major sign they show a neurodegenerative course of disease with loss of sensor and motor abilities and neurological deterioration. Mental retardation, hepatosplenomegaly, shortening of stature and corneal clouding appear like in different mucopolysaccharidoses.

In the past years, in our laboratory, a mouse line carrying a null mutation in the SUMF1 gene has been generated using a gene-trapping approach (Settembre et al. 2007). In these mice, the function of the entire sulfatase protein family has been completely abolished, mimicking the phenotype observed in MSD patients: massive accumulation of undegraded molecules, systemic inflammation and neurodegeneration. Moreover, the phenotype of these mice is severe and progressive; they display frequent early mortality (only the 10% reaches the age of 3 months), congenital growth retardation, skeletal abnormalities (including the typical flat facial appearance) and tremor and seizures due to defects of the CNS. Many tissues were examined for the presence of storage material, which was shown to increase with age; glycosaminoglycan accumulation was detected in liver,

kidney and, as a prime site, in macrophages which were massively present in all tissues. These macrophages and activated microglia in cerebellum and cortex, accompanied by neuronal cell loss and astroglyosis, indicate systemic neuroinflammation, which are thought to be key patho-physiological processes in MSD (Settembre et al. 2007).

In addition, nutrient-starved MSD mouse primary cells, as well as other monogenic LSDs, such as the Sanfilippo syndrome, or mucopolysaccharidosis type III A (MPSIIIA), present a block of autophagy as a consequence of decreased ability of lysosomes to fuse with autophagosomes; this leads to accumulation of toxic substrates, such as poly-ubiquitinated proteins and dysfunctional mitochondria, which are the putative mediators of cell death (Settembre et al. 2008).



**Figure 6. Mutations in the sulfatase-modifying factor-1 (SUMF1) gene result in the production of defective C-formylglycine-generating enzyme (FGE).**

Defective FGE cannot convert the cysteine (Cys) residue in the active site of lysosomal sulfatases to formylglycine (FGly). As a consequence, inactive sulfatases are transported to the lysosome, where they are unable to degrade their substrate, leading to their accumulation and subsequently to MSD pathology.

Model taken from Futerman and van Meer, 2004

## LSDs and autophagy

In the past years there has been an increased interest in investigating the possible involvement of autophagy in LSD pathogenesis (Cao et al. 2006; Koike et al. 2005; Fukuda et al. 2006; Jennings et al. 2006; Settembre et al. 2008). In our laboratory, we study two mouse models of neurodegenerative LSDs, MSD and MPSIIIA. Cells from both of these LSD models display: (1) increased numbers of autophagosomes, (2) reduced clearance of both endogenous and exogenous autophagic substrates and (3) defective organelle turnover (Settembre et al. 2008).

Interestingly, alterations in the autophagic/lysosomal pathway have been observed in more common multifactorial diseases (Levine and Kroemer 2008), such as Parkinson's disease (PD) (Pan et al. 2008; Ramirez et al. 2006) and Alzheimer's diseases (AD) (Nixon 2007), many forms of cancer (Kirkegaard 2009) and atherosclerosis (Martinet and De Meyer 2008). It is often not clear if the observed alterations represent causes or secondary consequences of the disease process.

Reports demonstrating that genetic disruption of autophagy causes neurodegeneration in mice (Hara et al. 2006; Komatsu et al. 2006) led to the hypothesis that the neurodegeneration in LSDs might be a consequence of impaired autophagy. Indeed, impaired autophagy has been reported also in other models of LSDs, including Pompe disease, Niemann-Pick disease (NPC), NCLs, MLIV, and GM1-gangliosidosis (Cao et al. 2006; Fukuda et al. 2006; Jennings et al. 2006; Pacheco, Kunkel, and Lieberman 2007; Venkatachalam et al. 2008).



## LSDs and exocytosis

Lysosomal function is intimately linked to exocytosis, and several LSDs.

An example is MLIV; when human MLIV fibroblasts are treated with ionomycin to elevate intracellular levels of  $\text{Ca}^{2+}$  and induce lysosomal exocytosis, the release of soluble lysosomal enzymes in the extracellular space is strongly reduced compared to healthy fibroblasts, suggesting that MCOLN1 plays an important role in this process (LaPlante et al. 2006). Further, transfection with wild-type MCOLN1 cDNA rescues exocytosis, suggesting the possibility of treatments based on the restoration of this crucial cellular function (LaPlante et al. 2006).

Another example is Niemann-Pick disease type 1 (NPC1); in fibroblasts derived from mouse models, cholesterol accumulation inhibits Rab guanosine triphosphatases (GTPases), thus perturbing membrane recycling; overexpressing Rab4 in these cells led to an activation of exocytosis and reduced lysosomal accumulation (Choudhury et al. 2004). Thus, enhancing exocytosis can not only reduce the storage burden, but also improve secondary phenotypes.

## **Transcriptional regulation of lysosomal biogenesis**

A commonly reported observation in several LSDs is a decrease in the activity of a disease-associated enzyme are concomitant with increases in other lysosomal enzymes, suggesting that gene expression required for their interdependence is similarly orchestrated (Schultz et al. 2011). On the other hand, it has been shown that expansion of the lysosomal compartment, which is a

common feature of all LSDs, is usually accompanied by increased activity (and release) of many lysosomal proteins (Moran et al. 2000). Thus, a coordinated control mechanism with enhanced transcriptional expression was long suspected.

Recently in our laboratory it was observed, by using the g:Profiler tool (Reimand et al. 2007), that genes encoding lysosomal proteins (hereafter referred to as lysosomal genes) tend to have coordinate expression. Furthermore, in most of them is present a common palindromic motif, which was named Coordinated Lysosomal Expression and Regulation (CLEAR) and which mediates their transcriptional activation (Sardiello et al. 2009). The CLEAR motif is a 10-base pair neucleotidic sequence (GTCACGTGAC), which is placed near the transcription start site of many lysosomal genes and is the target site of the bHLH transcription factor TFEB (Figure 7). It was found that most lysosomal genes share one or more copies of the regulatory motif in their promoters. The CLEAR network is comprised of several classes of genes, including genes that belong to the lysosomal complement (hydrolases, transporters, accessory proteins) and genes that participate in lysosomal biogenesis and function. Examples of the latter class are genes encoding subunits of the vacuolar proton pump, responsible for creating and maintaining the lysosomal acidic environment, and genes coding for the specialized transporters that import acid hydrolases into the lysosome.

It was observed that TFEB overexpression not only increases the number of lysosomes in the cell, but also improves cellular degradative capabilities. In fact, it was tested the clearing potential of TFEB on a neuronal cell model of Huntington's disease (HD), and found that TFEB transfection increased the clearance of the pathogenic polyglutamine-expanded huntingtin (Sardiello et al. 2009). These data

uncovered a regulatory network defining TFEB as a master regulator of lysosomal biogenesis. Furthermore, in cultured cell models of mucopolysaccharidosis type II (MPSII), MPSIIIA, and MSD, TFEB localizes primarily in the nucleus, but is cytoplasmic in control cells, suggesting that this pathway is activated under lysosomal storage conditions (Sardiello et al. 2009).

The observation that the process of lysosomal degradation is transcriptionally regulated raised the hypothesis that other lysosomal-related processes, like autophagy, might also be transcriptionally regulated by the same mechanism. In principle, enhancement of lysosomal function should result in a decrease in the number of autophagosomes due to increased degradation, whereas the opposite should occur in the presence of lysosomal inhibitors. However, it was observed that TFEB overexpression increases the number of autophagosomes and, conversely, RNA interference of TFEB decreases the number of autophagosomes, suggesting a role of TFEB in the regulation of the autophagic process as well (Settembre et al. 2011).


Interestingly, the fact that TFEB also regulates key autophagy switches indicates that the CLEAR network extends beyond the lysosomal complement to favor lysosome-dependent degradative pathways as a whole (Sardiello and Ballabio 2009).

Moreover, it was also hypothesized that TFEB may mediate starvation-induced autophagy. Interestingly, it was observed that upon starvation TFEB translocates from the cytoplasm (where it normally resides) to the nucleus where it is active and regulates the expression of its target genes (Settembre et al. 2011). This translocation occurs in a phosphorylation-dependent manner. In fact, it was

demonstrated that TFEB is maintained inactive in the cytoplasm through its phosphorylation on a critical serine residue (Ser142), and then it translocates to the nucleus when dephosphorylated (Settembre et al. 2012).

In particular, it was also shown that TFEB phosphorylation occurs on the lysosomal membrane by the master growth regulator, mammalian target of rapamycin (mTOR) complex 1 (mTORC1) (Settembre et al. 2012). Therefore, it was proposed the hypothesis that under full nutrients and in the absence of lysosomal stress the interaction between the lysosomal amino acid content and the v-ATPase complex, involved in lysosomal acidification, regulates Rag GTPases, which in turn activate mTORC1 by translocating it to the lysosomal surface (Sancak et al. 2008; Zoncu et al. 2011). At the lysosome, mTORC1 binds and phosphorylates TFEB, therefore controlling its subcellular localization and its inactive state. Indeed, phosphorylation by mTORC1 maintains TFEB in the cytoplasm and prevents it from translocating to the nucleus. Starvation, v-ATPase inhibition, or lysosomal stress switch the Rags off, leading to mTORC1 detachment from the lysosome and to its inactivation. TFEB can no longer be phosphorylated and thus it translocates to the nucleus, where it activates gene expression programs that boost lysosomal function and autophagy. These data demonstrated that TFEB mediates starvation-induced autophagy (Settembre et al. 2012).

Therefore, TFEB acts both as a sensor of lysosomal state, when on the lysosomal surface, and as an effector of lysosomal function when in the nucleus. This unique lysosome-to-nucleus signalling mechanism allows the lysosome to regulate its own function (Settembre et al. 2012).



**Figure 7. TFEB controls the expression of lysosomal genes and enhances cellular clearance.**

(A) Expression analysis of lysosomal genes following TFEB overexpression and silencing. Blue bars show the fold change of the mRNA levels of lysosomal genes in TFEB- vs. pcDNA3-transfected cells. Red bars show the fold change of mRNA levels in mimic-miR-128-transfected cells vs. cells transfected with a standard control microRNA (mimic-miR-cel-67). (B) Immunoblot analysis of TFEBEGFP-positive (+) and TFEB-EGFP-negative (-) HD43 cells (left panel) and immunofluorescence analysis of TFEB and HTT in HD43(Q105) cells transfected with 3xFLAG-TFEB construct (right panel).

Taken from Sardiello et al., 2009

## **Neural Stem Cells**

Stem cells are undifferentiated cells that are capable of giving rise to indefinitely more cells of the same type, and from which certain other types of cell arise by differentiation. Indeed, stem cells exhibit two defining characteristics: the self-renew, which is the ability to go through numerous cycles of cell division while maintaining the undifferentiated state, and the potency, which is the capacity to generate a diverse range of specialized cell types through differentiation (Gage 2000).

There are two types of mammalian stem cells: embryonic and adult. Embryonic stem cells (ESCs) derive from the inner cell mass of the blastocyst and are totipotent, which means that they can differentiate into all of the specialized embryonic tissues. Adult stem cells are found in adult tissues and act as a repair system for the body, replenishing specialized cells, but also maintaining the normal turnover of regenerative organs; unlike ESCs, they are often restricted to certain lineages (for example hematopoietic or neural fate) (Figure 8).

NSCs are self-renewing multipotent populations present in the developing and adult mammalian CNS (Chojnacki and Weiss 2008; Temple 2001). During the process of neurogenesis, NSCs generate the neurons and glia of the developing brain and also account for the limited regenerative potential of the adult brain.

Neurogenesis is the process of generating functional neurons from precursors and in mammals it begins with the induction of the neuroectoderm, which forms the neural plate (at embryonic day 7.5 (E7.5) in mice) and then folds to give rise to the

neural tube (at E8.5 in mice). These structures are made up by a layer of so-called neuroepithelial progenitors (NEPs) (Götz and Barde 2005), which are probably a complex and heterogeneous population. During this neural differentiation, ESCs undergo progressive lineage restrictions, leading to the generation of a range of distinct neural precursor populations that can be used to study the molecular and cellular events that occur during stage-specific transitions between different populations (Nishikawa, Jakt, and Era 2007; S.-C. Zhang 2006, 200).

Neurogenesis was traditionally viewed to occur only during embryonic and perinatal stages in mammals (Ming and Song 2005). Nevertheless, Altman's pioneering studies decades ago provided the first anatomical evidence for the presence of newly generated dentate granule cells in the postnatal rat hippocampus (Altman and Das 1965). Multipotent neural stem cells were later derived from the adult mammalian brain (Reynolds and Weiss 1992; Richards, Kilpatrick, and Bartlett 1992). Since then, significant progress has been made over the past decades in the study of almost every aspect of adult neurogenesis in the mammalian CNS.

In general, adult neurogenesis recapitulates the complete process of neuronal development in embryonic stages, but is spatially restricted under normal conditions to two specific “neurogenic” brain regions: the subgranular zone (SGZ) in the dentate gyrus of the hippocampus, where new dentate granule cells are generated, and the subventricular zone (SVZ) of the lateral ventricles in the forebrain, where new neurons are generated and then migrate through the rostral migratory stream (RMS) to the olfactory bulb to become interneurons (Gage 2000; Ming and Song 2011).

In the adult SGZ, proliferating radial and non-radial precursors give rise to intermediate progenitors, which in turn generate neuroblasts. Immature neurons migrate into the inner granule cell layer and differentiate into dentate granule cells in the hippocampus (Ming and Song 2012).

In the adult SVZ, proliferating radial glia-like cells give rise to transient amplifying (TA) cells, which in turn generate neuroblasts. In the RMS, neuroblasts form a chain and migrate toward the olfactory bulb through a tube formed by astrocytes (Lois, García-Verdugo, and Alvarez-Buylla 1996). Once reaching the core of the olfactory bulb, immature neurons detach from the RMS and migrate radially toward glomeruli where they differentiate into different subtypes of interneurons (Lledo, Alonso, and Grubb 2006).

Therefore, the SGZ and the SVZ are the two main niches that *in vivo* support self-renewal and regulate the balance between symmetrical self-renewal, by which NSCs proliferate, and fate-committed asymmetrical division, by which NSCs generate differentiated cells (Alvarez-Buylla and Lim 2004; Garcion et al. 2004; Shen et al. 2004; Shen et al. 2008). In fact, niches are defined as microenvironments that anatomically house stem cells and functionally control their development *in vivo*.

The size of the NSC pool in the SVZ is much larger than that in the SGZ (Lois and Alvarez-Buylla 1993; Morshead et al. 1994).

Due to the constitutive migration and high proliferation rate of neural progenitor cells in the SVZ (Lucassen et al. 2010; Curtis, Kam, and Faull 2011), it has been proposed that the neuronal differentiation of NSCs in the SVZ might be particularly important for the autonomous repair of the brain during the



pathogenesis of a disease. In fact, studies based on animal disease models revealed that neural progenitor cells in the SVZ can also migrate to regions where neuronal disorders occur to compensate for the loss of living neurons (Arvidsson et al. 2002; Tattersfield et al. 2004).

The proliferation and differentiation of NSCs are strictly regulated by a complex regulatory system, including a variety of intrinsic and extrinsic mechanisms, such as morphogens and growth factors, as well as transcription factors and epigenetic mechanisms. Morphogenic proteins and transcription factors are the fundamental forces that determine the fate of NSCs and the process of neurogenesis. Morphogens are a group of proteins that not only are vital for the embryonic development and patterning of the brain, but also function to regulate the self-renewal and differentiation of NSCs in the adult brain. This group of proteins includes Notch, sonic hedgehog (Shh), wingless-type MMTV integration site family (Wnt), fibroblast growth factor (FGF), and bone morphogenetic proteins (BMPs). During the process of embryonic development, ESCs in the ectoderm differentiate into excitatory and inhibitory neurons. These morphogenetic proteins, combined at different concentrations, act to pattern the brain along the anterior-posterior and dorsal-ventral axis into different regions. For instance, FGF is responsible for the anterior-posterior patterning and BMP and Shh are specific for the dorsal-ventral patterning; Wnt contributes to both processes. In the adult brain, the morphogenic proteins continue to subtly modulate the number and differentiation of neural precursor cells. In both the SGZ and the SVZ, Shh is essential for the maintenance of radial glia-like cells (Ahn and Joyner 2005; Balordi and Fishell 2007; Han et al. 2008), whereas Notch is fundamental for the neuronal

differentiation of NSCs (Imayoshi et al. 2010; Pierfelice, Alberi, and Gaiano 2011). Wnt can also promote the neuronal differentiation of NSCs in the SGZ (Lie et al. 2002), whereas BMP determines their glial fate (Lim et al. 2000; Bonaguidi et al. 2005; Mira et al. 2010).

The concurrent action of these morphogens via a concentration gradient leads to the differentiated expression of hundreds of transcription factors to determine the fate of newborn neurons. However, limited information is available on the roles that transcription factors play in NSC differentiation in the adult brain, and only a handful of transcription factors have been extensively studied. One such factor is Sox2, which is present in both the SGZ and SVZ, and colocalizes with NSC markers glial fibrillary acidic protein (GFAP), nestin, brain lipid-binding protein (BLBP), and Musashi-1 (Ferri et al. 2004, 200; Komitova and Eriksson 2004; Suh et al. 2007; Lugert et al. 2010). Evidence based on transgenic mice revealed that Sox2 acts probably through an interactive regulation with Notch signaling (Taranova et al. 2006; Ehm et al. 2010). Another well-studied transcription factor is Pax6, which is expressed in NSCs in the SGZ (Maekawa et al. 2005; Nacher et al. 2005; Hodge et al. 2008; Roybon et al. 2009) and in neuroblasts in the SVZ (Herold et al. 2011; Jones and Connor 2011) and functions to promote the dopaminergic fate determination of NSCs (Kohwi et al. 2005; Brill and Huguenard 2008; Spitere et al. 2008).

On the other hand, abundant evidence supports the finding that NSC differentiation and proliferation in the adult SVZ and SGZ is closely regulated by the local environmental factors, such as surrounding neurons, astrocytes, and other non-neuronal cells (Suh, Deng, and Gage 2009), either in an activity relevant

manner or through growth factor release.


In general, endogenous NSCs in their undifferentiated state are recognized for the expression of the nestin marker. The neural specific intermediate filament nestin, in fact, is utilized to visualize the regions of neurogenesis throughout the life of the animals. Cells that are immunoreactive for nestin are thought to be involved in neurogenesis (Doyle, Khan, and Cunningham 2001; Yue et al. 2006), and therefore to differentiate into neurons and glial cells (Itoh et al. 2006). During brain development, nestin is expressed by radial glia cells, and nestin expression starts to disappear around postnatal day 11 (P11) in the rat cortex (Kálmán and Ajtai 2001). Based on these data, nestin might provide an ideal marker to examine neurogenesis within the adult brain.

During the development of the CNS, NSCs are precursors of glia and neurons, both characterized by the expression of their own specific markers, GFAP and neuron specific class III  $\beta$ -tubulin (Tuj1), respectively.

GFAP is widely known as a marker for mature astrocytes in the adult brain. A large proportion of the newborn cells in the SGZ of the hippocampal region have also been found to be GFAP-positive (Eckenhoff and Rakic 1988; Maslov et al. 2004). However, the use of GFAP as a marker for neurogenesis is hampered by the finding that the glial cell lineage and mature astrocytes are also labeled. Thus, the nestin-positive, but not the GFAP-positive, precursors are the precursors involved in neurogenesis (Cao et al. 2006).

Tuj1 expression starts as early as embryonic day 8.5 (Easter, Ross, and Frankfurter 1993) and can be detected throughout brain development (Menezes and Luskin 1994). Tuj1 has been found to label newly generated immature

postmitotic and differentiated neurons (Menezes and Luskin 1994). With respect to adult neurogenesis, Tuj1 is used as a neuron-specific marker of newly generated cells (F Doetsch, García-Verdugo, and Alvarez-Buylla 1997; Gould et al. 2001).



**Figure 8. Schematic diagram illustrating lineage commitment of adult neural stem cells.**

*Pluripotent ESCs can form any body tissue (except for the placenta). During development, cells derived from these stem cells become progressively more specialized, like NSCs that are multipotent precursors of the two main cell type of CNS, glia and neurons.*

## Isolation of adult Neural Stem Cells

Isolation of NSCs from their adult natural niche and their purification and expansion have been problematic, as the factors and cell contacts required to maintain these cells in their physiological state are poorly understood (Conti and Cattaneo 2010). However, epidermal growth factor (EGF) and FGF2 have been key players in the identification of cell culture conditions that sustain prolonged cell division of cells with NSC properties (Reynolds and Weiss 1992; Reynolds and Weiss 1992; Laywell, Kukekov, and Steindler 1999).

Two main strategies have been developed for NSC isolation and *in vitro* long-term propagation, the neurosphere system and the monolayer system.

### Neurosphere system

Neurospheres are free-floating aggregates of neural progenitors, each potentially derived from a single NSC (Reynolds and Weiss 1992; Reynolds, Tetzlaff, and Weiss 1992; Laywell, Kukekov, and Steindler 1999). Their generation relies on tissue microdissection followed by exposure to mitogens (Chojnacki et al. 2008). Commonly, mouse and rat neurospheres are harvested from neural tissue at E10.5-E18.5 or from the adult SVZ (F Ciccolini 2001; Francesca Ciccolini et al. 2005; F Ciccolini and Svendsen 1998; Gritti et al. 1995; Louis and Reynolds 2005; Svendsen et al. 1998; Tropepe et al. 1999; Uchida et al. 2000). For their expansion, cells are plated in low-attachment tissue culture plastic dishes in serum-free media supplemented with EGF (10-20 ng per ml) and/or FGF2 (10-20 ng per

ml) (Singec et al. 2006). In these conditions, most differentiating or differentiated cells are expected to die, whereas the NSCs respond to the mitogens, divide and form floating aggregates (primary neurospheres) that can be dissociated and replated to generate secondary neurospheres. This procedure can be repeated several times to expand a NSC population.

Neurospheres have been used *in vitro* for defining, by extrapolation, the persistence and properties of NSCs *in vivo* (Golmohammadi et al. 2008; Marshall, Reynolds, and Laywell 2007). In fact, the cellular milieu of the neurosphere has been suggested to provide an *in vitro* counterpart to the *in vivo* neurogenic compartment, a microenvironment that is relevant for NSC maintenance, proliferation and differentiation. The concept of a neurosphere as an *in vitro* recapitulation of a niche-like structure has become extremely popular in the NSC field (Conti and Cattaneo 2010). The regulation of stem cell features in the niche requires both interactions between stem cells and interactions between stem cells and neighbouring differentiated cells, mediated by soluble and adhesion molecules and extracellular matrix components (Conti and Cattaneo 2010).

However, it has been demonstrated the tendency of neurospheres to generate differentiated cells in their core (Campos 2004), since different cells in the sphere can be exposed to suboptimal conditions due to their three-dimensional structure. Consequently, the interaction between differentiating cells and precursor cells may expose the NSCs to paracrine factors that promote differentiation. Therefore, the maintenance of the neurogenic versus gliogenic potential gradually declines with *in vitro* passages (Conti and Cattaneo 2010). Hence, neurospheres can be considered as the *in vitro* counterpart of the *in vivo* niche structure only for a

limited time after brain dissection.

Different neuronal differentiation protocols based on mitogen removal and exposure to fetal bovine serum and/or to specific substrates and cytokines have been developed (Garcion et al. 2004; Chojnacki and Weiss 2008; Tropepe et al. 1999; Grandbarbe et al. 2003; Weiss et al. 1996), but none of them generates cells that are positive for the early neuronal marker Tuj1 at a proportion greater than 20%. On the whole, this suggests that the neurosphere system is not particularly efficient in terms of neurogenic competence, but it can be useful for studying self-renew abilities and proliferation capacities of NSCs after tissue dissociation.

#### Monolayer system

Early attempts to culture NSCs in monolayer conditions relied on plating them on polyornithine-, laminin- or fibronectin-coated dishes in serum-free media (Johe et al. 1996) and in the presence of morphogens (Palmer, Takahashi, and Gage 1997). These cells show homogeneity for nestin and Sox2 expression, and symmetrical cell division continuously replenishes the supply of multipotent progenitors.

More recently, other strategies for the derivation and stable long-term propagation of NSC lines from different sources of rodent (Conti et al. 2005; Pollard et al. 2006, 200) and human (Sun et al. 2008) origin have been described. According to these procedures, neural precursors can be competently expanded as adherent, clonal, uniform NSC lines by exposure to EGF and FGF2 (Elkabetz et al. 2008; Koch et al. 2009; Conti et al. 2005). Under these conditions cells divide

symmetrically, retaining their tripotential differentiation capacity, indicating that monolayer culture systems can maintain almost pure NSC populations (Conti et al. 2005), with a negligible differentiated component. The key aspect of the NSC culture system lies in the combination of EGF and FGF2 used and the focus on cells that grow adherently. The continuous provision of EGF together with FGF2 seems to be essential for the derivation and propagation of these monolayer-growing NSCs (Palmer, Takahashi, and Gage 1997). When grown in these conditions, NSC population shows a remarkable antigenic similarity to forebrain neurogenic radial-glia (RG) (Conti et al. 2005; Pollard et al. 2006). The fact that NSCs can also be established from long-term expanded neurospheres indicates that RG-like cells might be the NSC fraction in neurospheres and that monolayer growth conditions may allow their enrichment and subsequent expansion (Conti et al. 2005).

Interestingly, cells in these EGF- and FGF2-dependent monolayers retain multipotency and neurogenic efficiency also after prolonged *in vitro* expansion and show a high competence to efficiently originate antigenically and electrophysiologically mature neurons on exposure to optimized differentiating conditions (Koch et al. 2009; Conti et al. 2005; Spiliotopoulos et al. 2009; Goffredo et al. 2008). This capacity can probably be interpreted as a consequence of the homogeneity of the starting population.



## AIM

The main objective of the research described in this thesis is to establish a cellular system to study the mechanisms of neurodegeneration in MSD pathology. This *in vitro* system must resemble the main hallmarks of the disease, such as the primary accumulation of undegraded substrates, secondary accumulation of undigested substrates, impaired autophagy and increased apoptosis.

Although cell death characterizes the later stages of the disease, for most of the clinical course the pathology mainly involves neuronal dysfunction rather than loss. Therefore, the ultimate goal will be to elucidate the intracellular mechanisms that lead to neuronal dysfunction after the pathologic accumulation of undegraded substrates.

Therefore, my thesis project aimed firstly at the isolation and characterization of NSCs from MSD and wild-type adult mice. For this purpose, I successfully built a robust protocol to isolate NSCs from postnatal brain tissue; once established in culture, I defined the progenitor identity of these cells. In order to assess whether NSCs could be a reliable tool to clarify the mechanisms of neurodegeneration in MSD pathology, I focused on the characterization of MSD-NSCs and on investigating whether they also reflect the main hallmarks of the disease, such as the progressive accumulation of undegraded GAGs, impaired autophagy and high levels of apoptosis, as seen in adult mice.

Furthermore, establishing an *in vitro* system that recapitulates the main hallmarks of LSDs would be useful also to identify relevant pathogenic intracellular

pathways leading to the developing of new therapeutics strategies for the treatment of MSD, as well as other neurodegenerative LSDs. An intriguing therapeutic strategy that allows us to test our *in vitro* system came from studies carried out in our laboratory on the transcription factor TFEB, a master gene for lysosomal biogenesis and function. TFEB overexpression is able to reduce mutant huntingtin in a cellular model of HD (Sardiello et al. 2009). It was shown that TFEB is able to increase the capacity of the lysosome to degrade by increasing the bulk of lysosomal components. Therefore, we tested the role of TFEB in the clearance of pathologic undegraded substrates in isolated MSD-NSCs. Surprisingly, we found that TFEB overexpression is able to reduce primary accumulation of GAGs in differentiated MSD-NSCs by inducing lysosomal exocytosis (Medina et al. 2011). Therefore, our studies envisage a novel tool, by targeting lysosomal exocytosis mechanism, to reduce the lysosomal burden in storage diseases.

To achieve all these objectives, I selected the following main goals:

- (1) isolation and characterization of NSCs from MSD mice;
- (2) phenotyping of MSD-NSCs to investigate the intracellular cascades involved in neurodegeneration;
- (3) modulating lysosomal function as a novel tool to treat LSDs.

## RESULTS

### **Isolation of NSCs from post-natal brain of wild-type and MSD mice**



The crucial point of this research project is the isolation of NSCs from the brain of postnatal wild-type and MSD mice. Recently, it has been established a methodology that allows for the isolation and continuous *ex vivo* expansion of NSCs from mouse brain tissue that can be easily cryopreserved and readily differentiate into neurons and glial cells (Conti et al. 2005).

Two steps basically constitute the NSCs isolation protocol carried out in this project: (1) neural tissue dissociation and (2) positive selection of NSCs with anti-prominin-1 MicroBeads (MACS, Miltenyi Biotec) (Peh et al. 2009) (Figure 9). In the first step, after brain tissue micro-dissection the cortical hemispheres dissociation is achieved with an enzymatic degradation using papain, a protease able to breaks the extracellular adhesion proteins holding the cells together; in this way, the tissue can be dissociated to single-cell suspensions. Then, the second step leads to an enrichment of the cell population in NSCs. In order to do that, I incubated the cell suspension with anti-prominin-1 antibody. Prominin-1 is a transmembrane glycoprotein expressed in various stem cells, including those from postnatal CNS (Peh et al. 2009). Therefore, NSCs were magnetically labeled with anti-prominin-1 MicroBeads and loaded onto a MACS® Column, which is placed in the magnetic field of a MACS Separator. The magnetically labeled prominin-1+ cells are retained within the column whereas the unlabeled cells run through. After removal of the

column from the magnetic field, the magnetically retained prominin-1+ cells can be eluted as the positively selected cell fraction.

As reported in literature (Conti et al. 2005), *in vitro* NSCs grow in so-called neurospheres, floating heterogeneous aggregates of cells, containing a large proportion of stem cells. Isolated neurospheres were propagated in culture at clonal density on uncoated plates in medium containing EGF and FGF2 and with penicillin/streptomycin (NS expansion medium). Over 3-5 days, cells formed aggregates that, after harvesting and sedimentation to remove debris, subsequently outgrew NSCs.

From neurospheres, NSCs were conveniently dissociated to single cells and plated directly on coated plates, to finally obtain a monolayer cell culture. These cells were propagated in culture with NS expansion medium. The entire isolation protocol was carried out for three wild-type and three *Sumf1*<sup>-/-</sup> mice.



**Figure 9. NSCs isolation protocol**

NSCs are isolated following a two step protocol: (1) brain tissue micro-dissection and neural tissue dissociation with papain, and (2) labeling of NSCs with magnetic anti-prominin-1 MicroBeads (MACS, Miltenyi Biotec) and positive selection through the magnetic field of a MACS Separator (MACS, Miltenyi Biotec).

## **NSCs uniformly express morphological and molecular features of radial glia progenitors**


Once established in culture, NSCs showed the typical elongated bipolar morphology with lamellate extensions, end-feet and oval nuclei anticipated for radial glia, with no substantial differences between MSD cells and their wild-type counterpart (Figure 10-A). In these conditions, NSCs proliferate continuously, with a doubling time of around 25 hours.

By flow cytometry analysis I observed that around 99.3% of the wild-type cells and 98.8% of MSD cells expressed the NSC marker nestin, suggesting that isolated NSCs have a defined progenitor identity (Figure 10-B).

Therefore, I analyzed their progenitor signature at a molecular level, testing a set of markers commonly used to define this cell population (Figure 11). By RT-PCR, I found that both wild-type and MSD-NSCs lacked the pluripotency marker genes typical of embryonic stem cells such as *oct4* and *nanog* (Schöler et al. 1990; Cavaleri and Schöler 2003), whereas they expressed Pax6, and BLBP mRNAs (Hack et al. 2004; Feng, Hatten, and Heintz 1994, 199). In addition, NSCs expressed the neural precursor markers *olig2*, *Sox2* and *mash1* (Gabay et al. 2003; Lo et al. 1991) and lacked expression of *dlx2*, a marker of transient amplifying neuroblasts but not of NSCs (Fiona Doetsch et al. 2002) and, as expected, they did not express the marker of neuronal differentiation NF-L (Schimmelpfeng, Weibezahn, and Dertinger 2004). This set of markers is considered diagnostic for neurogenic radial glia, precursors of both neurons and astrocytes during development of the nervous system (Campbell and Götz 2002;


Hartfuss et al. 2001; Noctor et al. 2001).

Therefore, NSCs isolated from wild-type as well as those isolated from MSD affected littermates uniformly express morphological and molecular features of radial glia progenitors.



**Figure 10. NSCs exhibit morphologic similarities to radial glia**

(A) Bright field pictures of isolated wild-type (WT) and MSD-NSCs showed elongated bipolar morphology with lamellate extensions, end-feet and oval nuclei anticipated for radial glia, and (B) Flow cytometry analysis revealed a high expression of the neurogenesis marker nestin in WT- (99.3 %) and MSD-NSCs (98.8 %).




**Figure 11. NSCs exhibit phenotypic similarities to radial glia**

Expression pattern of a set of markers by RT-PCR on cDNA obtained by RNA retrotrnscription. RNA extraction was obtained from wild-type (WT) and MSD undifferentiated NSCs, from wild-type ESCs, and from wild-type mouse brain. Genes tested were divided in five different groups: stem cell markers (oct4, nanog), radial glia markers (pax6, blbp), pan-neuronal and region specific transcriptional regulators (sox2, olig2, mash1), a neuroblast marker (dlx2), and a differentiated neuron marker (NF-L).



### **MSD-NSCs present a progressive loss of self-renewal**

To assess whether in absence of SUMF1 protein NSCs display a defect in their ability to self-renew, I tested them with the neurosphere assay (Figure 12). Cells were plated as single cells at a density of  $5 \times 10^4$  cells/ml in medium containing FGF2 and EGF. After incubation for 7 days, primary neurospheres were counted and then dissociated and re-plated in the same conditions; similarly, I generated secondary and tertiary neurospheres. I observed a significant decrease in the number of MSD tertiary neurospheres compared to wild-type counterpart, thus suggesting that accumulation of undegraded substrates is likely to impact on the ability of NSC population to self-renew. Interestingly, it was demonstrated that NSCs isolated from a mouse model of another neurodegenerative lysosomal disorder, Niemann-Pick disease type 1 (NPC1) show a similar defect in the self-renew (Yang et al. 2006); although a greater understanding of the mechanisms involved in this defect is needed, this observation raises the possibility that neurodegeneration observed in LSDs may be characterized by a general reduction in the NSCs population, due to a defect in their self-renew ability.




**Figure 12. MSD neurospheres show an impaired self-renewal**

Bright field images of neurospheres assay.  $5 \times 10^4$  cells/ml were plated in NS expansion medium and formed primary neurospheres (I); after 7 days primary neurospheres were counted and then dissociated and re-plated in the same conditions, generating secondary neurospheres (II); similarly, tertiary neurospheres (III) were generated. Scale bars represent 200  $\mu$ M. Data are mean of replicates ( $n=30$ )  $\pm$  SEM; \* $p < 0.05$  by Student's t-test.

### **MSD-NSCs are able to differentiate into astrocytes and neurons**

Neural progenitors are committed cells with multipotential fate. To confirm the nature of isolated NSCs, I tested their ability to give rise to the two main cell types of the CNS: astrocytes and neurons. Thus, cell differentiation was studied at molecular level by immunofluorescence and immunoblotting using specific antibodies for differentiation markers, such as GFAP for glial differentiation, and Tuj1 for neuronal cells. Fully differentiation capacity was assessed by immunofluorescence looking at the absence of nestin expression after glial or neuronal differentiation protocols (Figure 13-A).

As expected, both wild-type and MSD-NSCs showed uniform expression of the progenitor marker protein nestin when kept in the undifferentiated state. Moreover, wild-type differentiated cells showed a uniform expression of GFAP or Tuj1, after glial or neuronal differentiation, respectively; at the same time, they did not show expression of nestin. In a similar way, MSD-NSCs were able to differentiate into glia and neurons, showing the same uniform expression of GFAP and Tuj1, respectively, and no expression of nestin. The same results were obtained by western blot analysis of protein homogenates from wild-type and MSD-NSCs, both undifferentiated and differentiated to glial and neural cells (Figure 13-B).



**Figure 13. MSD-NSCs correctly express differentiation markers**

(A) Confocal microscopy image of wild-type (WT) and MSD undifferentiated NSCs (ND), glia (AG) and neurons stained with immunofluorescence detecting nestin (upper panel), GFAP (middle panel) and Tuj1 (lower panel). Scale bars represent 50  $\mu$ M. (B) Immunoblotting detecting GFAP (left panel) and Tuj1 (right panel) in protein extracts from NSCs, glia and neurons.


### **MSD neurons develop neurites and are electrophysiologically active**

During differentiation, neurons extend numerous processes that develop into dendrites and axons. These processes, also termed neurites, are critical for communication between neurons through interconnection of neuronal cell bodies. Moreover, neurite development was studied in another LSD, Sandhoff disease, which is a neurodegenerative disorder characterized by the deficiency in the hexosaminidase B (HEXB) gene; in particular in explant culture of retinal tissue from HexB <sup>-/-</sup> mice it was observed an impaired neurite outgrowth (Sango et al. 2005), suggesting that lack of a lysosomal enzyme has an effect on neuronal branching. Therefore I performed the neurite assay in order to establish whether the absence of SUMF1 protein could affect neurite outgrowth of 3- and 7-days differentiating neurons (Figure 14-A). Nevertheless, I observed no differences in neurite outgrowth between MSD neurons and their wild-type counterpart, suggesting once again that neuronal differentiation and processes extension is not affected in MSD cells.

For unambiguous assignment of neuronal identity, we investigated the electrophysiological properties of neural differentiated NSCs. Toward this goal, in collaboration with Dr. Francesco Miceli and Prof. Maurizio Tagliatela from University of Naples “Federico II”, we recorded currents from wild-type and MSD-derived neurons using the whole-cell configuration of the patch-clamp technique. During depolarizing test potentials, MSD neurons and their wild-type counterpart, showed an inward current followed by a sizeable outward voltage-gated current, with features of a delayed-rectifier K<sup>+</sup> current (Figure 14-B, upper panel).

Furthermore, in MSD neurons the fast inactivating inward current was blocked by the selective Na<sup>+</sup> channel blocker tetrodotoxin (TTX) (1  $\mu$ M) and peaked at a test potential of around -20 mV, typical features of voltage-gated Na<sup>+</sup> currents in neurons (Figure 14-B, lower panel). These preliminary electrophysiological data suggest that isolated NSCs are capable to give rise to electrophysiologically active neurons, exhibiting excitability properties and underlying conductances typical of maturing nerve cells. Most importantly, we did not find any differences in the electrophysiological properties between MSD derived neurons and their wild-type counterpart.

Taken together, these observations suggest that MSD pathology does not affect the ability of NSCs to differentiate into astrocytes and functional neurons.



**Figure 14. MSD differentiated neurons develop proper neurites and are electrophysiologically active**

(A) Neurite outgrowth assay and (B) electrophysiological test on NSC-derived neurons; superimposed inward and outward current tracings were obtained using the indicated electrophysiological protocol. Data are mean of replicates ( $n=2$ )  $\pm$  SEM.

## **MSD-NSCs recapitulate the progressive GAG accumulation**

MSD-affected mice present a massive accumulation of undegraded GAGs in brain tissue, vacuolization and increased neurodegeneration (Settembre et al. 2007). Thus, after the isolation and characterization of MSD NSCs, I started to study these pathologic features in differentiating cells. Firstly I observed that during both astrocyte and neuronal differentiation, MSD cells display a progressive and massive perinuclear vacuolization compared to their wild-type counterpart (Figure 15-A). In particular, MSD cells display a thick cell body with enlarged extensions, whilst wild-type cells acquired the typical morphology of terminally differentiated CNS cells. In addition, MSD cells vacuoles have increasing dimensions during the course of the differentiation process, eventually reaching, and in some cases exceeding, the diameter of the nucleus. Electron microscopy analysis confirmed the presence of vacuole structures containing heterogeneous undegraded material (Figure 15-B).

Then I investigated whether MSD cells reflect also the main hallmark of the disease, which is the progressive accumulation of undegraded GAGs (Figure 16). By alcian blue staining (Figure 16-A) and GAG colorimetric assay (Figure 16-B) I detected increased levels of GAGs in MSD not-differentiated cells and in both glial and neuronal fate, reflecting the GAG storage phenotype observed *in vivo*. In fact, MSD-NSCs showed massive accumulation of GAGs even from the undifferentiated state; the storage then becomes prominent during both glial and neuronal differentiation and also increases as the differentiation proceeds, thus recapitulating the progressive accumulation seen *in vivo*. Pulse-and-chase




experiments using  $H^3$ -glucosamine to label GAGs confirmed that MSD differentiated cells accumulate GAGs (Figure 16-C).

The hypothesis is that during the differentiation process cells arrest their proliferation rate thus not dividing themselves anymore, and non-mitotic cells cannot dilute accumulating cytosolic content by cell division; in the case of MSD, due to the enzymatic inactivity of sulfatases, cells are not able to burn off the undegraded substrates that subsequently accumulate. In this condition, MSD cells accumulate all the undegraded material in a progressive manner as the differentiation proceeds.


Interestingly, also in a neuronal model of mucopolysaccharidosis type VII it was found a massive accumulation of abnormally high levels of GAGs, thus giving confidence to my model (Heuer et al. 2001).

These results suggest that long-term differentiated MSD-NSCs are able to recapitulate the main hallmarks of the disease, which is the progressive storage of GAGs.



**Figure 15. Differentiating MSD-NSCs display progressive vacuolization and undegraded material**

(A) Bright field images of wild-type (WT) and MSD-NSCs, glia and neurons. (B) Electron Microscopy images of WT and MSD-derived glia cells. Scale bars represent 50  $\mu$ M (A) and 1  $\mu$ M (B).



**Figure 16. Differentiated MSD-NSCs display progressive accumulation of GAGs**

(A) Alcian-blu staining of GAGs on wild-type (WT) and MSD-NSCs, glia and neurons. Scale bars represent 50  $\mu$ M. (B) GAG quantitative assay on wild-type and MSD-NSCs, glia (left panel) and neurons (right panel). (C) Pulse-and-chase incorporation of  $H^3$ -glucosamine in wild-type and MSD-derived glia cells. Data are mean of replicates ( $n=5$ )  $\pm$  SEM; \* $p < 0.05$  by Student's  $t$ -test (B and C).

### **MSD differentiated cells suffer from impaired autophagy**


In a previous work from our laboratory, it was shown that LSDs are associated with a lysosomal dysfunction that impairs the autophagic pathway (Settembre et al. 2008). This impairment ultimately leads to cell death, although the detailed mechanism has not been described yet. In particular, it was demonstrated that in MSD pathology a block of autophagic pathway occurs as a consequence of decreased ability of lysosomes to fuse with autophagosomes. Accordingly to this previous *in vivo* data, I observed an increase of LC3-II levels in cellular extracts from glial and neuronal differentiated MSD-NSCs (Figure 17-A), thus indicating autophagic activation. However, the autophagy process requires the fusion of newly formed autophagosomes with lysosomes, in order to digest autophagosome content; in glia differentiated MSD-NSCs I observed a decreased intracellular co-localization of autophagosome punctae containing LC3-II molecules with the lysosomal membrane protein marker cathepsin D (CatD) (Figure 17-B), suggesting an impaired fusion of autophagosomes with lysosomes and a block of the autophagy process.

The consequential effect of defective autophagy is the accumulation of poly-ubiquitinated proteins normally destined for recycling in the lysosomal compartment; in fact, poli-ubiquitin is a well-known signal for protein degradation. As expected, I detected a massive accumulation of poly-ubiquitinated proteins in MSD not differentiated cells, but also in glia and neurons, by immunofluorescence (Figure 18-A, left panel) and immunoblotting (Figure 18-B, left panel). These results confirm those found in the previous *in vivo* work (Settembre et al. 2008), in which a

massive and progressive accumulation of ubiquitin-positive inclusions were observed in the cerebral cortex as well as in other brain regions of MSD mice.


In addition, I found that p62/SQSTM1, a protein involved in targeting poly-ubiquitinated proteins to the autophagosomes (Pankiv et al. 2007), significantly accumulates in differentiated MSD-NSCs, both glia and neurons (Figure 18-A and B, right panels). The p62/SQSTM1 protein is known to be a common component of ubiquitin-positive protein aggregates in neurodegenerative diseases, being involved in targeting poly-ubiquitinated proteins to the autophagosomes, where they are selectively degraded via the autophagic pathway.





**Figure 17. Differentiating MSD-NSCs display impaired autophagy**

(A) Immunoblotting of LC3-I and -II in wild-type (WT) and MSD undifferentiated cells (ND), glia and neurons (left panel). LC3-II/Bact ratio (right panel). (B) Confocal microscopy image of immunofluorescence detecting LC3 and CatD in WT and MSD-NSCs, undifferentiated and differentiated to glia. Scale bars represent 10  $\mu$ M. Arrows indicate colocalization between autophagosomes (marked with LC3) and lysosomes (marked with CatD), suggesting that in glia-differentiated WT cells autophagosomes properly fuse with lysosomes and, therefore, the autophagy process is working. Such colocalization is not present in glia-differentiated MSD cells, suggesting a block of the autophagy process.



**Figure 18. Differentiating MSD-NSCs display accumulation of poly-ubiquitinated proteins and p62/SQSTM1**

(A) Epifluorescence microscopy image of immunofluorescence detecting poly-ubiquitin (left panel) and p62/SQSTM1 (right panel) in wild-type (WT) and MSD undifferentiated cells (ND), glia and neurons. Scale bars represent 10  $\mu$ M. (B) Immunoblotting of poly-ubiquitin and p62/SQSTM1 in WT and MSD ND cells, glia and neurons.

### **MSD differentiated cells display the tendency to form aggresomes**

It has been demonstrated that when poly-ubiquitinated misfolded proteins cannot be properly cleared, they accumulate into the aggresome (Goldberg 2003; Kawaguchi et al. 2003), an inclusion body localized in the proximity of the microtubule-organizing centre (MTOC) (Iwata et al. 2005; Pandey et al. 2007), where protein aggregates are ensheathed by the intermediate filament protein vimentin (Johnston, Ward, and Kopito 1998). Microtubule-associated histone deacetylase 6 (HDAC6) mediates this process (Matthias, Yoshida, and Khochbin 2008) through its ubiquitin-binding domain (UBA): HDAC6 binds to and facilitates the transport of poly-ubiquitinated misfolded proteins along microtubules to aggresome (Kawaguchi et al. 2003).


In wild type NSCs differentiated to glia we observed a typical cytoskeleton-associated localization of HDAC6, while in glia-differentiated MSD-NSCs we found an increase in the amount of HDAC6 detected by immunoblotting analysis (Figure 19-A, left panel), as well as an altered punctate cytoplasmic staining, occasionally colocalizing with poly-ubiquitinated proteins, as shown by immunofluorescence on wild-type and MSD glia cells (Figure 19-B, upper panel). Immunoblotting analysis showed also a consistent increase in vimentin expression (Figure 19-A, right panel). These observations suggest that, as a consequence of impaired autophagy, the presence of poly-ubiquitinated proteins produce an elevation in the levels of HDAC6, whose role is to target them to the aggresome.

Aggresome clearance is then mediated by ubiquitin-binding proteins like p62/SQSTM1 and neighbor of BRCA1 gene 1 (NBR1) (Kirkin et al. 2009), and in




fact we observed a higher co-localization of p62/SQSTM1 and HDAC6 in glia differentiated MSD-NSCs compared to wild type cells (Figure 19-B, lower panel), suggesting an increased aggresome formation. As an adaptor protein, p62/SQSTM1 is then responsible for misfolded protein degradation through autophagy pathway (Kirkin et al. 2009; Komatsu et al. 2010; Komatsu et al. 2007), which is impaired in MSD pathology. In fact, we did not observed co-localization between poly-ubiquitinated protein aggregates and the autophagy marker LC3, suggesting that the block of the autophagy process observed *in vivo* impairs not only the fusion of lysosomes with autophagosomes, but also the sequestration of toxic protein aggregates within the cytoplasm. In fact, even when we induced autophagy activation through starvation of undifferentiated cells we still did not observe the incorporation of poly-ubiquitinated proteins inside autophagosomes, rather producing as the only effect an increase in the size of aggregates (Figure 20).

As far as we known this is the first time that aggresome has been described in brain-derived cells from mice affected of MSD. Therefore, more experiments are needed to assess the contribution of aggresome formation in MSD pathology, and in particular its role in neurodegeneration.



**Figure 19. Differentiating MSD-NSCs display the tendency to form aggresomes**

(A) Immunoblotting of HDAC6 and vimentin in wild-type (WT) and MSD-glia. (B) Epifluorescence microscopy image of immunofluorescence detecting poly-ubiquitin (upper panel) and p62/SQSTM (lower panel) in WT and MSD cells, glia and neurons. Scale bars represent 10  $\mu$ M.




**Figure 20. Defects in the autophagy pathway impairs toxic protein aggregates sequestration into autophagosomes.**

Epifluorescence microscopy image of immunofluorescence detecting poly-ubiquitin and LC3 in wild-type (WT) and MSD undifferentiated cells (ND). Scale bars represent 10  $\mu$ M. Incorporation of poly-ubiquitinated proteins inside autophagosomes in MSD ND cells was not observed upon starvation-induced autophagy.

## **MSD differentiated cells show increased apoptosis**

To determine whether the accumulation of GAGs, poly-ubiquitinated proteins, p62/SQSTM1 and the block of autophagy are likely to sensitize NSCs to cell death, I analyzed the levels of apoptosis in MSD-NSCs (Figure 21). I tested their viability in the undifferentiated state and also in the two main differentiation programs, glia and neurons. Apoptosis was measured by TUNEL (Terminal deoxynucleotidyl transferase dUTP nick end labeling) assay, a method for detecting DNA fragmentation resulting from apoptotic signaling cascades, by labeling the terminal end of nucleic acids. I observed that in undifferentiated conditions or during the differentiation programs MSD cells suffer an increased level of apoptosis. These findings well correlated with previous *in vivo* data, showing elevated apoptosis in brain cortex of MSD mice. These results suggest that brain progenitor cells from MSD brain are sensitized to apoptosis and, together with the reduced self-renew ability, this might count for the reduced brain size observed in early MSD pups (Settembre et al. 2007). In addition, after differentiation the cells are even more sensitized to apoptosis *in vitro* suggesting that the progression of lysosomal accumulation is even deleterious for post-mitotic NSCs.

In summary, MSD-NSCs represent a confident model to recapitulate *in vitro* the basic features of the disease, and that represent a useful tool to investigate the mechanisms of neurodegeneration.



**Figure 21. MSD-NSCs suffer increased apoptosis**


Tunel assay was performed following the manufacturer's manual (Roche) on NSCs, glia and neurons derived from wild-type (WT) and MSD cells. Data are mean of replicates (n=20) ± SEM; \*p < 0.05, \*\*p < 0.005, \*\*\*p < 0.0005 by Student's t-test.

## **TFEB induces lysosomal biogenesis in NSCs**

Lysosomal biogenesis and function are transcriptionally regulated by TFEB (Sardiello et al. 2009). Moreover, TFEB overexpression not only increases the number of lysosomes in the cell, but it is also able to improve the degradative capability of the cell, as showed by the reduction of accumulated expanded huntingtin in a neuronal cell model of HD (Sardiello et al. 2009).

Therefore we questioned whether TFEB could mediate the clearance of accumulated material also in a cellular model of LSD. In particular, we investigated whether TFEB overexpression could reduce GAG accumulation in MSD-NSCs.

Firstly we observed that TFEB overexpression in NSCs increased lysosomal compartment (Figure 22). We nucleofected wild-type and MSD-NSCs with a bicistronic plasmid expressing TFEB-GFP and performed an immuno-fluorescence against LAMP1, a lysosomal membrane protein, in order to visualize the lysosomal compartment. Cells overexpressing TFEB always showed an increased LAMP1 compared to non-transfected cells in their proximity, with a slightly enhanced signal in MSD cells.



**Figure 22. TFEB overexpression increases lysosomal compartment in NSCs**

Epifluorescence microscopy image of immunofluorescence of LAMP1 in NSCs transfected with a bicystronic plasmid expressing TFEB-GFP. Cells expressing TFEB were localized by the expression of GFP; non-transfected cells are indicated by asterisks. Scale bars represent 10 μM.

### **TFEB promotes cellular clearance in MSD-NSCs**


We tested whether TFEB-mediated increase of the lysosomal compartment could be exploited to induce cellular clearance in MSD-NSCs (Medina et al. 2011). Specifically, we evaluated the effect of TFEB overexpression on the clearance of GAGs in glia differentiated MSD-NSCs (Figure 23); we nucleofected cells with either a TFEB plasmid or with an empty plasmid and after 24 hours we induced glia differentiation for 48 hours; at the end of the differentiation program, we performed the alcian blue staining to reveal the amount of GAG accumulation within cells. Interestingly, TFEB overexpression resulted in a striking reduction of alcian blue stained GAGs in MSD glial cells (Figure 23-A), suggesting that TFEB is able to modulate cellular clearance also in cells affected by a lysosomal storage disorder.

This result was further confirmed by pulse-and-chase experiments using H<sup>3</sup>-glucosamine to label GAGs (Figure 23-B). Wild-type and MSD-NSCs were nucleofected either with a TFEB plasmid or with an empty plasmid, and after 16 hours, cells were pulsed with H<sup>3</sup>-glucosamine in differentiation medium and chased for 48 hours. Cell extracts obtained were quantified to determine the levels of labeled GAGs. The experiment showed a significant reduction of the levels of labeled GAGs in MSD glial cells overexpressing TFEB.

Finally, EM analysis revealed that TFEB-mediated clearance of GAGs in TFEB-overexpressing MSD cells was associated with both significant reduction of cellular vacuolization and recovery of normal intracellular morphology (Figure 23-C). Glia-differentiated MSD-NSCs were nucleofected with either TFEB or with an empty vector, fixed with glutaraldehyde and processed for standard electron



microscopy. The number of vacuoles per cell was significantly reduced in cells overexpressing TFEB compared to the empty vector, thus confirming the clearing potential of TFEB on pathologic vacuolization, typical of LSD cells and tissues.



**Figure 23. TFEB promotes cellular clearance in MSD-NSCs**

(A) Alcian-blu staining of GAGs of MSD-derived glia cells nucleofected with either an empty vector or TFEB plasmid. (B) Pulse-and-chase incorporation of  $H^3$ -glucosamine of wild-type and MSD-derived glia cells nucleofected with either an empty vector or a TFEB plasmid. (C) Electron Microscopy of MSD-derived glia cells nucleofected with either an empty vector or TFEB plasmid. Scale bars represent 100  $\mu$ M (A) and 10  $\mu$ M (B). Data are mean of replicates ( $n=3$ )  $\pm$  SEM; \* $p < 0.05$  by Student's t-test (B and C)


## TFEB Overexpression Induces Lysosomal Exocytosis

Since TFEB is not able to replace the missing *SUMF1* gene product in MSD NSCs, we postulated that the overexpression of TFEB may be able to induce the activation of lysosomal exocytosis, a secretory pathway that allows lysosomes to empty their content in the extracellular space. As we know, lysosomal exocytosis requires two sequential steps; in the first step lysosomes are recruited to the close proximity of the cell surface in a  $\text{Ca}^{2+}$ -independent manner (Jaiswal, Andrews, and Simon 2002), and in the second step the pool of predocked lysosomes fuse with the PM in a  $\text{Ca}^{2+}$ -dependent manner, thus emptying their content outside the cell (N W Andrews 2000; Jaiswal, Andrews, and Simon 2002; Tucker, Weber, and Chapman 2004).

Hence, a typical hallmark of lysosomal exocytosis is the translocation of lysosomal membrane markers to the PM (Reddy, Caler, and Andrews 2001; Rodríguez et al. 1997; Yogalingam et al. 2008). Therefore we detected LAMP1, a lysosomal membrane marker, using an antibody against its luminal portion, and in conditions of non-permeabilized wild-type NSCs, transfected with either a bicistronic plasmid expressing TFEB-GFP or an empty vector. Interestingly, TFEB overexpression resulted in an increased exposure of the luminal domain of LAMP1 on the PM, thus suggesting an increased translocation of lysosomes to the PM (Figure 24-A).

Consistently, also a quantitative analysis by flow cytometry (FACs) showed an increase of LAMP1 staining on the PM of TFEB-overexpressing wild-type NSCs (Figure 24-B).

Furthermore, a direct consequence of lysosomal exocytosis is the release of lysosomal enzymes into the cell culture medium (Rodríguez et al. 1997). Therefore we analyzed the presence of acid hydrolases in the culture medium of wild-type NSCs transfected with either a bicistronic plasmid expressing TFEB or an empty vector (Figure 24-C). Significantly higher levels of lysosomal hydrolases were detected in the medium of NSCs overexpressing TFEB compared with control cells. However, the increase of lysosomal enzymes in the medium was not associated with an increase in the levels of cytosolic lactate dehydrogenase (LDH) (Figure 24-D), thus excluding that the release of lysosomal enzymes was due to cell damage and that TFEB overexpression is cytotoxic. Together, these data indicate that TFEB induces lysosomal exocytosis (Medina et al. 2011).



**Figure 24. TFEB Overexpression Induces Lysosomal Exocytosis**

(A) Confocal microscopy image of immunofluorescence detecting the luminal portion of LAMP1 (with the antibody LAMP1-1DB4) in non-permeabilized wild type NSCs transfected with either a bicistronic plasmid expressing TFEB-GFP or with an empty vector. TFEB-transfected cells were localized by the expression of GFP; non-transfected cells are indicated by asterisks. (B) Quantitative analysis by flow cytometry of LAMP1 levels on the PM in wild-type NSCs that express either a bicistronic TFEB-GFP plasmid or GFP. Bars represent the fold increase of LAMP1 fluorescence in TFEB-transfected versus GFP-transfected (CTRL) cells. (C) Activities of lysosomal enzymes acid phosphatase,  $\beta$ -galactosidase, and  $\beta$ -hexosaminidase in the culture medium of wild-type NSCs nucleofected with either an empty vector or with a TFEB-expression vector. The figure shows percentages of enzyme activities released compared with total activities. (D) LDH activity was determined following the manufacturer's manual (Abcam) in supernatants of NSCs transfected either with TFEB or with an empty vector. Data are mean of replicates ( $n=4$ )  $\pm$  SEM (B, C and D). \* $p < 0.05$  by Student's  $t$ -test (B and C)

## **TFEB Overexpression Enhances Lysosomal Predocking to the PM and Elevates Intracellular $\text{Ca}^{2+}$**


Induction of lysosomal exocytosis involves the recruitment of lysosomes to the PM (Blott and Griffiths 2002). To clearly demonstrate that TFEB overexpression resulted in an increased motility of lysosomes we took advantage of a HeLa cell line stably expressing TFEB (HeLa CF7) using the immuno-EM approach (Figure 25-A). In HeLa control cells lysosomes were distributed randomly throughout the cells, whilst CF7 cells exhibited numerous lysosomes in the close proximity of the PM, indicating that TFEB overexpression significantly stimulates the recruitment of lysosomes to the PM, a step that is required for lysosomal exocytosis.

Several studies demonstrated that the elevation of  $\text{Ca}^{2+}$  concentrations is required for the fusion of lysosomes with the PM, but not for the previous step of the recruitment of lysosomes to the cell surface (N W Andrews 2000; Jaiswal, Andrews, and Simon 2002; Rodríguez et al. 1997). We also demonstrated that in HeLa control cells the overexpression of TFEB led to an elevation of intracellular  $\text{Ca}^{2+}$  levels (Figure 25-B), consistent with the role of TFEB in the induction of lysosomal exocytosis.

To assess whether the elevation of intracellular  $\text{Ca}^{2+}$  levels was responsible for the activation of lysosomal exocytosis and thus for the clearance of accumulated GAGs, we tested TFEB ability to reduce storage in presence of a  $\text{Ca}^{2+}$  inhibitor (Figure 25-C). Therefore, we nucleofected MSD-NSCs with a TFEB plasmid, we differentiated them to glia and at the same time we treated them with the  $\text{Ca}^{2+}$  chelator, BAPTA-AM, at increasing concentrations; then, after 48 hours,

alcian blue staining of GAGs was performed. We observed an inhibition of GAG clearance after the addition of BAPTA to TFEB overexpressing NSCs, confirming the involvement of  $\text{Ca}^{2+}$  in TFEB-mediated reduction of pathologic storage.

Together, these results indicate that in addition to promoting lysosomal recruitment to the PM, TFEB induces lysosomal exocytosis by enhancing  $\text{Ca}^{2+}$ -mediated fusion of lysosomes with the PM (Medina et al. 2011).



**Figure 25. TFEB enhances PM proximity of lysosomes and Intracellular Ca<sup>2+</sup> Release**

(A) Immuno-Electron Microscopy in control and HeLa CF7. Cells were fixed and labeled with the antibody against LAMP1 and prepared for immuno-EM. LAMP1 detected at a substantial distance from the cell surface are indicated by arrows, while lysosomes that are close to the PM are indicated by arrowheads. The distance between lysosomes and PM was estimated in thin sections and 100 lysosomes were counted for each condition. Scale bars represent 350 nm. (B) Analysis of intracellular Ca<sup>2+</sup> by confocal microscopy of HeLa cells transfected with a bicystronic TFEB-GFP construct. Data are displayed as the percentage of cells with Ca<sup>2+</sup> response compared with the non-transfected cells. (C) Ca<sup>2+</sup> involvement in TFEB-mediated GAG clearance in MSD-NSCs. Alcian blue staining of GAGs was performed on glia-differentiated MSD-NSCs nucleofected with a TFEB. The cells were treated with different concentrations of the Ca<sup>2+</sup> chelator BAPTA-AM for 12 hours.




## **TFEB Releases $\text{Ca}^{2+}$ from Acidic Stores through the Activation of Mucolipin-1**

Although we demonstrated that TFEB overexpression strongly activates lysosomal exocytosis and eventually leads to the clearance of pathologic material, the mechanism of action was still left to clarify.

In a separate study, we demonstrated that among other genes belonging to the network, TFEB regulates the expression of the gene encoding MCOLN1 (Palmieri et al. 2011), a lysosomal non-selective cation channel that is mutated in MLIV, a severe type of LSD (Bargal et al. 2000; Bargal et al. 2002; Bassi et al. 2000). Previous studies reported that lysosomal exocytosis is reduced in MLIV cells (LaPlante et al. 2006) and increased in cells expressing gain-of-function MCOLN1 mutations (X. Dong et al. 2009). These observations made MCOLN1 an appealing candidate to mediate TFEB effects on lysosomal exocytosis, suggesting that MCOLN1, upon a proper cellular stimulation, mediates intralysosomal  $\text{Ca}^{2+}$  release to trigger lysosomal exocytosis.

Therefore, we performed a flow-cytometry  $\text{Ca}^{2+}$  flux assay in NSCs transfected with a control vector, a vector containing a scramble shRNA plus TFEB plasmid, and a vector containing a pool of four fluorescently tagged vectors carrying specific MCOLN1-shRNAs plus TFEB plasmid (Figure 26-A). Levels of  $\text{Ca}^{2+}$  were determined in resting condition and after stimulation with ionomycin (10 micromolar), an ionophore that raises the intracellular level of  $\text{Ca}^{2+}$ . Remarkably, TFEB-mediated increase of intracellular  $\text{Ca}^{2+}$  was blocked in NSCs overexpressing TFEB by transient silencing of MCOLN1 with shRNAs, suggesting a crucial role of

MCOLN1 in TFEB-mediated activation of lysosomal exocytosis. This observation was further confirmed also in HeLa cells stably depleted for MCOLN1 (HeLa shMCOLN1) (Figure 26-B) and in human MLIV fibroblasts (Figure 26-C). In addition, stable depletion of MCOLN1 in HeLa cells also impaired TFEB-mediated fusion of LAMP1 with the PM (Figure 26-D) and secretion of lysosomal enzymes (Figure 26-E).



**Figure 26. TFEB elevates intracellular  $\text{Ca}^{2+}$  levels through the activation of MCOLN1**

(A) Flow-cytometry  $\text{Ca}^{2+}$  flux assay in NSCs transfected with a control vector, a vector containing a scramble shRNA plus TFEB plasmid, and a vector containing a specific shRNA against MCOLN1 plus TFEB plasmid.  $\text{Ca}^{2+}$  was determined in resting condition and after stimulation with ionomycin (10  $\mu\text{M}$ ). (B and C) Analyses of intracellular  $\text{Ca}^{2+}$  by confocal microscopy of (B) HeLa<sup>shMCOLN1</sup> and (C) human MLIV fibroblasts transfected with a bicistronic TFEB-GFP construct. Data are displayed as the percentage of cells with  $\text{Ca}^{2+}$  response compared with non-transfected cells. (D) Flow-cytometry analysis of LAMP1 on the PM of HeLa<sup>shMCOLN1</sup> cells transfected with TFEB. (E) Secretion of lysosomal b-galactosidase in HeLa<sup>shMCOLN1</sup> cells. Secretion efficiency was calculated as the % of enzymatic activity in the medium with respect to the total activity (medium and cellular pellet). Data represent mean of replicates ( $n=5$ )  $\pm$  SEM; \* $p < 0.05$  (A–E). Scale bars represent 10  $\mu\text{m}$  (B) and 25  $\mu\text{m}$  (C).


Furthermore, the lysosomal localization of MCOLN1 and its channel properties suggested that the elevation of intracellular  $\text{Ca}^{2+}$  levels induced by TFEB overexpression was due to the release of  $\text{Ca}^{2+}$  from lysosomal stores through MCOLN1. In fact, we treated cells with the inhibitor of the v-ATPase, Bafilomycin A1, which is responsible for the proton gradient driving lysosomal  $\text{Ca}^{2+}$  uptake (Christensen, Myers, and Swanson 2002), and therefore induces acidic  $\text{Ca}^{2+}$  release. The result clearly showed that both TFEB and MCOLN1 overexpressing HeLa cells were less sensitive to Bafilomycin A1-dependent depletion of lysosomal  $\text{Ca}^{2+}$  compared to HeLa control cells (Figure 27-A). This suggests that in a condition of induced lysosomal exocytosis, acidic stores of  $\text{Ca}^{2+}$  are actively being used to induce the fusion of lysosomes with PM and Bafilomycin A1 effect is less prominent if compared to control cells.

Moreover, we tested TFEB-mediated clearance of accumulated material in human MLIV fibroblast; cells were transfected with either TFEB-FLAG or with an empty vector and analyzed by confocal microscopy. TFEB overexpression did not reduce lipofuscin accumulation in human MLIV fibroblasts (Figure 27-B), thus confirming the importance of MCOLN1 function in TFEB-mediated clearance of lysosomal storage.

Together these data strongly suggest that MCOLN1-dependent release of  $\text{Ca}^{2+}$  from acidic  $\text{Ca}^{2+}$  stores plays a major role in TFEB-mediated lysosomal exocytosis (Medina et al. 2011).

At this point, we questioned whether MCOLN1 overexpression could mediate activation of lysosomal exocytosis, with no participation of TFEB. Thus, to assess whether MCOLN1 on its own was able to reduce GAG accumulation as well as

TFEB, we performed Alcian blu staining on glia-differentiated MSD-NSCs infected with either a lentiviral vector carrying TFEB or an adenoviral vector encoding MCOLN1. We observed reduced GAG accumulation in cells overexpressing MCOLN1, but to a lesser extent compared with TFEB, suggesting that  $\text{Ca}^{2+}$  elevation is required but not sufficient to mediate TFEB effects on lysosomal exocytosis. In fact, MCOLN1 overexpression only partially reduced GAG pathologic storage.




**Figure 27. MCOLN1 plays a central role in TFEB-mediated activation of lysosomal exocytosis**

(A)  $\text{Ca}^{2+}$  levels were measured by loading cells with the ratiometric fluorescent dye FuraRed. After 1.5 min of confocal time-lapse acquisition, cells were treated with 1  $\mu\text{M}$  Bafilomycin A1 to induce the release of  $\text{Ca}^{2+}$  from the acidic compartment. Data represent the  $F_{458}/F_{488}$  ratio of each experimental group compared with their basal ratio before stimulation ( $F/F_0 \times 100$ ). (B) Human MLIV disease fibroblasts were transfected with either TFEB-FLAG or with an empty vector and analyzed by confocal microscopy. (C) Alcian blue staining of GAGs in glia-differentiated MSD-NSCs infected with either a lentiviral vector carrying TFEB or an adenoviral vector encoding MCOLN1.

To further confirm that the clearance is effectively mediated by exocytosis, we measured the secretion efficiency of GAGs in the culture medium of MSD-NSCs overexpressing TFEB (Figure 28-A). Cells were nucleofected with either TFEB or an empty vector after pulse-chase incorporation of  $H^3$ -glucosamine and then radioactive GAGs were measured in the culture medium. When MSD-NSCs were overexpressing TFEB, we observed an increase in GAG secretion in the cell culture medium, thus confirming that clearance is mediated by exocytosis.

We then extended these studies to other types of LSDs associated with the storage of different types of lysosomal substrates, like Neuronal Ceroid Lipofuscinosls type 3 (CLN3 or Batten disease), and glycogenosis type II (or Pompe disease), characterized by the accumulation of lipofuscin and glycogen, respectively (Beratis, LaBadie, and Hirschhorn 1978; Persaud-Sawin et al. 2007). We found that TFEB overexpression strongly reduced lipofuscin autofluorescence in cells from a murine model of NCL3, and also in fibroblasts from a patient affected by glycogenosis type II, Pompe disease (Figure 28-B). These data indicate that induction of lysosomal exocytosis promotes cellular clearance in diseases due to accumulation of different types of lysosomal substrates. Notably, all diseases tested (i.e., MSD, Batten, and NCL) are due to deficiency of proteins whose activity is involved in crucial steps of different catabolic pathways. In addition, the cells analyzed were derived from patients and murine models carrying either null mutations or mutations that severely inactivate protein function. Therefore, it is unlikely that clearance of lysosomal substrates is due to either the enhancement of the activity of the defective enzymes, or to an overall induction of lysosomal catabolic processes, suggesting that clearance is mediated by exocytosis.



**Figure 28. TFEB clearance is mediated by exocytosis and is tested in Batten and Pompe diseases' cellular model.**

(A) Secretion efficiency of radioactive GAGs measured in the culture medium of MSD-NSCs nucleofected with either TFEB or an empty vector after pulse-chase incorporation of  $H^3$ -glucosamine. Data represent mean  $\pm$  SEM; \* $p < 0.05$  (B and C). (B) TFEB promotes clearance of lipofuscin in fibroblasts from a patient with Batten disease (upper panel) and of the fluorescent sugar 2-NBDG in human Pompe disease fibroblasts (lower panel). Cells were transfected with a vector carrying TFEB-Ruby (continuous red staining). After 24 hr, cells were examined by live imaging confocal analysis. Cells with increased TFEB (i.e., cells with red signal in the picture and outlined by dashed white lines in the middle panel) display highly reduced levels of lipofuscin or 2-NBDG (punctate green signal) and a normal cellular morphology compared with non-transfected cells (i.e., cells with intense green staining).




## TFEB induces storage clearance in a mouse model of MSD

Finally, we tested whether *in vivo* overexpression of TFEB in the mouse model of MSD had similar effects on cellular clearance (Figure 29). To this end, we injected systemically into adult MSD mice an adeno-associated virus type 2/9 (AAV2/9) that carries TFEB-3xflag or GFP, both under control of the cytomegalovirus (CMV) promoter. One month after injection, several tissues were collected to monitor transduction efficiency and GAG storage; AAV-mediated TFEB delivery was detected using a specific anti-flag antibody and resulted in efficient TFEB transduction (Figure 29-A, left panel). In both liver and skeletal muscles we observed a significant reduction of GAG amount, as detected by alcian blue staining and GAG quantification (Figure 29-A, right panel, and B).


Subsequently, we investigated whether TFEB-mediated clearance of GAGs resulted in the reduction of the pathologic hallmarks of MSD, such as macrophage infiltration and apoptosis (Settembre et al. 2007) (Figure 30). We found a striking reduction of CD68-positive cells in the liver of AAV-TFEB injected MSD mice compared with MSD non-injected littermates (Figure 30-A). Most importantly, we also observed a significant reduction of apoptotic cells in liver of 4-month-old MSD mice injected with an AAV2/9-CMV-TFEB3xflag viral vector (Figure 30-B); we counted the number of TUNEL-positive cells and compared it with age matched MSD non-injected mice.

These results indicate that TFEB activation of lysosomal exocytosis reduces both primary accumulation of GAGs and secondary pathological processes associated with LSDs, such as inflammation and cell death (Medina et al. 2011).



**Figure 29. TFEB overexpression reduces GAG storage in a mouse model of MSD**

(A) Representative immunofluorescence of liver and muscle sections infected with AAV-TFEB-FLAG (left panel) and alcian blue staining of GAG content in skeletal muscle and liver from mice injected systemically with either an AAV2/9-CMV-GFP or with an AAV2/9-CMV-TFEB3xflag viral vector (right panel). (B) Quantitative analysis of GAG content in liver (left panel) and skeletal muscle (right panel) of MSD mice injected with either an AAV2/9-CMV-GFP or with an AAV2/9-CMVTFEB3xflag viral vector. GAG content was displayed as mg of GAGs/mg of tissue extract. At least four mice per group were analyzed for each tissue examined (\* $p < 0.05$ ). Data are mean of replicates ( $n=5$ )  $\pm$  SEM; \* $p < 0.05$ .



**Figure 30. TFEB overexpression reduces tissue pathology in a mouse model of MSD**

(A) TFEB reduces inflammation in the liver of MSD mice. Macrophages and macrophage-related inflammatory cells were detected in liver sections from mice injected systemically with either an AAV2/9-CMV-GFP or with an AAV2/9-CMV-TFEB3xflag viral vector by immunofluorescence analysis using an antibody against CD68. (B) Reduction of TUNEL-positive cells (arrows) in 4-month-old MSD mice injected with an AAV2/9-CMV-TFEB3xflag viral vector compared with age-matched MSD non-injected mice. At least four mice per group were analyzed for each tissue examined). Data are mean of replicates ( $n=5$ )  $\pm$  SEM; \* $p < 0.05$  (B and D). Scale bars represent 100  $\mu$ m (A, C, and D).

## **DISCUSSION**

### **NSCs recapitulate the main hallmarks of MSD pathology**

Most of the LSDs present neurological involvement, but yet little is known about the mechanism of neurodegeneration. Intracellular accumulation of undegraded compounds are the primary effect observed in patients as well as in animal models, but whether they are the direct cause of cell death it is not clear; most likely the primary accumulation of undegraded substrates triggers secondary pathologic cascades, such as impaired autophagy, which in turn contributes together with global lysosomal dysfunction to neurodegeneration.

Post-mitotic neurons do not replicate in adult life and have a highly developed lysosomal network for membrane recycling: lysosomes are trafficked in axonal fibres using molecular motors to ensure that, as the cytoplasm extends to the far reaches and ramifications of the axon, distribution of the organelle is maintained (Tsukita and Ishikawa 1980). For this reason, the well-being of the lysosomal compartment has a particularly high relevance in post-mitotic neurons, and any perturbation of its proper function can cause neurological deficits, with or without cell death. In fact, in lysosomal diseases, electron microscopy of neurons, as well as other cell types, shows formation of vacuoles and lysosomes distended by recognizable cellular cargo (Walkley et al. 2010). Thus, it does not surprise that two-thirds of lysosomal diseases have potentially devastating consequences in the nervous system, and therefore future therapeutic research will require an

integrative understanding of the unitary steps in their neuronal pathogenesis.

Multiple Sulfatase Deficiency is a neurodegenerative lysosomal disease caused by the deficiency of a non-lysosomal protein; in fact, SUMF1 resides in the ER, where it is responsible for the post-translational activation of a whole family of enzymes, sulfatases. Patients suffering from MSD combine clinical symptoms of the different single sulfatase defects, with a severe impairment of neurological abilities. Sumf1 <sup>-/-</sup> mice recapitulate all the features of the disease observed in MSD patients, obviously including neurodegenerative aspects. The Sumf1 <sup>-/-</sup> mouse model not only allows a systematic study of the pathophysiology of MSD; importantly, it also provides a model to test therapeutic approaches to the treatment of MSD, similar to other mouse models of individual LSDs.

These observations prompted us to develop a reliable system to generate a neural cellular model from MSD mice, in order to investigate the signaling pathways involved in the neuronal pathology and eventually develop novel therapeutic strategies.

Furthermore, MSD mice are asymptomatic immediately after birth, but soon after they display congenital growth retardation and frequent mortality in the first weeks of life (Settembre et al. 2007). This observation suggested that early stages after birth are crucial for MSD pathology development, especially from the aspect of the neurological dysfunction, but that deeper investigation was needed.

Therefore, I isolated NSCs from neo-natal (P0) brain of wild-type and MSD mice, establishing a robust protocol that allows not only for the isolation, but also for the continuous *in vitro* expansion of NSCs, resembling and preserving all the morphological and molecular features of *in vivo* neuronal progenitors.

As a first observation, MSD-NSCs display similar properties of their wild-type counterpart, suggesting that, with SUMF1 lack of function, progenitor cells maintain their radial glia identity, although they seem to have a progressive reduction of self-renew.

It has been shown that Hematopoietic Stem Cells (HSCs) isolated from MSD mice are characterized by an altered extracellular signaling of FGF and Wnt pathways (Buono et al. 2010). Self-renewal and differentiation of HSCs are balanced by the concerted activities of FGF, Wnt, and Notch pathways; Sulf1 and Sulf2 are two non-lysosomal sulfatases, which are activated by SUMF1 post-translational modification and localize at the cell surface, where they mediate the remodeling of heparan sulfate proteoglycans (HSPGs). It has been demonstrated that Wnt controls tissue-specific cell fate decisions during embryogenesis, binding to the heparan sulfate moieties of HSPGs on the cell surface (Logan and Nusse 2004; Bejsovec 2005). Sulf enzymes remove the sulfate from heparan sulfate, and releases Wnt from HSPGs. This released Wnt associates with Frizzled (Fz) and LRP5/6 receptors, resulting in inactivation of a multiprotein destruction complex, which in turn leads to the translocation of  $\beta$ -catenin into the nucleus, where it activates several target genes (Hoppler and Kavanagh 2007).  $\beta$ -catenin translocation in the cell nucleus has been shown to enhance self-renewal and maintain totipotency of ESCs and multipotency of HSCs (Reya et al. 2003; Suh et al. 2007). Thus, the impairment in the activities of Sulf1 and Sulf2 in SUMF1 deficient cells may alter the action of important extracellular signals by modifying the sulfation state of the heparan sulfates contained in HSPGs. In fact, crystal structure studies have demonstrated that binding of FGF1 and FGF2 to the FGF

receptor is stabilized by sulfation of the heparan sulfates of the HSPGs (Pellegrini et al. 2000). It is also known that FGF signaling controls proliferation and subsequent lineage commitment of neural stem cells through a concerted action with  $\beta$ -catenin (Israsena et al. 2004).

Therefore, the self-renew impairment of MSD-NSCs observed in neurosphere assay may be ascribed to an alteration in the local concentration of important mitogenic factors bound to the HSPGs. Conversely, I did not observe any major block in the differentiation of MSD-NSCs, as glia and neurons expressed typical glia and neuronal markers, respectively, and they both did not show expression of the progenitor marker, as well as neurons outgrow neurites and were electrophysiologically active; nevertheless, more detailed and specific experiments are needed, in order to better quantify the extent of the differentiated cell population.

Isolated NSCs have the potency to generate the two main cell types of the CNS, glia and neurons, thus providing an *in vitro* model that can easily resemble all the main features of the developing brain. In fact, I did not observe defects in the differentiation of NSCs to the two main cell types of the brain, glia and neurons. However, the protocols I followed is one of the most accepted in order to visualize differentiation capacities in a grossly manner (Conti et al., 2005), but does not allow for a more specific analysis of diverse sub-populations actually present. In fact, NSCs can give rise also to oligodendrocytes, as well as different types of neurons; therefore, more detailed investigation on this aspect is needed, in order to evaluate whether the lack of SUMF1 can interfere with one or more of these cellular fate.

Furthermore, cellular differentiation is a progressive and committed process,

in which a single defect becomes usually amplified and triggers a cascade of subsequent intracellular malfunctions, eventually leading to a severe neurodegeneration. The more the cells proceed in the developmental progression, the more restricted they become in their differentiation potential, losing their self-renewal ability.

Altered autophagy is a hallmark of various LSDs, such as MSD and MPSIIIA (Settembre et al. 2008). As a degradative process, autophagy is responsible for constitutive protein turnover, a crucial function in neuronal cells and thus relevant to neurodegenerative diseases (Reggiori and Klionsky 2002). In agreement with *in vivo* data, we observed an increase of LC3-II levels in cellular extracts from differentiated MSD-NSCs, and accumulation of p62/SQSTM1 and poly-ubiquitinated proteins, both common components of protein aggregates in neurodegenerative diseases (Bjørkøy, Lamark, and Johansen 2006). We found that the accumulation of GAGs, poly-ubiquitinated proteins, and p62/SQSTM1 are likely to be associated with cell death. In fact, we observed that MSD-NSCs were more sensitive to apoptosis compared with wild-type cells, and in particular during the differentiation toward glial or neural cells. These findings correlate with the recent observation that defect in the recycling of dysfunctional mitochondria, through autophagy, could be involved in CNS neurodegeneration in MSD mouse model (de Pablo-Latorre et al. 2012).

Furthermore, I found a possible interesting correlation between impaired autophagy and aggresome formation and, although very preliminary, my data can suggest that, through this mechanism, the cell is protecting itself from toxic accumulation of proteins. Accumulation of misfolded proteins, indeed, is a



prominent pathological feature common to many neurodegenerative diseases, including Parkinson's disease (PD), Alzheimer's disease (AD), HD, Amyotrophic Lateral Sclerosis (ALS) and many others; protein quality control is particularly important to neuronal homeostasis and normal function because neurons are post-mitotic and unable to dilute cytotoxic misfolded proteins through cell division (Ross and Poirier 2004). Genetic mutations or environmental insults can induce many different proteins to misfold and aggregate, suggesting that a common pathological mechanism may link clinically distinct neurodegenerative diseases (Bucciantini et al. 2002; Kaye et al. 2003; Fändrich, Fletcher, and Dobson 2001; Glabe 2004). Interestingly, MSD and MPSIIIA cells present increased accumulation of overexpressed mutant forms of huntingtin and  $\alpha$ -synuclein compared with wild-type counterparts, suggesting that protein aggregation may be activated in these diseases due to impaired autophagy (Settembre et al, 2008). In addition, recent findings demonstrate that certain regions of the brain of MPSIIIB mice show accumulation of hyperphosphorylated tau (Ptau) (Ohmi et al., 2009) and beta amyloid aggregations (Ohmi et al., 2011), both reminiscent of Alzheimer's disease, suggesting that LSDs are likely to produce toxic protein aggregates, as well as other more known neurodegenerative diseases. Therefore, in order to clarify the aspect of protein aggregation in MSD pathology, a future challenge will be to detect endogenous toxic proteins, such as huntingtin and  $\alpha$ -synuclein, and follow their accumulation in post-mitotic cells.

In cultured cell, when the production of misfolded proteins exceeds the capacity of the ubiquitin-proteasome degradation pathway, misfolded proteins are actively transported to the aggresome. Aggresome formation is recognized as a

cytoprotective response serving to sequester potentially toxic misfolded proteins and facilitate their clearance by autophagy (Fortun et al. 2003; Taylor et al. 2003; Iwata et al. 2005; Ravikumar, Duden, and Rubinsztein 2002). However, the deficit in autophagosome fusion with lysosome observed both *in vivo* and *in vitro* in MSD pathology can neutralize this cellular protective response, eventually worsening cellular viability.

### **TFEB-mediated activation of lysosomal exocytosis promotes the clearance of undegraded substrates**

Establishing an *in vitro* system that was able to recapitulate all the main features of MSD prompted us to take advantage of the usefulness of this tool to explore possible therapeutic approaches, in the direction of reverting the pathologic phenotype. Towards this goal, we took advantage of the studies previously carried out in our laboratory on the bHLH transcription factor EB (TFEB) that was shown to coordinate lysosomal biogenesis, autophagy and also clearance in a neuronal model of HD (Sardiello et al. 2009; Settembre et al. 2011). Therefore we questioned whether TFEB-mediated increase of the lysosomal compartment could be exploited to induce the clearance of accumulated GAGs also in a neuronal cellular model of MSD.

Interestingly, TFEB overexpression resulted in a striking reduction of stored GAGs in MSD glial cells, as well as it induced recovery of normal intracellular morphology.


We also demonstrated that TFEB-mediated clearance of undegraded material

is actually due to the activation of one of his target genes, the cation-channel MCOLN1, which is then responsible for the promotion of lysosomal exocytosis; in fact, MCOLN1 triggers the intracellular  $\text{Ca}^{2+}$  elevation, required to induce lysosomes to move to the proximity of the PM; once there, they expel their content in the extracellular space, thus mitigating the intracellular burden (Figure 31).

Finally, we confirmed the importance of our result, showing that TFEB delivery rescues tissue pathology in a mouse model of MSD; one month after TFEB systemic injection, we observed a significant reduction of GAG storage in crucial organs, such as liver and muscles. Interestingly, also macrophage infiltration and apoptosis were strongly reduced, thus indicating that TFEB action ameliorates not only primary defects, such as the accumulation of undegraded material, but also those secondary defects, such as inflammation and cell death, that are the main pathologic features of MSD. Future studies overexpressing TFEB in the brain of MSD mice will allow us to further confirm the benefits of modulating lysosomal function in order to reduce pathologic lysosomal accumulation in the CNS.

Our data indicate that lysosomal exocytosis can be exploited to promote cellular clearance in lysosomal storage diseases, suggesting an alternative strategy to treat disorders due to intracellular storage, such as LSDs and other more common neurodegenerative diseases. Several approaches, such as gene delivery, pharmacological induction of TFEB, and target gene activation, could be exploited to promote cellular clearance in target tissues. These strategies will have to be tested by long-term *in vivo* studies in animal models to verify the therapeutic potential of this discovery.

As future investigation, it is particularly relevant that NSCs can be the perfect tool for drug screening, in order to find compounds able to induce cellular clearance, either in a TFEB-dependent or -independent way. As a second step, a very interesting goal will be to find genetic modulators of TFEB, whose expression can be modulated in order to achieve the clearance of undegraded substrates in LSDs. Toward this goal, I plan to use the very powerful and rapid genetic system of the fruit fly, *Drosophila Melanogaster*. Once generated all the fly models of LSDs, they can be used to validate *in vivo* drug targets that have been found to activate TFEB expression in a high-throughput cell screening. Furthermore, I can also conduct unbiased genetic screens on the whole fly genome to find genes that modify the phenotype of the diseases. This can enable us to uncover molecular pathways that are involved in the progression of LSDs. The screen may underlie interesting differences amongst them, but since several disorders share common features, it is very likely that the genetic screens will reveal common modifiers.



**Figure 31. Schematic representation of TFEB mechanism of action.**

*TFEB overexpression activates the network of lysosomal genes, including MCOLN1, which in turn promotes lysosomal exocytosis, reducing the storage of undegraded substrates.*

## **MATERIALS AND METHODS**

### **Isolation of NSCs and cell culture conditions**

Neural tissue dissociation and positive selection of NSCs was achieved as described in results and following the manufacturer's manual (Miltenyi Biotec, Cologne, Germany).

Isolated neurospheres were propagated in culture at clonal density on uncoated plates (Nunc, Waltham, Massachusetts, USA) in ESGRO medium (Chemicon, Temecula, California, USA) containing 20 ng/mL EGF and 10 ng/mL FGF2 (Peprotech, Rocky Hill, New Jersey, USA) and with penicillin/streptomycin (NSC expansion medium). Over 3–5 days, cells formed aggregates that, after harvesting and sedimentation to remove debris, subsequently attached to fresh plastic and outgrew NS cells.

For derivation from established neurospheres, NSC monolayer cultures was achieved by dissociating to single cells using Accutase (Sigma, St. Louis, Missouri, USA) and plating at  $10^4$  cells/ml on poly-ornithine (Sigma, St. Louis, Missouri, USA)/laminin (Invitrogen, Carlsbad, California, USA) coated culture plates in NSC expansion medium. For passaging established NSC lines, it was routinely used accutase (Sigma), cells were collected in phosphate-buffered saline (PBS) and split 1:3 to 1:5 every 2–3 days. The entire isolation protocol was carried out for three wild type and three Sumf1  $-/-$  mice.

### **Flow cytometry analysis of nestin**

NSCs were detached and dissociated with Accutase (Sigma, St. Louis, Missouri, USA), washed in PBS and triturated to a single cell suspension in PFN (15% PBS, 2% FCS, 0.1% sodium azide). Cells were distributed into 96-well U-bottomed microtiter plates (Nunc), fixed in 2% PFA (Sigma, St. Louis, Missouri, USA) for 20 minutes on ice, washed in PBS and incubated in PBS 0.5% saponin for 20 minutes on ice. After three washes in PBS 0.1% saponin, cells were incubated for 30 minutes on ice with a mouse anti-nestin primary antibody (Covance, Berkeley, California, USA) diluted 1:200 in PBS containing 0.1% saponin. After a further three washes, the cells were incubated for 30 minutes with a FITC-anti-mouse IgG diluted 1:200 in PBS 0.1% saponin. The cells were then washed in PBS 0.1% saponin and resuspended in PFN prior to Fluorescence-Activated Cell Sorting (FACS) analysis.

### **RT-PCR analysis**

Total RNA was extracted from NSCs using RNeasy kit (Qiagen, Valencia, California, USA), and cDNA was generated using Superscript II (Invitrogen, Carlsbad, California, USA). Polymerase Chain Reaction (PCR) was performed for 30 cycles for all markers except B-actin (25 cycles). The primers used were as follows:  $\beta$ -actin (forward) 5'-GGCCCAGAGCAAGAGAGGTATCC-3' and (reverse) 5'-ACGCACGATTTCCCTCTCAGC-3'; oct4 (forward) 5'-GGCGTTCTCTTTGGAAAGGTGTTC-3' and (reverse) 5'-

CTCGAACCACATCCTTCTCT-3';	nanog	(forward)	5'-
ATGAAGTGCAAGCGGTGGCAGAAA-3'	and	(reverse)	5'-
CCTGGTGGAGTCACAGAGTAGTTC-3';	pax6	(forward)	5'-
GCTTCATCCGAGTCTTCTCCGTTAG-3'	and	(reverse)	5'-
CCATCTTTGCTTGGGAAATCCG-3';	BLBP	(forward)	5'-
GGGTAAGACCCGAGTTCCTC-3' and (reverse) 5'-ATCACCACCTTTGCCACCTTC-			
3'; sox2 (forward) 5'-GGCGGCAACCAGAAGAACAG-3' and (reverse) 5'-			
GCTTGGCCTGCGTCGATGAAC-3';	olig2	(forward)	5'-
GGCGGTGGCTTCAAGTCATC-3'	and	(reverse)	5'-
TAGTTTCGCGCCAGCAGCAG-3';	mash1	(forward)	5'-
CTCGTCCTCTCCGGAAGTATG-3'	and	(reverse)	5'-
CGACAGGACGCCGCGCTGAAAG-3';	dlx2	(forward)	5'-
AACCACGCACCATCTACTCC-3' and (reverse) 5'-CCGCTTTTCCACATCTTCTT-			
3'; nf-1 (forward) 5'-GGATTTCGCACAGCCTTCTC-3' and (reverse) 5'-			
CCCTTCCTCTTCCAGCTTCT-3'.			

### Neurosphere assay

Cells were plated at 10 cells/ $\mu$ L in 24-well (0.5 mL/well) uncoated plates (Nunc) in NSC expansion medium. The total number of spheres that formed in each well was counted after 7 days; the process was repeated similarly to generate secondary and tertiary neurospheres, after 15 and 21 days, respectively. Only colonies with a diameter > 100  $\mu$ m were counted as spheres.



## **Cell Differentiation**

For glia differentiation, NSCs were plated onto 24-well gelatine coated plates at  $10^5$  cells/well in ESGRO medium supplemented with 1% fetal bovine serum (FBS) (Hyclone, Logan, Utah, USA) and without any supplemented growth factor (glia differentiation medium); rapid differentiation of NSC to GFAP positive glia occurs within 2 days.

For neural differentiation, NSCs were plated onto 24-well poly-ornithine/laminin coated plates in ESGRO medium (Chemicon, Temecula, California, USA) 0.5% B27 (GIBCO, San Diego, California, USA) and with 10 ng/mL FGF2 (Peprotech, Rocky Hill, New Jersey, USA); a half volume of medium is replaced every 2-3 days to maintain conditioning of medium. After 7 days in these conditions, the media was switched to ESGRO medium (Chemicon, Temecula, California, USA) 0.5% B27 (GIBCO, San Diego, California, USA), without any growth factor. Half of the medium was exchanged every 2–3 days during the differentiation.

## **Immunofluorescence**

To detect expression of intracellular markers, cells were plated on coated coverslips and fixed in PBS pH 7.4, 4% paraformaldehyde (PFA) (Sigma, St. Louis, Missouri, USA) for 20 minutes, quenched with 50 mM  $\text{NH}_4\text{Cl}$  for 15 minutes. Cells were incubated per 20 minutes in FBS (Hyclone, Logan, Utah, USA) with 0.2% Triton X-100 to block nonspecific binding and permeabilize membranes, and

stained over-night with primary antibodies and for 2 hours with appropriate Alexa-594 and Alexa-488 conjugated secondary antibodies. Coverslips were mounted on glass slides in Vectashield with DAPI (Vector Laboratories, California, USA) to nuclear counterstaining and viewed on an epi-fluorescent or on a Zeiss LSM 510 META confocal microscope (LSM510; Carl Zeiss, Thornwood, New York, USA) equipped with a Plan-Neofluar 63x immersion objective (Carl Zeiss, Inc.). Mice tissues were collected after PBS perfusion and fixed with 4% PFA (Sigma, St. Louis, Missouri, USA) for 12 h at 4°C and then subjected to a sucrose gradient (from 10 to 30%) and incubated over night in 30% sucrose at 4°C, before OCT embedding. Immunofluorescence analyses were performed on 10-mm-thick serial cryosections. The specimens were incubated for 1 hour with blocking solution (PBS, 0.2% Tween-20) and 10% goat normal serum (Sigma) before incubation over-night with the specific primary antibody. After washing, sections were incubated for 40 min with secondary antibody. Stained sections were mounted with Vectashield with DAPI (Vector Laboratories, California, USA). Primary antibodies were used at the following dilutions: mouse anti-Nestin (1:400) (Covance, Berkeley, California, USA); mouse anti-GFAP (1:300) (Sigma, St. Louis, Missouri, USA); mouse anti-Tuj1 (1:200) (Covance, Berkeley, California, USA); rabbit anti-LC3 (1:200) (Novus Biological, Colorado, USA); mouse anti-CathD (1:500) (Sigma, St. Louis, Missouri, USA); rabbit anti-ubiquitin (1:100) (DakoCytomation, Carpinteria, California, USA); mouse anti-p62/SQSTM1 (1:200) (BD Biosciences, Franklin Lakes, New Jersey, USA); rabbit anti-HDAC6 (1:300) (Abcam, Cambridge, Massachusetts, USA); mouse anti-LAMP1 (1:500) (Sigma, St. Louis, Missouri, USA); rabbit anti-CD68 (1:250) (Serotech, Ontario, Canada) and mouse anti-flag

(1:200) (Sigma, St. Louis, Missouri, USA). Secondary antibodies were: goat anti-rabbit (1:3000) and donkey anti-mouse (1:5000) conjugated to Alexa Fluor 488 or 594 (Molecular Probes, Eugene, Oregon, USA).

### **Immunoblotting**

Cells were lysed in cold lysis buffer (20 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1% TritonX-100) in the presence of protease inhibitors (Roche Diagnostics, Indianapolis, Indiana, USA) for 30 minutes on ice. Proteins were quantified by the Bradford method. 10-20 ug of protein samples were separated on SDS-PAGE acrylamide gel and transferred onto nitrocellulose membrane (Amersham Pharmacia Biotech, Uppsala, Sweden). Primary and HRP-conjugated secondary antibodies were diluted in 5% milk TBS-T. Bands were visualized using the ECL detection reagent (Pierce, Rockford, Illinois, USA) and normalized against actin. Antibodies were used as follows: mouse anti-GFAP (1:300) (Sigma, St. Louis, Missouri, USA); mouse anti-Tuj1 (1:200) (Covance, Berkeley, California, USA); rabbit anti-LC3 (1:200) (Novus Biological, Colorado, USA); rabbit anti-ubiquitin (1:100) (DakoCytomation, Carpinteria, California, USA); mouse anti-p62/SQSTM1 (1:200) (BD Biosciences, Franklin Lakes, New Jersey, USA); rabbit anti-HDAC6 (1:300) (Abcam, Cambridge, Massachusetts, USA); mouse anti-vimentin (1:300) (Santa Cruz Biotechnology, Santa Cruz, California, USA); and rabbit anti-Bactin (1:10000) (Sigma, St. Louis, Missouri, USA). HRP-conjugated secondary antibodies were: rabbit anti-mouse (1:3000) and mouse anti-rabbit (1:3000) (Amersham, Uppsala, Sweden).

## **Neurite Outgrowth Assay**

Neurite assay was performed following the manufacturer's manual (Millipore). Differentiating neurons were placed in Millicell 12-well inserts containing neural differentiation medium at a concentration of 100,000 cells/100  $\mu$ L ( $1 \times 10^6$  cells/mL). Plates were incubated at 37°C for 3 and 7 days. Following the neurite extension period, each insert was removed from the culture well, washed with PBS and fixed in cold methanol for 20 minutes at room temperature. Then the insert was stained for 15-30 minutes with Neurite Stain Solution, washed with PBS and then cell bodies were gently swabbed from top of insert. Neurite Stain Extraction Buffer was added to the top of each swabbed inserts and incubate for 5 minutes at room temperature. Inserts were spinned and then read at an absorbance of 590 nm.

## **Electrophysiology and patch clamp recording**

Recordings were made from NSC-derived neurons, differentiated between passages 20-25. Seals between electrodes and cells were established in a bath solution consisting of (in mmoles/l): 138 NaCl, 2 CaCl<sub>2</sub>, 5.4 KCl, 1 MgCl<sub>2</sub>, 10 glucose and 10 HEPES, pH 7.4 with NaOH; the pipette (intracellular) solution contained (in millimolar): 140 KCl, 2 MgCl<sub>2</sub>, 10 EGTA, 10 HEPES, 5 Mg-ATP, pH 7.3–7.4 with KOH. The pCLAMP software (version 10.0.2) was used for data acquisition and analysis.

Ionic currents were recorded under voltage-clamp conditions using the patch-clamp whole-cell configuration at room temperature (20-24°C) with an Axopatch

200B patch-clamp amplifier (Axon Instruments, Burlingame, California, USA). For ionic currents recording the following protocol was applied: from an holding potential of -90 mV, a short (50 ms) pulse to -100 mV followed by a series of progressively increasing depolarizations (from -100 mV to +40 mV) of 50 ms duration, before a final 50 ms step to -100 mV was applied. Data were filtered at 5 kHz and sampled at 50 kHz. Capacitance currents were compensated by analog circuitry and subtracted on-line by using a p/-4 protocol from a subtracting holding potential of -100 mV.

### **Electron Microscopy (EM) and immuno-gold analysis**

Cells were washed with PBS and fixed at room temperature in 0.05% glutaraldehyde (Polysciences, Warrington, Pennsylvania, USA) dissolved in 0.2 M Hepes buffer (pH 7.4) for 30 minutes at room temperature. Then, cells were scraped off the dish, pelleted by centrifugation and postfixed for 2 hours in 1% OsO<sub>4</sub> (Polysciences, Warrington, Pennsylvania, USA) in the same buffer. After en-bloc staining with 1% uranyl acetate for 1 hour and ethanol dehydration, cells were embedded in Epon-812 (Fluka, Ronkonkoma, New York, USA) and polymerized at 60°C for 72 hours. Thin sections were cut at the Leica EM UC6 and counterstained with uranyl acetate and lead citrate. Images were acquired from thin sections using a Philips Tecnai-12 electron microscope equipped with an ULTRA VIEW CCD digital camera (Philips, Eindhoven, Netherlands).

For immuno-gold HeLa and CF7 cells were fixed with a mixture of 4% paraformaldehyde and 0.05% glutaraldehyde, labeled with a monoclonal antibody

against LAMP1 according the gold-enhance protocol, embedded in Epon-812, and cut as described previously (Polishchuk et al. 2003). EM images were acquired from thin sections using a Philips Tecnai-12 electron microscope equipped with an ULTRA VIEW CCD digital camera (Philips, Eindhoven, Netherlands). Quantification of vacuolization was performed using the AnalySIS software (Soft Imaging Systems GmbH, Muenster, Germany). Evaluation of lysosome distance from the PM was done in EM images using the iTEM software (Soft Imaging Systems GmbH). Selection of cells for quantification was based on their suitability for stereologic analysis, i.e., only cells sectioned through their central region (detected on the basis of the presence of Golgi membranes) were analyzed.

### **Alcian Blue staining**

Undifferentiated cells, glia and neurons were stained with 1% Alcian blue (Sigma, St. Louis, Missouri, USA) in hydrochloric acid. The counterstaining was performed for 2 minutes with Nuclear-Fast red (Sigma, St. Louis, Missouri, USA).

After the perfusion of the animals with PBS, the tissues were collected and fixed in methacarn solution (30% chloroform, 60% methanol and 10% acetic acid) for 24 hours at 4°C. The next day, the tissues were embedded in paraffin (Sigma, St. Louis, Missouri, USA) after their dehydration with a 70–100% ethanol gradient. Finally, the tissues were sectioned into 7 mm thick serial sections on a microtome. Sections of paraffin-embedded tissues were stained with 1% Alcian blue (Sigma, St. Louis, Missouri, USA) and counterstained with Nuclear-Fast red (Sigma, St. Louis, Missouri, USA).

### **GAG quantitative assay**

The protein extracts were assayed with the dimethylmethylene blue-based spectrophotometry of glycosaminoglycans (de Jong et al. 1989). The samples were read at 520 nm and the GAG concentrations were determined using the heparan sulfate standard curve (Sigma, St. Louis, Missouri, USA). Tissue GAG amount was expressed as  $\mu\text{g GAG}/\mu\text{g protein}$ .

### **GAG pulse-and-chase analysis**

Cells were grown in differentiation medium in presence of  $7\mu\text{Ci/ml } ^3\text{H}$ -glucosamine hydrochloride ( $37.75 \text{ Ci/mmol}$ , Perkin Elmer, Massachusetts, USA) for 24 hours, washed extensively with PBS and then chased. At the end of the chasing time, cells were harvested, homogenized and subject to chromatography on Sephadex G-25 columns (GE Healthcare, Sweden) to eliminate unincorporated  $^3\text{H}$ -glucosamine hydrochloride. The amounts of incorporated or secreted radioactivity was measured by liquid scintillation in a Beckman LS6500 counter (Beckman Instruments, Fullerton, CA, USA).

### **TUNEL assay**

Cells apoptosis was detected by TUNEL assay following the manufacturer's manual (Roche, Basle, Switzerland). TUNEL-positive cells were quantitated microscopically.

TUNEL assay on tissue was performed by using the ApopTag Peroxidase In Situ Apoptosis Detection kit following the manufacturer's manual (Oncor, Gaithersburg, Maryland, USA).

### **Transfection and nucleofection**

NSCs, HeLa cells and human fibroblasts were transfected using PolyFect Transfection Reagent (QIAGEN, Hilden, Germany), according to the manufacturer's protocols. HeLa CF7 stable cell lines was previously described (Sardiello et al. 2009). The HeLa<sup>shMCOLN1</sup> cell line was generated by infection with MCOLN1 lentiviral shRNA. NSCs were transfected by using nucleofection (Amaxa, Lonza, Walkersville, Maryland, USA).

### **Staining for Surface LAMP1**

Cells were grown on glass coverslips, incubated with anti-rat LAMP1 (1DB4; Santa Cruz Biotechnology, Santa Cruz, CA) diluted in PBS 1% BSA at 4°C for 30 minutes. Cells were washed in PBS and fixed in 4% PFA (Sigma, St. Louis, Missouri, USA) for 15 minutes at 4°C, washed in PBS, and incubated with Alexa-594 conjugated anti-rat secondary antibodies (Molecular Probes, Eugene, Oregon, USA) for 30 minutes at room temperature. Coverslips were mounted on glass slides with Vectashield (Vector Laboratories, California, USA). Finally, cells were analyzed on a confocal microscope (LSM510; Carl Zeiss, Thornwood, New York, USA) equipped with Plan-Neofluar 63x immersion objective.



### **Flow Cytometry analysis of surface LAMP1**

Confluent cells transfected with TFEB-GFP constructs were trypsinized and washed twice with PBS before incubation with PBS for 5 min at 37°C. 10<sup>6</sup> cells for each assay were centrifuged and resuspended in PBS 1% BSA with anti-rat LAMP1-1DB4 at 4°C for 30 minutes. Cells were washed in PBS and fixed in 2% paraformaldehyde for 15 minutes. Cells were further incubated with Alexa-594 conjugated anti-rat secondary antibodies (Molecular Probes, Eugene, Oregon, USA) for 30 minutes at room temperature. Finally, cells were washed, resuspended in 0.5 ml PBS, and analyzed on a FACS Aria Flow Cytometer (Becton Dickinson & Co., Mountain View, California, USA). Forward angle scatter, right angle scatter, and fluorescence intensity were recorded from 50,000 cells whose forward angle scatter fell above a threshold used to distinguish intact GFP-positive cells from both non-transfected or damaged cells.

### **Enzymatic Activities**

Enzyme activities were measured with the appropriate fluorimetric or colorimetric substrates. Specifically, acid phosphatase and  $\beta$ -hexosaminidase activities were measured using the Acid-Phosphatase and  $\beta$ -N-Acetylglucosaminidase assay kit (Sigma, St. Louis, Missouri, USA), respectively.  $\beta$ -galactosidase was measured by a colorimetric assay using 4-methylumbelliferyl- $\beta$ -D-galactopyranoside as substrate in 0.5M NaAc buffer, pH 5.0. Lactate dehydrogenase (LDH) activity was measured using the LDH-Cytotoxicity Assay Kit

(Abcam, Cambridge, Massachusetts, USA). To measure enzyme activities in the medium, cells were incubated in medium containing 1% BSA (w/v). Protein concentrations were determined using the BCA-assay (Pierce, Rockford, Illinois, USA).

### **Calcium Measurements by Confocal Imaging**

TFEB-GFP-transfected cells were treated with FuraRed for 30 minutes in a  $\text{Ca}^{2+}$  imagin buffer and analyzed according to the manufacturer's instructions (Invitrogen).

### **Flow Cytometric Calcium Flux Assay**

Cell preparation and loading was performed following a protocol already described (Schepers et al. 2009) with some modifications. Briefly, cells were loaded with Fluo-3AM and FuraRed-AM (Molecular Probes, Eugene, Oregon, USA) for 30 minutes at 37°C. After a wash in PBS without  $\text{Ca}^{2+}$ , the cells were resuspended in the appropriate buffer in accordance to the different conditions and kept at RT until analysis.  $\text{Ca}^{2+}$ -entry is prevented by the use of a PBS buffer without  $\text{Ca}^{2+}$  and containing 1 mM sodium pyruvate, 25 mM HEPES and 5 mM EGTA, the latter to exclude remaining traces of  $\text{Ca}^{2+}$  contamination. In these Fluo3/FuraRed-loaded cells the release of  $\text{Ca}^{2+}$  from the intracellular stores can be studied. Samples were analysed using the FACS Aria Flow Cytometer (Becton

Dickinson & Co., Mountain View, California, USA). Following preparation, samples were aspirated during 30 seconds to determine the baseline fluorescence of the Fluo3 and FuraRed. Then, after the addition of ionomycin (5  $\mu$ M), the acquisition was resumed with changes in Ca<sup>2+</sup> concentration being recorded over a 150 seconds time period. Changes in the fluorescence (FL) intensity of the Fluo3 and FuraRed were measured on the FL-1 and FL-2 channels. The ratio of baseline Fluo3/FuraRed was plotted. Data are expressed as means  $\pm$  standard deviation (SD). A p-value of less than 0.05 was considered significant.

## REFERENCES

Ahn, Sohyun, and Alexandra L Joyner. "In Vivo Analysis of Quiescent Adult Neural Stem Cells Responding to Sonic Hedgehog." *Nature* 437, no. 7060 (October 6, 2005): 894–897.

Allison AC, Mallucci L. Lysosomes in dividing cells, with special reference to lymphocytes. *Lancet*. 1964 Dec 26;2(7374):1371–1373.

Altman, J, and G D Das. "Autoradiographic and Histological Evidence of Postnatal Hippocampal Neurogenesis in Rats." *The Journal of Comparative Neurology* 124, no. 3 (June 1965): 319–335.

Alvarez-Buylla, Arturo, and Daniel A Lim. "For the Long Run: Maintaining Germinal Niches in the Adult Brain." *Neuron* 41, no. 5 (March 4, 2004): 683–686.

Andrews, N W. "Regulated Secretion of Conventional Lysosomes." *Trends in Cell Biology* 10, no. 8 (August 2000): 316–321.

Andrews, Norma W. "Lysosomes and the Plasma Membrane: Trypanosomes Reveal a Secret Relationship." *The Journal of Cell Biology* 158, no. 3 (August 5, 2002): 389–394.

Anton, Roman, Hans A Kestler, and Michael Kühl. "Beta-catenin Signaling Contributes to Stemness and Regulates Early Differentiation in Murine Embryonic Stem Cells." *FEBS Letters* 581, no. 27 (November 13, 2007): 5247–5254.

Arvidsson, Andreas, Tove Collin, Deniz Kirik, Zaal Kokaia, and Olle Lindvall. "Neuronal Replacement from Endogenous Precursors in the Adult Brain After Stroke." *Nature Medicine* 8, no. 9 (September 2002): 963–970.

Baker, P F, and M J Whitaker. "Trifluoperazine Inhibits Exocytosis in Sea-urchin Eggs [proceedings]." *The Journal of Physiology* 298 (January 1980): 55P.

Ballabio, Andrea, and Volkmar Gieselmann. "Lysosomal Disorders: From Storage to Cellular Damage." *Biochimica Et Biophysica Acta* 1793, no. 4 (April 2009): 684–696.

Balordi, Francesca, and Gord Fishell. "Hedgehog Signaling in the Subventricular Zone Is Required for Both the Maintenance of Stem Cells and the Migration of Newborn Neurons." *The Journal of Neuroscience: The Official Journal of the Society for Neuroscience* 27, no. 22 (May 30, 2007): 5936–5947.

Bargal, R, N Avidan, E Ben-Asher, Z Olender, M Zeigler, A Frumkin, A Raas-Rothschild, G Glusman, D Lancet, and G Bach. "Identification of the Gene Causing Mucopolidosis Type IV." *Nature Genetics* 26, no. 1 (September 2000): 118–123.

Bargal, R, H H Goebel, E Latta, and G Bach. "Mucopolidosis IV: Novel Mutation and Diverse Ultrastructural Spectrum in the Skin." *Neuropediatrics* 33, no. 4 (August 2002): 199–202.

Bassi, M T, M Manzoni, E Monti, M T Pizzo, A Ballabio, and G Borsani. "Cloning of the Gene Encoding a Novel Integral Membrane Protein, Mucopolidin-and Identification of the Two Major Founder Mutations Causing Mucopolidosis Type IV." *American Journal of Human Genetics* 67, no. 5 (November 2000): 1110–1120.

Bejsovec, Amy. "Wnt Pathway Activation: New Relations and Locations." *Cell* 120, no. 1 (January 14, 2005): 11–14.

Bellettato, Cinzia Maria, and Maurizio Scarpa. "Pathophysiology of Neuropathic Lysosomal Storage Disorders." *Journal of Inherited Metabolic Disease* 33, no. 4 (August 2010): 347–362.

Beratis, N G, G U LaBadie, and K Hirschhorn. "Characterization of the Molecular Defect in Infantile and Adult Acid Alpha-glucosidase Deficiency Fibroblasts." *The Journal of Clinical Investigation* 62, no. 6 (December 1978): 1264–1274.

Bezprozvanny, Ilya. "Calcium Signaling and Neurodegenerative Diseases." *Trends in Molecular Medicine* 15, no. 3 (March 2009): 89–100.

Bischel, M, J Austin, and M Kemeny. "Metachromatic Leukodystrophy (MLD). VII. Elevated Sulfated Acid Polysaccharide Levels in Urine and Postmortem Tissues." *Archives of Neurology* 15, no. 1 (July 1966): 13–28.

Bjørkøy, Geir, Trond Lamark, and Terje Johansen. "p62/SQSTM1: a Missing Link Between Protein Aggregates and the Autophagy Machinery." *Autophagy* 2, no. 2 (June 2006): 138–139.

Blott, Emma J, and Gillian M Griffiths. "Secretory Lysosomes." *Nature Reviews. Molecular Cell Biology* 3, no. 2 (February 2002): 122–131.

Boissy, R E, Y Zhao, and W A Gahl. "Altered Protein Localization in Melanocytes from Hermansky-Pudlak Syndrome: Support for the Role of the HPS Gene Product in Intracellular Trafficking." *Laboratory Investigation; a Journal of Technical Methods and Pathology* 78, no. 9 (September 1998): 1037–1048.

Bonaguidi, Michael A, Tammy McGuire, Min Hu, Lixin Kan, Jayshree Samanta, and John A Kessler. "LIF and BMP Signaling Generate Separate and Discrete Types of GFAP-expressing Cells." *Development (Cambridge, England)* 132, no. 24 (December 2005): 5503–5514.

Bonifacino, Juan S. "Insights into the Biogenesis of Lysosome-related Organelles from the Study of the Hermansky-Pudlak Syndrome." *Annals of the New York Academy of Sciences* 1038 (December 2004): 103–114.

Bossi, Giovanna, and Gillian M Griffiths. "CTL Secretory Lysosomes: Biogenesis and Secretion of a Harmful Organelle." *Seminars in Immunology* 17, no. 1 (February 2005): 87–94.

Braulke T, Bonifacino JS (2009) Sorting of lysosomal proteins. *Biochim Biophys Acta* 1793:605–614

Brill, Julia, and John R Huguenard. "Sequential Changes in AMPA Receptor Targeting in the Developing Neocortical Excitatory Circuit." *The Journal of Neuroscience: The Official Journal of the Society for Neuroscience* 28, no. 51 (December 17, 2008): 13918–13928.

Bucciantini, Monica, Elisa Giannoni, Fabrizio Chiti, Fabiana Baroni, Lucia Formigli, Jesús Zurdo, Niccolò Taddei, Giampietro Ramponi, Christopher M Dobson, and Massimo Stefani. "Inherent Toxicity of Aggregates Implies a Common Mechanism for Protein Misfolding Diseases." *Nature* 416, no. 6880 (April 4, 2002): 507–511.

Buono, Mario, Ilaria Visigalli, Roberta Bergamasco, Alessandra Biffi, and Maria Pia Cosma. "Sulfatase Modifying Factor 1-mediated Fibroblast Growth Factor Signaling Primes Hematopoietic Multilineage Development." *The Journal of Experimental Medicine* 207, no. 8 (August 2, 2010): 1647–1660.

Callahan, John W, Richard D Bagshaw, and Don J Mahuran. "The Integral Membrane of Lysosomes: Its Proteins and Their Roles in Disease." *Journal of Proteomics* 72, no. 1 (February 15, 2009): 23–33.

Campbell, Kenneth, and Magdalena Götz. "Radial Glia: Multi-purpose Cells for Vertebrate Brain Development." *Trends in Neurosciences* 25, no. 5 (May 2002): 235–238.

Campos, Lia Scotti. "Neurospheres: Insights into Neural Stem Cell Biology." *Journal of Neuroscience Research* 78, no. 6 (December 15, 2004): 761–769.

Cao, Yi, Janice A Espinola, Elisa Fossale, Ashish C Massey, Ana Maria Cuervo, Marcy E MacDonald, and Susan L Cotman. "Autophagy Is Disrupted in a Knock-in Mouse Model of Juvenile Neuronal Ceroid Lipofuscinosis." *The Journal of Biological Chemistry* 281, no. 29 (July 21, 2006): 20483–20493.

Cavaleri, Fatima, and Hans R Schöler. "Nanog: a New Recruit to the Embryonic Stem Cell Orchestra." *Cell* 113, no. 5 (May 30, 2003): 551–552.

H.A. Chapman Jr., J.S. Munger, G.P. Shi. The role of thiol proteases in tissue injury and remodeling. *Am. J. Respir. Crit. Care Med.*, 150 (1994), pp. S155–S159

Chojnacki, Andrew, John J P Kelly, Walter Hader, and Samuel Weiss. "Distinctions Between Fetal and Adult Human Platelet-derived Growth Factor-responsive Neural Precursors." *Annals of Neurology* 64, no. 2 (August 2008): 127–142.

Chojnacki, Andrew, and Samuel Weiss. "Production of Neurons, Astrocytes and Oligodendrocytes from Mammalian CNS Stem Cells." *Nature Protocols* 3, no. 6 (2008): 935–940.

Choudhury, Amit, Deepak K Sharma, David L Marks, and Richard E Pagano. "Elevated Endosomal Cholesterol Levels in Niemann-Pick Cells Inhibit Rab4 and Perturb Membrane Recycling." *Molecular Biology of the Cell* 15, no. 10 (October 2004): 4500–4511.

Christensen, Kenneth A, Jesse T Myers, and Joel A Swanson. "pH-dependent Regulation of Lysosomal Calcium in Macrophages." *Journal of Cell Science* 115, no. Pt 3 (February 1, 2002): 599–607.

Ciccolini, F. "Identification of Two Distinct Types of Multipotent Neural Precursors That Appear Sequentially During CNS Development." *Molecular and Cellular Neurosciences* 17, no. 5 (May 2001): 895–907.

Ciccolini, F, and C N Svendsen. "Fibroblast Growth Factor 2 (FGF-2) Promotes Acquisition of Epidermal Growth Factor (EGF) Responsiveness in Mouse Striatal Precursor Cells: Identification of Neural Precursors Responding to Both EGF and FGF-2." *The Journal of Neuroscience: The Official Journal of the Society for Neuroscience* 18, no. 19 (October 1, 1998): 7869–7880.

Ciccolini, Francesca, Claudia Mandl, Gabriele Hölzl-Wenig, Angelika Kehlenbach, and Andrea Hellwig. "Prospective Isolation of Late Development Multipotent Precursors Whose Migration Is Promoted by EGFR." *Developmental Biology* 284, no. 1 (August 1, 2005): 112–125.

Conti, Luciano, Steven M Pollard, Thorsten Gorba, Erika Reitano, Mauro Toselli, Gerardo Biella, Yirui Sun, et al. "Niche-independent Symmetrical Self-renewal of a Mammalian Tissue Stem Cell." *PLoS Biology* 3, no. 9 (September 2005): e283.

Conti L, Cattaneo E (2010) Neural stem cell systems: physiological players or *in vitro* entities? *Nature reviews Neuroscience* 11: 176–187.



Conus, Sébastien, and Hans-Uwe Simon. "Cathepsins: Key Modulators of Cell Death and Inflammatory Responses." *Biochemical Pharmacology* 76, no. 11 (December 1, 2008): 1374–1382.

Cosma, Maria Pia, Stefano Pepe, Ida Annunziata, Robert F Newbold, Markus Grompe, Giancarlo Parenti, and Andrea Ballabio. "The Multiple Sulfatase Deficiency Gene Encodes an Essential and Limiting Factor for the Activity of Sulfatases." *Cell* 113, no. 4 (May 16, 2003): 445–456.

Coutinho, Maria Francisca, Maria João Prata, and Sandra Alves. "Mannose-6-phosphate Pathway: a Review on Its Role in Lysosomal Function and Dysfunction." *Molecular Genetics and Metabolism* 105, no. 4 (April 2012): 542–550.

Curtis, Maurice A, Monica Kam, and Richard L M Faull. "Neurogenesis in Humans." *The European Journal of Neuroscience* 33, no. 6 (March 2011): 1170–1174.

Dahl, N, P O Hillborg, and A Olofsson. "Gaucher Disease (Norrbottnian Type III): Probable Founders Identified by Genealogical and Molecular Studies." *Human Genetics* 92, no. 5 (November 1993): 513–515.

Dehay, Benjamin, Jordi Bové, Natalia Rodríguez-Muela, Celine Perier, Ariadna Recasens, Patricia Boya, and Miquel Vila. "Pathogenic Lysosomal Depletion in Parkinson's Disease." *The Journal of Neuroscience: The Official Journal of the Society for Neuroscience* 30, no. 37 (September 15, 2010): 12535–12544.

Dell'Angelica, Esteban C. "Melanosome Biogenesis: Shedding Light on the Origin of an Obscure Organelle." *Trends in Cell Biology* 13, no. 10 (October 2003): 503–506.

Dierks, Thomas, Bernhard Schmidt, Ljudmila V Borissenko, Jianhe Peng, Andrea Preusser, Malaiyalam Mariappan, and Kurt von Figura. "Multiple Sulfatase Deficiency Is Caused by Mutations in the Gene Encoding the Human C(alpha)-formylglycine Generating Enzyme." *Cell* 113, no. 4 (May 16, 2003): 435–444.

Doetsch, F, and A Alvarez-Buylla. "Network of Tangential Pathways for Neuronal Migration in Adult Mammalian Brain." *Proceedings of the National Academy of*

*Sciences of the United States of America* 93, no. 25 (December 10, 1996): 14895–14900.

Doetsch, F, J M García-Verdugo, and A Alvarez-Buylla. "Cellular Composition and Three-dimensional Organization of the Subventricular Germinal Zone in the Adult Mammalian Brain." *The Journal of Neuroscience: The Official Journal of the Society for Neuroscience* 17, no. 13 (July 1, 1997): 5046–5061.

Doetsch, Fiona, Leopoldo Petreanu, Isabelle Caille, Jose Manuel Garcia-Verdugo, and Arturo Alvarez-Buylla. "EGF Converts Transit-amplifying Neurogenic Precursors in the Adult Brain into Multipotent Stem Cells." *Neuron* 36, no. 6 (December 19, 2002): 1021–1034.

Doherty, Gary J, and Harvey T McMahon. "Mechanisms of Endocytosis." *Annual Review of Biochemistry* 78 (2009): 857–902.

Dong, Xian-Ping, Xiping Cheng, Eric Mills, Markus Delling, Fudi Wang, Tino Kurz, and Haoxing Xu. "The Type IV Mucopolidosis-associated Protein TRPML1 Is an Endolysosomal Iron Release Channel." *Nature* 455, no. 7215 (October 16, 2008): 992–996.

Dong, Xian-ping, Xiang Wang, Dongbiao Shen, Su Chen, Meiling Liu, Yanbin Wang, Eric Mills, Xiping Cheng, Markus Delling, and Haoxing Xu. "Activating Mutations of the TRPML1 Channel Revealed by Proline-scanning Mutagenesis." *The Journal of Biological Chemistry* 284, no. 46 (November 13, 2009): 32040–32052.

Doyle, K L, M Khan, and A M Cunningham. "Expression of the Intermediate Filament Protein Nestin by Sustentacular Cells in Mature Olfactory Neuroepithelium." *The Journal of Comparative Neurology* 437, no. 2 (August 20, 2001): 186–195.

De Duve, C, B C Pressman, R Gianetto, R Wattiaux, and F Appelmans. "Tissue Fractionation Studies. 6. Intracellular Distribution Patterns of Enzymes in Rat-liver Tissue." *The Biochemical Journal* 60, no. 4 (August 1955): 604–617.

De Duve, C. "The Lysosome." *Scientific American* 208 (May 1963): 64–72.

de Jong, J G, R A Wevers, C Laarakkers, and B J Poorthuis. "Dimethylmethylen Blue-based Spectrophotometry of Glycosaminoglycans in Untreated Urine: a Rapid Screening Procedure for Mucopolysaccharidoses." *Clinical Chemistry* 35, no. 7 (July 1989): 1472–1477.

de Pablo-Latorre, Raquel, Assunta Saide, Elena V Polishuck, Edoardo Nusco, Alessandro Fraldi, and Andrea Ballabio. "Impaired Parkin-mediated Mitochondrial Targeting to Autophagosomes Differentially Contributes to Tissue Pathology in Lysosomal Storage Diseases." *Human Molecular Genetics* 21, no. 8 (April 15, 2012): 1770–1781.

Easter, S S, Jr, L S Ross, and A Frankfurter. "Initial Tract Formation in the Mouse Brain." *The Journal of Neuroscience: The Official Journal of the Society for Neuroscience* 13, no. 1 (January 1993): 285–299.

Eckenhoff, M F, and P Rakic. "Nature and Fate of Proliferative Cells in the Hippocampal Dentate Gyrus During the Life Span of the Rhesus Monkey." *The Journal of Neuroscience: The Official Journal of the Society for Neuroscience* 8, no. 8 (August 1988): 2729–2747.

Ehm, Oliver, Christian Göritz, Marcela Covic, Iris Schäffner, Tobias J Schwarz, Esra Karaca, Bettina Kempkes, et al. "RBPJkappa-dependent Signaling Is Essential for Long-term Maintenance of Neural Stem Cells in the Adult Hippocampus." *The Journal of Neuroscience: The Official Journal of the Society for Neuroscience* 30, no. 41 (October 13, 2010): 13794–13807.

Eng CM, Banikazemi M, Gordon RE et al (2001b) A phase 1/2 clinical trial of enzyme replacement in Fabry disease: pharmacokinetic, substrate clearance, and safety studies. *Am J Hum Genet* 68:711–722

Elkabetz, Yechiel, Georgia Panagiotakos, George Al Shamy, Nicholas D Socci, Viviane Tabar, and Lorenz Studer. "Human ES Cell-derived Neural Rosettes

Reveal a Functionally Distinct Early Neural Stem Cell Stage.” *Genes & Development* 22, no. 2 (January 15, 2008): 152–165.

Eng, C M, N Guffon, W R Wilcox, D P Germain, P Lee, S Waldek, L Caplan, G E Linthorst, and R J Desnick. “Safety and Efficacy of Recombinant Human Alpha-galactosidase A--replacement Therapy in Fabry’s Disease.” *The New England Journal of Medicine* 345, no. 1 (July 5, 2001): 9–16.

Eskelinen, Eeva-Liisa. “Maturation of Autophagic Vacuoles in Mammalian Cells.” *Autophagy* 1, no. 1 (April 2005): 1–10.

Fan, Xiaolian, Huiwen Zhang, Sunqu Zhang, Richard D Bagshaw, Michael B Tropak, John W Callahan, and Don J Mahuran. “Identification of the Gene Encoding the Enzyme Deficient in Mucopolysaccharidosis IIIC (Sanfilippo Disease Type C).” *American Journal of Human Genetics* 79, no. 4 (October 2006): 738–744.

Fändrich, M, M A Fletcher, and C M Dobson. “Amyloid Fibrils from Muscle Myoglobin.” *Nature* 410, no. 6825 (March 8, 2001): 165–166.

Feng, L, M E Hatten, and N Heintz. “Brain Lipid-binding Protein (BLBP): a Novel Signaling System in the Developing Mammalian CNS.” *Neuron* 12, no. 4 (April 1994): 895–908.

Ferri, Anna L M, Maurizio Cavallaro, Daniela Braidà, Antonello Di Cristofano, Annalisa Canta, Annamaria Vezzani, Sergio Ottolenghi, et al. “Sox2 Deficiency Causes Neurodegeneration and Impaired Neurogenesis in the Adult Mouse Brain.” *Development (Cambridge, England)* 131, no. 15 (August 2004): 3805–3819.

Filocamo M, Morrone A. Lysosomal storage disorders: molecular basis and laboratory testing. *Hum Genomics*. 2011 Mar;5(3):156-69.

Fortun, Jenny, William A Dunn Jr, Shale Joy, Jie Li, and Lucia Notterpek. “Emerging Role for Autophagy in the Removal of Aggresomes in Schwann Cells.” *The Journal of Neuroscience: The Official Journal of the Society for Neuroscience* 23, no. 33 (November 19, 2003): 10672–10680.

Fraldi, Alessandro, Fabio Annunziata, Alessia Lombardi, Hermann-Josef Kaiser, Diego Luis Medina, Carmine Spampinato, Anthony Olind Fedele, et al. "Lysosomal Fusion and SNARE Function Are Impaired by Cholesterol Accumulation in Lysosomal Storage Disorders." *The EMBO Journal* 29, no. 21 (November 3, 2010): 3607–3620.

Fukuda, Tokiko, Ashley Roberts, Meghan Ahearn, Kristien Zaal, Evelyn Ralston, Paul H Plotz, and Nina Raben. "Autophagy and Lysosomes in Pompe Disease." *Autophagy* 2, no. 4 (December 2006): 318–320.

Futerman, Anthony H, and Gerrit van Meer. "The Cell Biology of Lysosomal Storage Disorders." *Nature Reviews. Molecular Cell Biology* 5, no. 7 (July 2004): 554–565.

Gabay, Limor, Sally Lowell, Lee L Rubin, and David J Anderson. "Deregulation of Dorsoventral Patterning by FGF Confers Trilineage Differentiation Capacity on CNS Stem Cells in Vitro." *Neuron* 40, no. 3 (October 30, 2003): 485–499.

Gage, F H. "Mammalian Neural Stem Cells." *Science (New York, N.Y.)* 287, no. 5457 (February 25, 2000): 1433–1438.

Garcion, Emmanuel, Aida Halilagic, Andreas Faissner, and Charles French-Constant. "Generation of an Environmental Niche for Neural Stem Cell Development by the Extracellular Matrix Molecule Tenascin C." *Development (Cambridge, England)* 131, no. 14 (July 2004): 3423–3432.

Gieselmann, V. "Lysosomal Storage Diseases." *Biochimica Et Biophysica Acta* 1270, no. 2–3 (April 24, 1995): 103–136.

Glabe, Charles G. "Conformation-dependent Antibodies Target Diseases of Protein Misfolding." *Trends in Biochemical Sciences* 29, no. 10 (October 2004): 542–547.

Goffredo, D, L Conti, F Di Febo, G Biella, A Tosoni, G Vago, I Biunno, et al. "Setting the Conditions for Efficient, Robust and Reproducible Generation of Functionally Active Neurons from Adult Subventricular Zone-derived Neural Stem Cells." *Cell Death and Differentiation* 15, no. 12 (December 2008): 1847–1856.

Goldberg, Alfred L. "Protein Degradation and Protection Against Misfolded or Damaged Proteins." *Nature* 426, no. 6968 (December 18, 2003): 895–899.

Golmohammadi, Mohammad G, Daniel G Blackmore, Beatrice Large, Hassan Azari, Ebrahim Esfandiary, George Paxinos, Keith B J Franklin, Brent A Reynolds, and Rodney L Rietze. "Comparative Analysis of the Frequency and Distribution of Stem and Progenitor Cells in the Adult Mouse Brain." *Stem Cells (Dayton, Ohio)* 26, no. 4 (April 2008): 979–987.

Götz, Magdalena, and Yves-Alain Barde. "Radial Glial Cells Defined and Major Intermediates Between Embryonic Stem Cells and CNS Neurons." *Neuron* 46, no. 3 (May 5, 2005): 369–372.

Gould, E, N Vail, M Wagers, and C G Gross. "Adult-generated Hippocampal and Neocortical Neurons in Macaques Have a Transient Existence." *Proceedings of the National Academy of Sciences of the United States of America* 98, no. 19 (September 11, 2001): 10910–10917.

Grandbarbe, Luc, Julien Bouissac, Matt Rand, Martin Hrabé de Angelis, Spyros Artavanis-Tsakonas, and Eliane Mohier. "Delta-Notch Signaling Controls the Generation of Neurons/glia from Neural Stem Cells in a Stepwise Process." *Development (Cambridge, England)* 130, no. 7 (April 2003): 1391–1402.

Gritti, A, L Cova, E A Parati, R Galli, and A L Vescovi. "Basic Fibroblast Growth Factor Supports the Proliferation of Epidermal Growth Factor-generated Neuronal Precursor Cells of the Adult Mouse CNS." *Neuroscience Letters* 185, no. 3 (February 13, 1995): 151–154.

Gritti, A, E A Parati, L Cova, P Frolichsthal, R Galli, E Wanke, L Faravelli, et al. "Multipotential Stem Cells from the Adult Mouse Brain Proliferate and Self-renew in Response to Basic Fibroblast Growth Factor." *The Journal of Neuroscience: The Official Journal of the Society for Neuroscience* 16, no. 3 (February 1, 1996): 1091–1100.

Guicciardi ME, Leist M, Gores GJ. Lysosomes in cell death. *Oncogene* 2004;23:2881–2890.

Hack, M A, M Sugimori, C Lundberg, M Nakafuku, and M Götz. “Regionalization and Fate Specification in Neurospheres: The Role of Olig2 and Pax6.” *Molecular and Cellular Neurosciences* 25, no. 4 (April 2004): 664–678.

Han, Young-Goo, Nathalie Spassky, Miriam Romaguera-Ros, Jose-Manuel Garcia-Verdugo, Andrea Aguilar, Sylvie Schneider-Maunoury, and Arturo Alvarez-Buylla. “Hedgehog Signaling and Primary Cilia Are Required for the Formation of Adult Neural Stem Cells.” *Nature Neuroscience* 11, no. 3 (March 2008): 277–284.

Hanson, Sarah R, Michael D Best, and Chi-Huey Wong. “Sulfatases: Structure, Mechanism, Biological Activity, Inhibition, and Synthetic Utility.” *Angewandte Chemie (International Ed. in English)* 43, no. 43 (November 5, 2004): 5736–5763.

Hara, Taichi, Kenji Nakamura, Makoto Matsui, Akitsugu Yamamoto, Yohko Nakahara, Rika Suzuki-Migishima, Minesuke Yokoyama, et al. “Suppression of Basal Autophagy in Neural Cells Causes Neurodegenerative Disease in Mice.” *Nature* 441, no. 7095 (June 15, 2006): 885–889.

Hartfuss, E, R Galli, N Heins, and M Götz. “Characterization of CNS Precursor Subtypes and Radial Glia.” *Developmental Biology* 229, no. 1 (January 1, 2001): 15–30.

Hasilik, A, A Waheed, and K von Figura. “Enzymatic Phosphorylation of Lysosomal Enzymes in the Presence of UDP-N-acetylglucosamine. Absence of the Activity in I-cell Fibroblasts.” *Biochemical and Biophysical Research Communications* 98, no. 3 (February 12, 1981): 761–767.

Herold, S, R Jagasia, K Merz, K Wassmer, and D C Lie. “CREB Signalling Regulates Early Survival, Neuronal Gene Expression and Morphological Development in Adult Subventricular Zone Neurogenesis.” *Molecular and Cellular Neurosciences* 46, no. 1 (January 2011): 79–88.

Hers, H G. "alpha-Glucosidase Deficiency in Generalized Glycogenstorage Disease (Pompe's Disease)." *The Biochemical Journal* 86 (January 1963): 11–16.

Heuer, G G, A F Skorupa, R K Prasad Alur, K Jiang, and J H Wolfe. "Accumulation of Abnormal Amounts of Glycosaminoglycans in Murine Mucopolysaccharidosis Type VII Neural Progenitor Cells Does Not Alter the Growth Rate or Efficiency of Differentiation into Neurons." *Molecular and Cellular Neurosciences* 17, no. 1 (January 2001): 167–178.

Hodge, Rebecca D, Thomas D Kowalczyk, Susanne A Wolf, Juan M Encinas, Caitlin Rippey, Grigori Enikolopov, Gerd Kempermann, and Robert F Hevner. "Intermediate Progenitors in Adult Hippocampal Neurogenesis: Tbr2 Expression and Coordinate Regulation of Neuronal Output." *The Journal of Neuroscience: The Official Journal of the Society for Neuroscience* 28, no. 14 (April 2, 2008): 3707–3717.

E. Holtzman. The origin and fate of secretory packages, especially synaptic vesicles. *Neuroscience*, 2 (1977), pp. 327–355

Hoppler, Stefan, and Claire Louise Kavanagh. "Wnt Signalling: Variety at the Core." *Journal of Cell Science* 120, no. Pt 3 (February 1, 2007): 385–393.

Hopwood JJ, Ballabio A (2001) Multiple sulfatase deficiency and the nature of the sulfatase family. In *The Metabolic and Molecular Basis of Inherited Disease*, Scriver CR, Beaudet AL, Valle D, Sly WS (eds) Vol 3, pp 3725–3732. New York, USA: McGraw-Hill.

Hopwood, J.; Brooks, D., *An Introduction to the Basic Science and Biology of the Lysosome and Storage Diseases*. In *Organelle Diseases*; Applegarth, D., Dimmick, J., Hall, J., Eds.; Chapman & Hall Medical: New York, 1997; pp 7–35.

Hrebícek, Martin, Lenka Mrázová, Volkan Seyrantepe, Stéphanie Durand, Nicole M Roslin, Lenka Nosková, Hana Hartmannová, et al. "Mutations in TMEM76\* Cause Mucopolysaccharidosis IIIC (Sanfilippo C Syndrome)." *American Journal of Human Genetics* 79, no. 5 (November 2006): 807–819.



Idone, Vincent, Christina Tam, John W Goss, Derek Toomre, Marc Pypaert, and Norma W Andrews. "Repair of Injured Plasma Membrane by Rapid  $\text{Ca}^{2+}$ -dependent Endocytosis." *The Journal of Cell Biology* 180, no. 5 (March 10, 2008): 905–914.

Imayoshi, Itaru, Masayuki Sakamoto, Masahiro Yamaguchi, Kensaku Mori, and Ryoichiro Kageyama. "Essential Roles of Notch Signaling in Maintenance of Neural Stem Cells in Developing and Adult Brains." *The Journal of Neuroscience: The Official Journal of the Society for Neuroscience* 30, no. 9 (March 3, 2010): 3489–3498.

Israsena, Nipan, Min Hu, Weimin Fu, Lixin Kan, and John A Kessler. "The Presence of FGF2 Signaling Determines Whether Beta-catenin Exerts Effects on Proliferation or Neuronal Differentiation of Neural Stem Cells." *Developmental Biology* 268, no. 1 (April 1, 2004): 220–231.

Itoh, Tatsuki, Takao Satou, Shozo Nishida, Shigeo Hashimoto, and Hiroyuki Ito. "Cultured Rat Astrocytes Give Rise to Neural Stem Cells." *Neurochemical Research* 31, no. 11 (November 2006): 1381–1387.

Iwata, Atsushi, Brigit E Riley, Jennifer A Johnston, and Ron R Kopito. "HDAC6 and Microtubules Are Required for Autophagic Degradation of Aggregated Huntingtin." *The Journal of Biological Chemistry* 280, no. 48 (December 2, 2005): 40282–40292.

Jaiswal, Jyoti K, Norma W Andrews, and Sanford M Simon. "Membrane Proximal Lysosomes Are the Major Vesicles Responsible for Calcium-dependent Exocytosis in Nonsecretory Cells." *The Journal of Cell Biology* 159, no. 4 (November 25, 2002): 625–635.

Jalanko, Anu, and Thomas Braulke. "Neuronal Ceroid Lipofuscinoses." *Biochimica Et Biophysica Acta* 1793, no. 4 (April 2009): 697–709.

Jennings, John J, Jr, Jian-Hui Zhu, Youssef Rbaibi, Xiang Luo, Charleen T Chu, and Kirill Kiselyov. "Mitochondrial Aberrations in Mucopolidosis Type IV." *The Journal of Biological Chemistry* 281, no. 51 (December 22, 2006): 39041–39050.

Jentsch, Thomas J. "Chloride and the Endosomal-lysosomal Pathway: Emerging Roles of CLC Chloride Transporters." *The Journal of Physiology* 578, no. Pt 3 (February 1, 2007): 633–640.

Jeyakumar, Mylvaganam, Raymond A Dwek, Terry D Butters, and Frances M Platt. "Storage Solutions: Treating Lysosomal Disorders of the Brain." *Nature Reviews. Neuroscience* 6, no. 9 (September 2005): 713–725.

Johe, K K, T G Hazel, T Muller, M M Dugich-Djordjevic, and R D McKay. "Single Factors Direct the Differentiation of Stem Cells from the Fetal and Adult Central Nervous System." *Genes & Development* 10, no. 24 (December 15, 1996): 3129–3140.

Johnston, J A, C L Ward, and R R Kopito. "Aggresomes: a Cellular Response to Misfolded Proteins." *The Journal of Cell Biology* 143, no. 7 (December 28, 1998): 1883–1898.

Jones, Kathryn S, and Bronwen Connor. "Proneural Transcription Factors Dlx2 and Pax6 Are Altered in Adult SVZ Neural Precursor Cells Following Striatal Cell Loss." *Molecular and Cellular Neurosciences* 47, no. 1 (May 2011): 53–60.

Juhasz G., Neufeld T.P. 2006. Autophagy: a forty-year search for a missing membrane source. *PLoS Biol.* 4:e36. doi: 10.1371/journal.pbio.0040036.

Kabeya, Y, N Mizushima, T Ueno, A Yamamoto, T Kirisako, T Noda, E Kominami, Y Ohsumi, and T Yoshimori. "LC3, a Mammalian Homologue of Yeast Apg8p, Is Localized in Autophagosome Membranes After Processing." *The EMBO Journal* 19, no. 21 (November 1, 2000): 5720–5728.

Kálmán, M, and B M Ajtai. "A Comparison of Intermediate Filament Markers for Presumptive Astroglia in the Developing Rat Neocortex: Immunostaining Against Nestin Reveals More Detail, Than GFAP or Vimentin." *International Journal of*

*Developmental Neuroscience: The Official Journal of the International Society for Developmental Neuroscience* 19, no. 1 (February 2001): 101–108.

Kamimoto, Takahiro, Shisako Shoji, Tunda Hidvegi, Noboru Mizushima, Kyohei Umebayashi, David H Perlmutter, and Tamotsu Yoshimori. "Intracellular Inclusions Containing Mutant Alpha1-antitrypsin Z Are Propagated in the Absence of Autophagic Activity." *The Journal of Biological Chemistry* 281, no. 7 (February 17, 2006): 4467–4476.

Kanai, K., and E. Kondo. 1970. A suggested role of the lysosomal membrane as a part of the defense mechanism against tuberculous infection. *Jap. J. Med. Sci. Biol.* 23:295-302.

Kao, Joseph P Y, Gong Li, and Darryl A Auston. "Practical Aspects of Measuring Intracellular Calcium Signals with Fluorescent Indicators." *Methods in Cell Biology* 99 (2010): 113–152.

Kawaguchi, Yoshiharu, Jeffrey J Kovacs, Adam McLaurin, Jeffery M Vance, Akihiro Ito, and Tso Pang Yao. "The Deacetylase HDAC6 Regulates Aggresome Formation and Cell Viability in Response to Misfolded Protein Stress." *Cell* 115, no. 6 (December 12, 2003): 727–738.

Kayed, Rakez, Elizabeth Head, Jennifer L Thompson, Theresa M McIntire, Saskia C Milton, Carl W Cotman, and Charles G Glabe. "Common Structure of Soluble Amyloid Oligomers Implies Common Mechanism of Pathogenesis." *Science (New York, N.Y.)* 300, no. 5618 (April 18, 2003): 486–489.

Kimura S, Noda T, Yoshimori T (2007) Dissection of the autophagosome maturation process by a novel reporter protein, tandem fluorescent-tagged LC3. *Autophagy* 3: 452–460

Kirkegaard, Karla. "Subversion of the Cellular Autophagy Pathway by Viruses." *Current Topics in Microbiology and Immunology* 335 (2009): 323–333.

Kirkin, Vladimir, Trond Lamark, Terje Johansen, and Ivan Dikic. "NBR1 Cooperates with P62 in Selective Autophagy of Ubiquitinated Targets." *Autophagy* 5, no. 5 (July 2009): 732–733.

Klein, Diana, Heinrich Büssow, Simon Ngamli Fewou, and Volkmar Gieselmann. "Exocytosis of Storage Material in a Lysosomal Disorder." *Biochemical and Biophysical Research Communications* 327, no. 3 (February 18, 2005): 663–667.

Klionsky, Daniel J. "The Molecular Machinery of Autophagy: Unanswered Questions." *Journal of Cell Science* 118, no. Pt 1 (January 1, 2005): 7–18.

Klumperman, J, A Hille, T Veenendaal, V Oorschot, W Stoorvogel, K von Figura, and H J Geuze. "Differences in the Endosomal Distributions of the Two Mannose 6-phosphate Receptors." *The Journal of Cell Biology* 121, no. 5 (June 1993): 997–1010.

Koch, Philipp, Thoralf Opitz, Julius A Steinbeck, Julia Ladewig, and Oliver Brüstle. "A Rosette-type, Self-renewing Human ES Cell-derived Neural Stem Cell with Potential for in Vitro Instruction and Synaptic Integration." *Proceedings of the National Academy of Sciences of the United States of America* 106, no. 9 (March 3, 2009): 3225–3230.

Kohwi, Minoree, Noriko Osumi, John L R Rubenstein, and Arturo Alvarez-Buylla. "Pax6 Is Required for Making Specific Subpopulations of Granule and Periglomerular Neurons in the Olfactory Bulb." *The Journal of Neuroscience: The Official Journal of the Society for Neuroscience* 25, no. 30 (July 27, 2005): 6997–7003.

Koike, Masato, Masahiro Shibata, Satoshi Waguri, Kentaro Yoshimura, Isei Tanida, Eiki Kominami, Takahiro Gotow, et al. "Participation of Autophagy in Storage of Lysosomes in Neurons from Mouse Models of Neuronal Ceroid-lipofuscinoses (Batten Disease)." *The American Journal of Pathology* 167, no. 6 (December 2005): 1713–1728.

Komatsu, Masaaki, Hirofumi Kurokawa, Satoshi Waguri, Keiko Taguchi, Akira Kobayashi, Yoshinobu Ichimura, Yu-Shin Sou, et al. "The Selective Autophagy Substrate P62 Activates the Stress Responsive Transcription Factor Nrf2 Through Inactivation of Keap1." *Nature Cell Biology* 12, no. 3 (March 2010): 213–223.

Komatsu, Masaaki, Satoshi Waguri, Tomoki Chiba, Shigeo Murata, Jun-ichi Iwata, Isei Tanida, Takashi Ueno, et al. "Loss of Autophagy in the Central Nervous System Causes Neurodegeneration in Mice." *Nature* 441, no. 7095 (June 15, 2006): 880–884.

Komatsu, Masaaki, Satoshi Waguri, Masato Koike, Yu-Shin Sou, Takashi Ueno, Taichi Hara, Noboru Mizushima, et al. "Homeostatic Levels of P62 Control Cytoplasmic Inclusion Body Formation in Autophagy-deficient Mice." *Cell* 131, no. 6 (December 14, 2007): 1149–1163.

Komitova, Mila, and Peter S Eriksson. "Sox-2 Is Expressed by Neural Progenitors and Astroglia in the Adult Rat Brain." *Neuroscience Letters* 369, no. 1 (October 7, 2004): 24–27.

Kornfeld, S, and I Mellman. "The Biogenesis of Lysosomes." *Annual Review of Cell Biology* 5 (1989): 483–525.

Kornfeld, S. "Trafficking of Lysosomal Enzymes in Normal and Disease States." *The Journal of Clinical Investigation* 77, no. 1 (January 1986): 1–6.

Lakka, Sajani S, Christopher S Gondi, Niranjana Yanamandra, William C Olivero, Dzong H Dinh, Meena Gujrati, and Jasti S Rao. "Inhibition of Cathepsin B and MMP-9 Gene Expression in Glioblastoma Cell Line via RNA Interference Reduces Tumor Cell Invasion, Tumor Growth and Angiogenesis." *Oncogene* 23, no. 27 (June 10, 2004): 4681–4689.

Lang, T, S Reiche, M Straub, M Bredschneider, and M Thumm. "Autophagy and the Cvt Pathway Both Depend on AUT9." *Journal of Bacteriology* 182, no. 8 (April 2000): 2125–2133.

Lang, Thorsten, and Reinhard Jahn. "Core Proteins of the Secretory Machinery." *Handbook of Experimental Pharmacology*, no. 184 (2008): 107–127.

Lange Y, Ye J, Steck TL (1998) Circulation of cholesterol between lysosomes and the plasma membrane. *J Biol Chem* 273: 18915–18922.

LaPlante, Janice M, John Falardeau, Mei Sun, Marie Kanazirska, Edward M Brown, Susan A Slaugenhaupt, and Peter M Vassilev. "Identification and Characterization of the Single Channel Function of Human Mucolipin-1 Implicated in Mucopolidosis Type IV, a Disorder Affecting the Lysosomal Pathway." *FEBS Letters* 532, no. 1–2 (December 4, 2002): 183–187.

LaPlante, Janice M, Mei Sun, John Falardeau, Daisy Dai, Edward M Brown, Susan A Slaugenhaupt, and Peter M Vassilev. "Lysosomal Exocytosis Is Impaired in Mucopolidosis Type IV." *Molecular Genetics and Metabolism* 89, no. 4 (December 2006): 339–348.

Laywell, E D, V G Kukekov, and D A Steindler. "Multipotent Neurospheres Can Be Derived from Forebrain Subependymal Zone and Spinal Cord of Adult Mice After Prolonged Postmortem Intervals." *Experimental Neurology* 156, no. 2 (April 1999): 430–433.

Levine, Beth, and Daniel J Klionsky. "Development by Self-digestion: Molecular Mechanisms and Biological Functions of Autophagy." *Developmental Cell* 6, no. 4 (April 2004): 463–477.

Levine, Beth, and Guido Kroemer. "Autophagy in the Pathogenesis of Disease." *Cell* 132, no. 1 (January 11, 2008): 27–42.

Li, Dongdong, Nicole Ropert, Annette Koulakoff, Christian Giaume, and Martin Oheim. "Lysosomes Are the Major Vesicular Compartment Undergoing Ca<sup>2+</sup>-regulated Exocytosis from Cortical Astrocytes." *The Journal of Neuroscience: The Official Journal of the Society for Neuroscience* 28, no. 30 (July 23, 2008): 7648–7658.

Lie, D Chichung, Gustavo Dziewczapolski, Andrew R Willhoite, Brian K Kaspar, Clifford W Shults, and Fred H Gage. "The Adult Substantia Nigra Contains Progenitor Cells with Neurogenic Potential." *The Journal of Neuroscience: The Official Journal of the Society for Neuroscience* 22, no. 15 (August 1, 2002): 6639–6649.

Lim, D A, A D Tramontin, J M Trevejo, D G Herrera, J M García-Verdugo, and A Alvarez-Buylla. "Noggin Antagonizes BMP Signaling to Create a Niche for Adult Neurogenesis." *Neuron* 28, no. 3 (December 2000): 713–726.

Little, L, M Alcouloumre, A M Drotar, S Herman, R Robertson, R Y Yeh, and A L Miller. "Properties of N-acetylglucosamine 1-phosphotransferase from Human Lymphoblasts." *The Biochemical Journal* 248, no. 1 (November 15, 1987): 151–159.

Liu, Gumei, Inês Martins, John A Wemmie, John A Chiorini, and Beverly L Davidson. "Functional Correction of CNS Phenotypes in a Lysosomal Storage Disease Model Using Adeno-associated Virus Type 4 Vectors." *The Journal of Neuroscience: The Official Journal of the Society for Neuroscience* 25, no. 41 (October 12, 2005): 9321–9327.

Lledo, Pierre-Marie, Mariana Alonso, and Matthew S Grubb. "Adult Neurogenesis and Functional Plasticity in Neuronal Circuits." *Nature Reviews. Neuroscience* 7, no. 3 (March 2006): 179–193.

Lo, L C, J E Johnson, C W Wuenschell, T Saito, and D J Anderson. "Mammalian Achaete-scute Homolog 1 Is Transiently Expressed by Spatially Restricted Subsets of Early Neuroepithelial and Neural Crest Cells." *Genes & Development* 5, no. 9 (September 1991): 1524–1537.

Logan, Catriona Y, and Roel Nusse. "The Wnt Signaling Pathway in Development and Disease." *Annual Review of Cell and Developmental Biology* 20 (2004): 781–810.

Lois, C, and A Alvarez-Buylla. "Proliferating Subventricular Zone Cells in the Adult Mammalian Forebrain Can Differentiate into Neurons and Glia." *Proceedings of the National Academy of Sciences of the United States of America* 90, no. 5 (March 1, 1993): 2074–2077.

Lois, C, J M García-Verdugo, and A Alvarez-Buylla. "Chain Migration of Neuronal Precursors." *Science (New York, N.Y.)* 271, no. 5251 (February 16, 1996): 978–981.

Louis, Sharon A, and Brent A Reynolds. "Generation and Differentiation of Neurospheres from Murine Embryonic Day 14 Central Nervous System Tissue." *Methods in Molecular Biology (Clifton, N.J.)* 290 (2005): 265–280.

Louzao, M Carmen, Begoña Espiña, Mercedes R Vieytes, Felix V Vega, Juan A Rubiolo, Otto Baba, Tatsuo Terashima, and Luis M Botana. "'Fluorescent Glycogen' Formation with Sensibility for in Vivo and in Vitro Detection." *Glycoconjugate Journal* 25, no. 6 (August 2008): 503–510.

Lübke, Torben, Peter Lobel, and David E Sleat. "Proteomics of the Lysosome." *Biochimica Et Biophysica Acta* 1793, no. 4 (April 2009): 625–635.

Lucassen, Paul J, Michiel W Stumpel, Qian Wang, and Eleonora Aronica. "Decreased Numbers of Progenitor Cells but No Response to Antidepressant Drugs in the Hippocampus of Elderly Depressed Patients." *Neuropharmacology* 58, no. 6 (May 2010): 940–949.

Luciani, Alessandro, Valeria Rachela Villella, Speranza Esposito, Nicola Brunetti-Pierri, Diego Medina, Carmine Settembre, Manuela Gavina, et al. "Defective CFTR Induces Aggresome Formation and Lung Inflammation in Cystic Fibrosis Through ROS-mediated Autophagy Inhibition." *Nature Cell Biology* 12, no. 9 (September 2010): 863–875.

Lugert, Sebastian, Onur Basak, Philip Knuckles, Ute Haussler, Klaus Fabel, Magdalena Götz, Carola A Haas, Gerd Kempermann, Verdon Taylor, and Claudio Giachino. "Quiescent and Active Hippocampal Neural Stem Cells with Distinct



Morphologies Respond Selectively to Physiological and Pathological Stimuli and Aging." *Cell Stem Cell* 6, no. 5 (May 7, 2010): 445–456.

Luzio, J Paul, Paul R Pryor, Sally R Gray, Matthew J Gratian, Robert C Piper, and Nicholas A Bright. "Membrane Traffic to and from Lysosomes." *Biochemical Society Symposium*, no. 72 (2005): 77–86.

Maekawa, Motoko, Noriko Takashima, Yoko Arai, Tadashi Nomura, Kaoru Inokuchi, Shigeki Yuasa, and Noriko Osumi. "Pax6 Is Required for Production and Maintenance of Progenitor Cells in Postnatal Hippocampal Neurogenesis." *Genes to Cells: Devoted to Molecular & Cellular Mechanisms* 10, no. 10 (October 2005): 1001–1014.

Mandeville JT, Maxfield FR (1996) Calcium and signal transduction in granulocytes. *Curr Opin Hematol* 3: 63–70.

Marshall, Gregory P, 2nd, Brent A Reynolds, and Eric D Laywell. "Using the Neurosphere Assay to Quantify Neural Stem Cells in Vivo." *Current Pharmaceutical Biotechnology* 8, no. 3 (June 2007): 141–145.

Marshansky, Vladimir, and Masamitsu Futai. "The V-type H<sup>+</sup>-ATPase in Vesicular Trafficking: Targeting, Regulation and Function." *Current Opinion in Cell Biology* 20, no. 4 (August 2008): 415–426.

Martinet, Wim, and Guido R Y De Meyer. "Autophagy in Atherosclerosis." *Current Atherosclerosis Reports* 10, no. 3 (June 2008): 216–223.

Maslov, Alexander Y, Tara A Barone, Robert J Plunkett, and Steven C Pruitt. "Neural Stem Cell Detection, Characterization, and Age-related Changes in the Subventricular Zone of Mice." *The Journal of Neuroscience: The Official Journal of the Society for Neuroscience* 24, no. 7 (February 18, 2004): 1726–1733.

Matlin, K S, and K Simons. "Sorting of an Apical Plasma Membrane Glycoprotein Occurs Before It Reaches the Cell Surface in Cultured Epithelial Cells." *The Journal of Cell Biology* 99, no. 6 (December 1984): 2131–2139.

Matthias, Patrick, Minoru Yoshida, and Saadi Khochbin. "HDAC6 a New Cellular Stress Surveillance Factor." *Cell Cycle (Georgetown, Tex.)* 7, no. 1 (January 1, 2008): 7–10.

Medina, Diego L, Alessandro Fraldi, Valentina Bouche, Fabio Annunziata, Gelsomina Mansueto, Carmine Spampinato, Claudia Puri, et al. "Transcriptional Activation of Lysosomal Exocytosis Promotes Cellular Clearance." *Developmental Cell* 21, no. 3 (September 13, 2011): 421–430.

Meléndez, Alicia, and Beth Levine. "Autophagy in *C. Elegans*." *WormBook: The Online Review of C. Elegans Biology* (2009): 1–26.

Menezes, J R, and M B Luskin. "Expression of Neuron-specific Tubulin Defines a Novel Population in the Proliferative Layers of the Developing Telencephalon." *The Journal of Neuroscience: The Official Journal of the Society for Neuroscience* 14, no. 9 (September 1994): 5399–5416.

Mijaljica, Dalibor, Mark Prescott, and Rodney J Devenish. "A Fluorescence Microscopy Assay for Monitoring Mitophagy in the Yeast *Saccharomyces Cerevisiae*." *Journal of Visualized Experiments: JoVE*, no. 53 (2011).

Ming, Guo-li, and Hongjun Song. "Adult Neurogenesis in the Mammalian Central Nervous System." *Annual Review of Neuroscience* 28 (2005): 223–250.

Ming GL, Song H. Adult neurogenesis in the mammalian brain: significant answers and significant questions. *Neuron*. 2011;70:687–702.

Mira, Helena, Zoraida Andreu, Hoonkyo Suh, D Chichung Lie, Sebastian Jessberger, Antonella Consiglio, Juana San Emeterio, et al. "Signaling Through BMPR-IA Regulates Quiescence and Long-term Activity of Neural Stem Cells in the Adult Hippocampus." *Cell Stem Cell* 7, no. 1 (July 2, 2010): 78–89.

Mizushima, N, T Noda, T Yoshimori, Y Tanaka, T Ishii, M D George, D J Klionsky, M Ohsumi, and Y Ohsumi. "A Protein Conjugation System Essential for Autophagy." *Nature* 395, no. 6700 (September 24, 1998): 395–398.

Mizushima, N, H Sugita, T Yoshimori, and Y Ohsumi. "A New Protein Conjugation System in Human. The Counterpart of the Yeast Apg12p Conjugation System Essential for Autophagy." *The Journal of Biological Chemistry* 273, no. 51 (December 18, 1998): 33889–33892.

Mizushima, N, A Yamamoto, M Hatano, Y Kobayashi, Y Kabeya, K Suzuki, T Tokuhisa, Y Ohsumi, and T Yoshimori. "Dissection of Autophagosome Formation Using Apg5-deficient Mouse Embryonic Stem Cells." *The Journal of Cell Biology* 152, no. 4 (February 19, 2001): 657–668.

Mizushima, Noboru, Yoshinori Ohsumi, and Tamotsu Yoshimori. "Autophagosome Formation in Mammalian Cells." *Cell Structure and Function* 27, no. 6 (December 2002): 421–429.

Moran, M T, J P Schofield, A R Hayman, G P Shi, E Young, and T M Cox. "Pathologic Gene Expression in Gaucher Disease: Up-regulation of Cysteine Proteinases Including Osteoclastic Cathepsin K." *Blood* 96, no. 5 (September 1, 2000): 1969–1978.

Morshead, C M, B A Reynolds, C G Craig, M W McBurney, W A Staines, D Morassutti, S Weiss, and D van der Kooy. "Neural Stem Cells in the Adult Mammalian Forebrain: a Relatively Quiescent Subpopulation of Subependymal Cells." *Neuron* 13, no. 5 (November 1994): 1071–1082.

Morshead, Cindi M, A Denize Garcia, Michael V Sofroniew, and Derek van Der Kooy. "The Ablation of Glial Fibrillary Acidic Protein-positive Cells from the Adult Central Nervous System Results in the Loss of Forebrain Neural Stem Cells but Not Retinal Stem Cells." *The European Journal of Neuroscience* 18, no. 1 (July 2003): 76–84.

Nacher, Juan, Emilio Varea, Jose M Blasco-Ibañez, Esther Castillo-Gomez, Carlos Crespo, Francisco J Martinez-Guijarro, and Bruce S McEwen. "Expression of the Transcription Factor Pax 6 in the Adult Rat Dentate Gyrus." *Journal of Neuroscience Research* 81, no. 6 (September 15, 2005): 753–761.

Nakagawa, Ichiro, Atsuo Amano, Noboru Mizushima, Akitsugu Yamamoto, Hitomi Yamaguchi, Takahiro Kamimoto, Atsuki Nara, et al. "Autophagy Defends Cells Against Invading Group A Streptococcus." *Science (New York, N.Y.)* 306, no. 5698 (November 5, 2004): 1037–1040.

Nemoto, Takahiro, Isei Tanida, Emiko Tanida-Miyake, Naoko Minematsu-Ikeguchi, Masahiro Yokota, Mariko Ohsumi, Takashi Ueno, and Eiki Kominami. "The Mouse APG10 Homologue, an E2-like Enzyme for Apg12p Conjugation, Facilitates MAP-LC3 Modification." *The Journal of Biological Chemistry* 278, no. 41 (October 10, 2003): 39517–39526.

Neufeld, E F. "Lessons from Genetic Disorders of Lysosomes." *Harvey Lectures* 75 (1980 1979): 41–60.

Newman, T M, M Tian, and B D Gomperts. "Ultrastructural Characterization of Tannic Acid-arrested Degranulation of Permeabilized Guinea Pig Eosinophils Stimulated with GTP-gamma-S." *European Journal of Cell Biology* 70, no. 3 (July 1996): 209–220.

Nishikawa, Shin-Ichi, Lars Martin Jakt, and Takumi Era. "Embryonic Stem-cell Culture as a Tool for Developmental Cell Biology." *Nature Reviews. Molecular Cell Biology* 8, no. 6 (June 2007): 502–507.

Nixon, Ralph A. "Autophagy, Amyloidogenesis and Alzheimer Disease." *Journal of Cell Science* 120, no. Pt 23 (December 1, 2007): 4081–4091.

Nizami, Sohaib, Vivian W Y Lee, Jennifer Davies, Philip Long, Jasmina N Jovanovic, and Talvinder S Sihra. "Presynaptic Roles of Intracellular Ca(2+) Stores in Signalling and Exocytosis." *Biochemical Society Transactions* 38, no. 2 (April 2010): 529–535.

Noctor, S C, A C Flint, T A Weissman, R S Dammerman, and A R Kriegstein. "Neurons Derived from Radial Glial Cells Establish Radial Units in Neocortex." *Nature* 409, no. 6821 (February 8, 2001): 714–720.

Noda, T, J Kim, W P Huang, M Baba, C Tokunaga, Y Ohsumi, and D J Klionsky. "Apg9p/Cvt7p Is an Integral Membrane Protein Required for Transport Vesicle Formation in the Cvt and Autophagy Pathways." *The Journal of Cell Biology* 148, no. 3 (February 7, 2000): 465–480.

NOVIKOFF, A B, H BEAUFAY, and C DE DUVE. "Electron Microscopy of Lysosomeric Fractions from Rat Liver." *The Journal of Biophysical and Biochemical Cytology* 2, no. 4 Suppl (July 25, 1956): 179–184.

Ogawa, Michinaga, Tamotsu Yoshimori, Toshihiko Suzuki, Hiroshi Sagara, Noboru Mizushima, and Chihiro Sasakawa. "Escape of Intracellular Shigella from Autophagy." *Science (New York, N.Y.)* 307, no. 5710 (February 4, 2005): 727–731.

Ohmi, Kazuhiro, Lili C Kudo, Sergey Ryazantsev, Hui-Zhi Zhao, Stanislav L Karsten, and Elizabeth F Neufeld. "Sanfilippo Syndrome Type B, a Lysosomal Storage Disease, Is Also a Tauopathy." *Proceedings of the National Academy of Sciences of the United States of America* 106, no. 20 (May 19, 2009): 8332–8337.

Ohmi, Kazuhiro, Hui-Zhi Zhao, and Elizabeth F Neufeld. "Defects in the Medial Entorhinal Cortex and Dentate Gyrus in the Mouse Model of Sanfilippo Syndrome Type B." *PloS One* 6, no. 11 (2011): e27461.

Owada, M, and E F Neufeld. "Is There a Mechanism for Introducing Acid Hydrolases into Liver Lysosomes That Is Independent of Mannose 6-phosphate Recognition? Evidence from I-cell Disease." *Biochemical and Biophysical Research Communications* 105, no. 3 (April 14, 1982): 814–820.

Ozkara, Hatice Asuman, and Meral Topçu. "Sphingolipidoses in Turkey." *Brain & Development* 26, no. 6 (September 2004): 363–366.

Pacheco, Chris D, Robin Kunkel, and Andrew P Lieberman. "Autophagy in Niemann-Pick C Disease Is Dependent Upon Beclin-1 and Responsive to Lipid Trafficking Defects." *Human Molecular Genetics* 16, no. 12 (June 15, 2007): 1495–1503.

Palmer, T D, J Takahashi, and F H Gage. "The Adult Rat Hippocampus Contains Primordial Neural Stem Cells." *Molecular and Cellular Neurosciences* 8, no. 6 (1997): 389–404.

Palmieri, Michela, Soren Impey, Hyojin Kang, Alberto di Ronza, Carl Pelz, Marco Sardiello, and Andrea Ballabio. "Characterization of the CLEAR Network Reveals an Integrated Control of Cellular Clearance Pathways." *Human Molecular Genetics* 20, no. 19 (October 1, 2011): 3852–3866.

Pan, Tianhong, Seiji Kondo, Weidong Le, and Joseph Jankovic. "The Role of Autophagy-lysosome Pathway in Neurodegeneration Associated with Parkinson's Disease." *Brain: a Journal of Neurology* 131, no. Pt 8 (August 2008): 1969–1978.

Pandey, Udai Bhan, Zhiping Nie, Yakup Batlevi, Brett A McCray, Gillian P Ritson, Natalia B Nedelsky, Stephanie L Schwartz, et al. "HDAC6 Rescues Neurodegeneration and Provides an Essential Link Between Autophagy and the UPS." *Nature* 447, no. 7146 (June 14, 2007): 859–863.

Pankiv, Serhiy, Terje Høyvarde Clausen, Trond Lamark, Andreas Brech, Jack-Ansgar Bruun, Heidi Outzen, Aud Øvervatn, Geir Bjørkøy, and Terje Johansen. "p62/SQSTM1 Binds Directly to Atg8/LC3 to Facilitate Degradation of Ubiquitinated Protein Aggregates by Autophagy." *The Journal of Biological Chemistry* 282, no. 33 (August 17, 2007): 24131–24145.

Parenti, G, G Meroni, and A Ballabio. "The Sulfatase Gene Family." *Current Opinion in Genetics & Development* 7, no. 3 (June 1997): 386–391.

Parkinson-Lawrence EJ, Shandala T, Prodoehl M, Plew R, Borlace GN, et al. (2010) Lysosomal storage disease: revealing lysosomal function and physiology. *Physiology (Bethesda)* 25: 102–115.

Parton, R G, K Prydz, M Bomsel, K Simons, and G Griffiths. "Meeting of the Apical and Basolateral Endocytic Pathways of the Madin-Darby Canine Kidney Cell in Late Endosomes." *The Journal of Cell Biology* 109, no. 6 Pt 2 (December 1989): 3259–3272.

Pawelek, J M, and A B Lerner. "5,6-Dihydroxyindole Is a Melanin Precursor Showing Potent Cytotoxicity." *Nature* 276, no. 5688 (December 7, 1978): 626–628.

Peh, Gary S-L, Richard J Lang, Martin F Pera, and Susan M Hawes. "CD133 Expression by Neural Progenitors Derived from Human Embryonic Stem Cells and Its Use for Their Prospective Isolation." *Stem Cells and Development* 18, no. 2 (March 2009): 269–282.

Pellegrini, L, D F Burke, F von Delft, B Mulloy, and T L Blundell. "Crystal Structure of Fibroblast Growth Factor Receptor Ectodomain Bound to Ligand and Heparin." *Nature* 407, no. 6807 (October 26, 2000): 1029–1034.

Persaud-Sawin, Dixie-Ann, Talal Mousallem, Christine Wang, Adam Zucker, Eiki Kominami, and Rose-Mary N Boustany. "Neuronal Ceroid Lipofuscinosis: a Common Pathway?" *Pediatric Research* 61, no. 2 (February 2007): 146–152.

Pierfelice, Tarran, Lavinia Alberi, and Nicholas Gaiano. "Notch in the Vertebrate Nervous System: An Old Dog with New Tricks." *Neuron* 69, no. 5 (March 10, 2011): 840–855.

Polishchuk, Elena V, Alessio Di Pentima, Alberto Luini, and Roman S Polishchuk. "Mechanism of Constitutive Export from the Golgi: Bulk Flow via the Formation, Protrusion, and En Bloc Cleavage of Large Trans-golgi Network Tubular Domains." *Molecular Biology of the Cell* 14, no. 11 (November 2003): 4470–4485.

Polishchuk, Roman, Alessio Di Pentima, and Jennifer Lippincott-Schwartz. "Delivery of Raft-associated, GPI-anchored Proteins to the Apical Surface of Polarized MDCK Cells by a Transcytotic Pathway." *Nature Cell Biology* 6, no. 4 (April 2004): 297–307.

Pollard, Steven M, Luciano Conti, Yirui Sun, Donato Goffredo, and Austin Smith. "Adherent Neural Stem (NS) Cells from Fetal and Adult Forebrain." *Cerebral Cortex* (New York, N.Y.: 1991) 16 Suppl 1 (July 2006): i112–120.

Pongratz, D, I Schlossmacher, C Koppenwallner, and G Hübner. "An Especially Mild Myopathic Form of Glycogenosis Type II. Problems of Clinical and Light Microscopic Diagnosis." *Pathologia Europaea* 11, no. 1 (1976): 39–44.

Puri, Claudia. "Loss of Myosin VI No Insert Isoform (NoI) Induces a Defect in Clathrin-mediated Endocytosis and Leads to Caveolar Endocytosis of Transferrin Receptor." *The Journal of Biological Chemistry* 284, no. 50 (December 11, 2009): 34998–35014.

Ramirez, Alfredo, André Heimbach, Jan Gründemann, Barbara Stiller, Dan Hampshire, L Pablo Cid, Ingrid Goebel, et al. "Hereditary Parkinsonism with Dementia Is Caused by Mutations in ATP13A2, Encoding a Lysosomal Type 5 P-type ATPase." *Nature Genetics* 38, no. 10 (October 2006): 1184–1191.

Raposo, Graça, Michael S Marks, and Daniel F Cutler. "Lysosome-related Organelles: Driving post-Golgi Compartments into Specialisation." *Current Opinion in Cell Biology* 19, no. 4 (August 2007): 394–401.

Raposo G, Marks MS. The dark side of lysosome-related organelles: specialization of the endocytic pathway for melanosome biogenesis. *Traffic*. 2002;3:237–248.

Ravikumar, Brinda, Rainer Duden, and David C Rubinsztein. "Aggregate-prone Proteins with Polyglutamine and Polyalanine Expansions Are Degraded by Autophagy." *Human Molecular Genetics* 11, no. 9 (May 1, 2002): 1107–1117.

Ravikumar, Brinda, Marie Futter, Luca Jahreiss, Viktor I Korolchuk, Maike Lichtenberg, Shouqing Luo, Dunecan C O Massey, et al. "Mammalian Macroautophagy at a Glance." *Journal of Cell Science* 122, no. Pt 11 (June 1, 2009): 1707–1711.

Raychowdhury, Malay K, Silvia González-Perrett, Nicolás Montalbetti, Gustavo A Timpanaro, Bernard Chasan, Wolfgang H Goldmann, Stefanie Stahl, Adele Cooney, Ehud Goldin, and Horacio F Cantiello. "Molecular Pathophysiology of Mucopolipidosis Type IV: pH Dysregulation of the Mucopolipin-1 Cation Channel." *Human Molecular Genetics* 13, no. 6 (March 15, 2004): 617–627.



Reddy, A, E V Caler, and N W Andrews. "Plasma Membrane Repair Is Mediated by Ca(2+)-regulated Exocytosis of Lysosomes." *Cell* 106, no. 2 (July 27, 2001): 157–169.

Reggiori, Fulvio, and Daniel J Klionsky. "Autophagy in the Eukaryotic Cell." *Eukaryotic Cell* 1, no. 1 (February 2002): 11–21.

Reimand, Jüri, Meelis Kull, Hedi Peterson, Jaanus Hansen, and Jaak Vilo. "g:Profiler--a Web-based Toolset for Functional Profiling of Gene Lists from Large-scale Experiments." *Nucleic Acids Research* 35, no. Web Server issue (July 2007): W193–200.

Reitman, M L, A Varki, and S Kornfeld. "Fibroblasts from Patients with I-cell Disease and pseudo-Hurler Polydystrophy Are Deficient in Uridine 5'-diphosphate-N-acetylglucosamine: Glycoprotein N-acetylglucosaminylphosphotransferase Activity." *The Journal of Clinical Investigation* 67, no. 5 (May 1981): 1574–1579.

Reya, Tannishtha, Andrew W Duncan, Laurie Ailles, Jos Domen, David C Scherer, Karl Willert, Lindsay Hintz, Roel Nusse, and Irving L Weissman. "A Role for Wnt Signalling in Self-renewal of Haematopoietic Stem Cells." *Nature* 423, no. 6938 (May 22, 2003): 409–414.

Reynolds, B A, W Tetzlaff, and S Weiss. "A Multipotent EGF-responsive Striatal Embryonic Progenitor Cell Produces Neurons and Astrocytes." *The Journal of Neuroscience: The Official Journal of the Society for Neuroscience* 12, no. 11 (November 1992): 4565–4574.

Reynolds, B A, and S Weiss. "Generation of Neurons and Astrocytes from Isolated Cells of the Adult Mammalian Central Nervous System." *Science (New York, N.Y.)* 255, no. 5052 (March 27, 1992): 1707–1710.

Richards, L J, T J Kilpatrick, and P F Bartlett. "De Novo Generation of Neuronal Cells from the Adult Mouse Brain." *Proceedings of the National Academy of Sciences of the United States of America* 89, no. 18 (September 15, 1992): 8591–8595.

Rodríguez, A, I Martinez, A Chung, C H Berlot, and N W Andrews. "cAMP Regulates Ca<sup>2+</sup>-dependent Exocytosis of Lysosomes and Lysosome-mediated Cell Invasion by Trypanosomes." *The Journal of Biological Chemistry* 274, no. 24 (June 11, 1999): 16754–16759.

Rodríguez, A, P Webster, J Ortego, and N W Andrews. "Lysosomes Behave as Ca<sup>2+</sup>-regulated Exocytic Vesicles in Fibroblasts and Epithelial Cells." *The Journal of Cell Biology* 137, no. 1 (April 7, 1997): 93–104.

Rohrer J., Kornfeld R. Lysosomal hydrolase mannose 6-phosphate uncovering enzyme resides in the trans-Golgi network. *Mol. Biol. Cell.* 2001;12:1623–1631.

Ross, Christopher A, and Michelle A Poirier. "Protein Aggregation and Neurodegenerative Disease." *Nature Medicine* 10 Suppl (July 2004): S10–17.

Roybon, Laurent, Tomas Deierborg, Patrik Brundin, and Jia-Yi Li. "Involvement of Ngn2, Tbr and NeuroD Proteins During Postnatal Olfactory Bulb Neurogenesis." *The European Journal of Neuroscience* 29, no. 2 (January 2009): 232–243.

Ruivo, Raquel, Christine Anne, Corinne Sagné, and Bruno Gasnier. "Molecular and Cellular Basis of Lysosomal Transmembrane Protein Dysfunction." *Biochimica Et Biophysica Acta* 1793, no. 4 (April 2009): 636–649.

Saftig P. In Mehta A, Beck M, Sunder-Plassmann G, editors. *Fabry Disease: Perspectives from 5 Years of FOS*. Oxford: Oxford PharmaGenesis; 2006. Chapter 3.

Saftig, Paul, and Judith Klumperman. "Lysosome Biogenesis and Lysosomal Membrane Proteins: Trafficking Meets Function." *Nature Reviews. Molecular Cell Biology* 10, no. 9 (September 2009): 623–635.

Sancak, Yasemin, Liron Bar-Peled, Roberto Zoncu, Andrew L Markhard, Shigeyuki Nada, and David M Sabatini. "Ragulator-Rag Complex Targets mTORC1 to the Lysosomal Surface and Is Necessary for Its Activation by Amino Acids." *Cell* 141, no. 2 (April 16, 2010): 290–303.

Sancak, Yasemin, Timothy R Peterson, Yoav D Shaul, Robert A Lindquist, Carson C Thoreen, Liron Bar-Peled, and David M Sabatini. "The Rag GTPases Bind Raptor and Mediate Amino Acid Signaling to mTORC1." *Science (New York, N.Y.)* 320, no. 5882 (June 13, 2008): 1496–1501.

Sango, Kazunori, Masahiko Takano, Kyoko Ajiki, Akiko Tokashiki, Nobutaka Arai, Hitoshi Kawano, Hidenori Horie, and Shoji Yamanaka. "Impaired Neurite Outgrowth in the Retina of a Murine Model of Sandhoff Disease." *Investigative Ophthalmology & Visual Science* 46, no. 9 (September 2005): 3420–3425.

Sardiello, Marco, Michela Palmieri, Alberto di Ronza, Diego Luis Medina, Marta Valenza, Vincenzo Alessandro Gennarino, Chiara Di Malta, et al. "A Gene Network Regulating Lysosomal Biogenesis and Function." *Science (New York, N.Y.)* 325, no. 5939 (July 24, 2009): 473–477.

Sardiello M, Ballabio A. Lysosomal enhancement: a CLEAR answer to cellular degradative needs. *Cell Cycle* 2009; 8:4021-2

Schepers, Eva, Griet Glorieux, Annemieke Dhondt, Luc Leybaert, and Raymond Vanholder. "Flow Cytometric Calcium Flux Assay: Evaluation of Cytoplasmic Calcium Kinetics in Whole Blood Leukocytes." *Journal of Immunological Methods* 348, no. 1–2 (August 31, 2009): 74–82.

Schimmelpfeng, J, K-F Weibezahn, and H Dertinger. "Quantification of NGF-dependent Neuronal Differentiation of PC-12 Cells by Means of neurofilament-L mRNA Expression and Neuronal Outgrowth." *Journal of Neuroscience Methods* 139, no. 2 (October 30, 2004): 299–306.

Schmidt, B, T Selmer, A Ingendoh, and K von Figura. "A Novel Amino Acid Modification in Sulfatases That Is Defective in Multiple Sulfatase Deficiency." *Cell* 82, no. 2 (July 28, 1995): 271–278.

Schöler, H R, S Ruppert, N Suzuki, K Chowdhury, and P Gruss. "New Type of POU Domain in Germ Line-specific Protein Oct-4." *Nature* 344, no. 6265 (March 29, 1990): 435–439.

Schröder, Bernd, Christian Wrocklage, Cuiping Pan, Ralf Jäger, Bernd Kösters, Helmut Schäfer, Hans-Peter Elsässer, Matthias Mann, and Andrej Hasilik. "Integral and Associated Lysosomal Membrane Proteins." *Traffic (Copenhagen, Denmark)* 8, no. 12 (December 2007): 1676–1686.

Schröder, B. A., Wrocklage, C., Hasilik, A. and Saftig, P. (2010) The proteome of lysosomes. *Proteomics* 10, 4053-4076

Schultz ML, Tecedor L, Chang M, Davidson BL (2011) Clarifying lysosomal storage diseases. *Trends Neurosci* 34: 401–410.

Seiler, Magdalene J, Biju B Thomas, Zhenhai Chen, Rongjuan Wu, Srinivas R Sadda, and Robert B Aramant. "Retinal Transplants Restore Visual Responses: Trans-synaptic Tracing from Visually Responsive Sites Labels Transplant Neurons." *The European Journal of Neuroscience* 28, no. 1 (July 2008): 208–220.

Settembre, Carmine, Ida Annunziata, Carmine Spampinato, Daniela Zarcone, Gilda Cobellis, Edoardo Nusco, Ester Zito, Carlo Tacchetti, Maria Pia Cosma, and Andrea Ballabio. "Systemic Inflammation and Neurodegeneration in a Mouse Model of Multiple Sulfatase Deficiency." *Proceedings of the National Academy of Sciences of the United States of America* 104, no. 11 (March 13, 2007): 4506–4511.

Settembre, Carmine, Emilio Arteaga-Solis, Marc D McKee, Raquel de Pablo, Qais Al Awqati, Andrea Ballabio, and Gerard Karsenty. "Proteoglycan Desulfation Determines the Efficiency of Chondrocyte Autophagy and the Extent of FGF Signaling During Endochondral Ossification." *Genes & Development* 22, no. 19 (October 1, 2008): 2645–2650.

Settembre, Carmine, Alessandro Fraldi, Luca Jahreiss, Carmine Spampinato, Consuelo Venturi, Diego Medina, Raquel de Pablo, Carlo Tacchetti, David C Rubinsztein, and Andrea Ballabio. "A Block of Autophagy in Lysosomal Storage Disorders." *Human Molecular Genetics* 17, no. 1 (January 1, 2008): 119–129.

Settembre, Carmine, Chiara Di Malta, Vinicia Assunta Polito, Moises Garcia Arencibia, Francesco Vetrini, Serkan Erdin, Serpil Uckac Erdin, et al. "TFEB Links Autophagy to Lysosomal Biogenesis." *Science (New York, N.Y.)* 332, no. 6036 (June 17, 2011): 1429–1433.

Settembre, Carmine, Roberto Zoncu, Diego L Medina, Francesco Vetrini, Serkan Erdin, SerpilUckac Erdin, Tuong Huynh, et al. "A Lysosome-to-nucleus Signalling Mechanism Senses and Regulates the Lysosome via mTOR and TFEB." *The EMBO Journal* 31, no. 5 (March 7, 2012): 1095–1108.

Shen, Qin, Susan K Goderie, Li Jin, Nithin Karanth, Yu Sun, Natalia Abramova, Peter Vincent, Kevin Pumiglia, and Sally Temple. "Endothelial Cells Stimulate Self-renewal and Expand Neurogenesis of Neural Stem Cells." *Science (New York, N.Y.)* 304, no. 5675 (May 28, 2004): 1338–1340.

Shen, Qin, Yue Wang, Erzsebet Kokovay, Gang Lin, Shu-Mien Chuang, Susan K Goderie, Badrinath Roysam, and Sally Temple. "Adult SVZ Stem Cells Lie in a Vascular Niche: a Quantitative Analysis of Niche Cell-cell Interactions." *Cell Stem Cell* 3, no. 3 (September 11, 2008): 289–300.

Siintola, Eija, Meral Topcu, Nina Aula, Hannes Lohi, Berge A Minassian, Andrew D Paterson, Xiao-Qing Liu, et al. "The Novel Neuronal Ceroid Lipofuscinosis Gene MFSD8 Encodes a Putative Lysosomal Transporter." *American Journal of Human Genetics* 81, no. 1 (July 2007): 136–146.

Singec, Ilyas, Rolf Knoth, Ralf P Meyer, Jaroslaw Maciaczyk, Benedikt Volk, Guido Nikkhah, Michael Frotscher, and Evan Y Snyder. "Defining the Actual Sensitivity and Specificity of the Neurosphere Assay in Stem Cell Biology." *Nature Methods* 3, no. 10 (October 2006): 801–806.

Sleat, David E, Henry Lackland, Yanhong Wang, Istvan Sohar, Gang Xiao, Hong Li, and Peter Lobel. "The Human Brain Mannose 6-phosphate Glycoproteome: a Complex Mixture Composed of Multiple Isoforms of Many Soluble Lysosomal Proteins." *Proteomics* 5, no. 6 (April 2005): 1520–1532.

Sobota, Jacqueline A, Nils Bäck, Betty A Eipper, and Richard E Mains. "Inhibitors of the V0 Subunit of the Vacuolar H<sup>+</sup>-ATPase Prevent Segregation of Lysosomal- and Secretory-pathway Proteins." *Journal of Cell Science* 122, no. Pt 19 (October 1, 2009): 3542–3553.

Spiliotopoulos, D, D Goffredo, L Conti, F Di Febo, G Biella, M Toselli, and E Cattaneo. "An Optimized Experimental Strategy for Efficient Conversion of Embryonic Stem (ES)-derived Mouse Neural Stem (NS) Cells into a Nearly Homogeneous Mature Neuronal Population." *Neurobiology of Disease* 34, no. 2 (May 2009): 320–331.

Spitere, Katie, André Toulouse, David B O'Sullivan, and Aideen M Sullivan. "TAT-PAX6 Protein Transduction in Neural Progenitor Cells: a Novel Approach for Generation of Dopaminergic Neurones in Vitro." *Brain Research* 1208 (May 7, 2008): 25–34.

Suh, Hoonkyo, Antonella Consiglio, Jasodhara Ray, Toru Sawai, Kevin A D'Amour, and Fred H Gage. "In Vivo Fate Analysis Reveals the Multipotent and Self-renewal Capacities of Sox2<sup>+</sup> Neural Stem Cells in the Adult Hippocampus." *Cell Stem Cell* 1, no. 5 (November 2007): 515–528.

Suh, Hoonkyo, Wei Deng, and Fred H Gage. "Signaling in Adult Neurogenesis." *Annual Review of Cell and Developmental Biology* 25 (2009): 253–275.

Sun, Yirui, Steven Pollard, Luciano Conti, Mauro Toselli, Gerardo Biella, Georgina Parkin, Lionel Willatt, Anna Falk, Elena Cattaneo, and Austin Smith. "Long-term Tripotent Differentiation Capacity of Human Neural Stem (NS) Cells in Adherent Culture." *Molecular and Cellular Neurosciences* 38, no. 2 (June 2008): 245–258.

Svendsen, C N, M G ter Borg, R J Armstrong, A E Rosser, S Chandran, T Ostenfeld, and M A Caldwell. "A New Method for the Rapid and Long Term Growth of Human Neural Precursor Cells." *Journal of Neuroscience Methods* 85, no. 2 (December 1, 1998): 141–152.

Tanida, I, E Tanida-Miyake, T Ueno, and E Kominami. "The Human Homolog of *Saccharomyces Cerevisiae* Apg7p Is a Protein-activating Enzyme for Multiple Substrates Including Human Apg12p, GATE-16, GABARAP, and MAP-LC3." *The Journal of Biological Chemistry* 276, no. 3 (January 19, 2001): 1701–1706.

Tanida, Isei, Tomohito Nishitani, Takahiro Nemoto, Takashi Ueno, and Eiki Kominami. "Mammalian Apg12p, but Not the Apg12p.Apg5p Conjugate, Facilitates LC3 Processing." *Biochemical and Biophysical Research Communications* 296, no. 5 (September 6, 2002): 1164–1170.

Taranova, Olena V, Scott T Magness, B Matthew Fagan, Yongqin Wu, Natalie Surzenko, Scott R Hutton, and Larysa H Pevny. "SOX2 Is a Dose-dependent Regulator of Retinal Neural Progenitor Competence." *Genes & Development* 20, no. 9 (May 1, 2006): 1187–1202.

Tattersfield, A S, R J Croon, Y W Liu, A P Kells, R L M Faull, and B Connor. "Neurogenesis in the Striatum of the Quinolinic Acid Lesion Model of Huntington's Disease." *Neuroscience* 127, no. 2 (2004): 319–332.

Taylor, J Paul, Fumiaki Tanaka, Jon Robitschek, C Miguel Sandoval, Addis Taye, Silva Markovic-Plese, and Kenneth H Fischbeck. "Aggresomes Protect Cells by Enhancing the Degradation of Toxic Polyglutamine-containing Protein." *Human Molecular Genetics* 12, no. 7 (April 1, 2003): 749–757.

Temple, S. "The Development of Neural Stem Cells." *Nature* 414, no. 6859 (November 1, 2001): 112–117.

Treusch, Sebastian, Sarah Knuth, Susan A Slaugenhaupt, Ehud Goldin, Barth D Grant, and Hanna Fares. "Caenorhabditis Elegans Functional Orthologue of Human Protein H-mucolin-1 Is Required for Lysosome Biogenesis." *Proceedings of the National Academy of Sciences of the United States of America* 101, no. 13 (March 30, 2004): 4483–4488.

Tropepe, V, M Sibilio, B G Ciruna, J Rossant, E F Wagner, and D van der Kooy. "Distinct Neural Stem Cells Proliferate in Response to EGF and FGF in the

Developing Mouse Telencephalon." *Developmental Biology* 208, no. 1 (April 1, 1999): 166–188.

Tsukita, S, and H Ishikawa. "The Movement of Membranous Organelles in Axons. Electron Microscopic Identification of Anterogradely and Retrogradely Transported Organelles." *The Journal of Cell Biology* 84, no. 3 (March 1980): 513–530.

Tu, Chun, Cesar F Ortega-Cava, Gengsheng Chen, Norvin D Fernandes, Dora Cavallo-Medved, Bonnie F Sloane, Vimla Band, and Hamid Band. "Lysosomal Cathepsin B Participates in the Podosome-mediated Extracellular Matrix Degradation and Invasion via Secreted Lysosomes in v-Src Fibroblasts." *Cancer Research* 68, no. 22 (November 15, 2008): 9147–9156.

Tucker, Ward C, Thomas Weber, and Edwin R Chapman. "Reconstitution of Ca<sup>2+</sup>-regulated Membrane Fusion by Synaptotagmin and SNAREs." *Science (New York, N.Y.)* 304, no. 5669 (April 16, 2004): 435–438.

Uchida, N, D W Buck, D He, M J Reitsma, M Masek, T V Phan, A S Tsukamoto, F H Gage, and I L Weissman. "Direct Isolation of Human Central Nervous System Stem Cells." *Proceedings of the National Academy of Sciences of the United States of America* 97, no. 26 (December 19, 2000): 14720–14725.

Venkatachalam, Kartik, A Ashleigh Long, Rebecca Elsaesser, Daria Nikolaeva, Kendal Broadie, and Craig Montell. "Motor Deficit in a Drosophila Model of Mucopolysaccharidosis Type IV Due to Defective Clearance of Apoptotic Cells." *Cell* 135, no. 5 (November 28, 2008): 838–851.

Vergarajauregui, Silvia, and Rosa Puertollano. "Two Di-leucine Motifs Regulate Trafficking of Mucopolysaccharidosis Type IV to Lysosomes." *Traffic (Copenhagen, Denmark)* 7, no. 3 (March 2006): 337–353.

Vitner, Einat B, Frances M Platt, and Anthony H Futerman. "Common and Uncommon Pathogenic Cascades in Lysosomal Storage Diseases." *The Journal of Biological Chemistry* 285, no. 27 (July 2, 2010): 20423–20427.



Waguri, Satoshi, Frédérique Dewitte, Roland Le Borgne, Yves Rouillé, Yasuo Uchiyama, Jean-François Dubremetz, and Bernard Hoflack. "Visualization of TGN to Endosome Trafficking Through Fluorescently Labeled MPR and AP-1 in Living Cells." *Molecular Biology of the Cell* 14, no. 1 (January 2003): 142–155.

Waheed, A, R Pohlmann, A Hasilik, K von Figura, A van Elsen, and J G Leroy. "Deficiency of UDP-N-acetylglucosamine:lysosomal Enzyme N-acetylglucosamine-1-phosphotransferase in Organs of I-cell Patients." *Biochemical and Biophysical Research Communications* 105, no. 3 (April 14, 1982): 1052–1058.

Walkley, Steven U, Jakub Sikora, Matthew Micsenyi, Cristin Davidson, and Kostantin Dobrenis. "Lysosomal Compromise and Brain Dysfunction: Examining the Role of Neuroaxonal Dystrophy." *Biochemical Society Transactions* 38, no. 6 (December 2010): 1436–1441.

Weiss, S, C Dunne, J Hewson, C Wohl, M Wheatley, A C Peterson, and B A Reynolds. "Multipotent CNS Stem Cells Are Present in the Adult Mammalian Spinal Cord and Ventricular Neuroaxis." *The Journal of Neuroscience: The Official Journal of the Society for Neuroscience* 16, no. 23 (December 1, 1996): 7599–7609.

Wilcox, William R. "Lysosomal Storage Disorders: The Need for Better Pediatric Recognition and Comprehensive Care." *The Journal of Pediatrics* 144, no. 5 Suppl (May 2004): S3–14.

Wisniewski, K E, A A Golabek, and E Kida. "Increased Urine Concentration of Subunit c of Mitochondrial ATP Synthase in Neuronal Ceroid Lipofuscinoses Patients." *Journal of Inherited Metabolic Disease* 17, no. 2 (1994): 205–210.

Yang, Se-Ran, Sun-Jung Kim, Kyoung-Hee Byun, Brian Hutchinson, Bong-Hee Lee, Makoto Michikawa, Yong-Soon Lee, and Kyung-Sun Kang. "NPC1 Gene Deficiency Leads to Lack of Neural Stem Cell Self-renewal and Abnormal Differentiation Through Activation of P38 Mitogen-activated Protein Kinase Signaling." *Stem Cells (Dayton, Ohio)* 24, no. 2 (February 2006): 292–298.

Yogalingam, Gouri, Erik J Bonten, Diantha van de Vlekkert, Huimin Hu, Simon Moshia, Samuel A Connell, and Alessandra d' Azzo. "Neuraminidase 1 Is a Negative Regulator of Lysosomal Exocytosis." *Developmental Cell* 15, no. 1 (July 2008): 74–86.

Yoshimori, Tamotsu. "Autophagy: a Regulated Bulk Degradation Process Inside Cells." *Biochemical and Biophysical Research Communications* 313, no. 2 (January 9, 2004): 453–458.

Young, Andrew R J, Edmond Y W Chan, Xiao Wen Hu, Robert Köchl, Samuel G Crawshaw, Stephen High, Dale W Hailey, Jennifer Lippincott-Schwartz, and Sharon A Tooze. "Starvation and ULK1-dependent Cycling of Mammalian Atg9 Between the TGN and Endosomes." *Journal of Cell Science* 119, no. Pt 18 (September 15, 2006): 3888–3900.

Yue, Feng, Biao Chen, Di Wu, Kai Dong, Si-en Zeng, and Yu Zhang. "Biological Properties of Neural Progenitor Cells Isolated from the Hippocampus of Adult Cynomolgus Monkeys." *Chinese Medical Journal* 119, no. 2 (January 20, 2006): 110–116.

Zhang L, Sheng R, Qin Z (2009). The lysosome and neurodegenerative diseases. *Acta Biochim Biophys Sin (Shanghai)* 41: 437–445.

Zhang, Su-Chun. "Neural Subtype Specification from Embryonic Stem Cells." *Brain Pathology (Zurich, Switzerland)* 16, no. 2 (April 2006): 132–142.

Zhang, Zhijun, Gang Chen, Wei Zhou, Aihong Song, Tao Xu, Qingming Luo, Wei Wang, Xiao-song Gu, and Shumin Duan. "Regulated ATP Release from Astrocytes Through Lysosome Exocytosis." *Nature Cell Biology* 9, no. 8 (August 2007): 945–953.

Zito, Ester, Mario Buono, Stefano Pepe, Carmine Settembre, Ida Annunziata, Enrico Maria Surace, Thomas Dierks, et al. "Sulfatase Modifying Factor 1 Trafficking Through the Cells: From Endoplasmic Reticulum to the Endoplasmic Reticulum." *The EMBO Journal* 26, no. 10 (May 16, 2007): 2443–2453.

Zoncu, Roberto, Liron Bar-Peled, Alejo Efeyan, Shuyu Wang, Yasemin Sancak, and David M Sabatini. "mTORC1 Senses Lysosomal Amino Acids Through an Inside-out Mechanism That Requires the Vacuolar H(+)-ATPase." *Science (New York, N.Y.)* 334, no. 6056 (November 4, 2011): 678–683.

## ACKNOWLEDGEMENTS

First of all I would like to thank my internal supervisor prof. Andrea Ballabio for his incredible support and helpful discussions during the course of these investigations, and for his help in writing this thesis.

I would like to thank also my external supervisor prof. Elena Irene Rugarli for all the suggestions she gave to me and for her continuous encouragement in the scientific career.

A very special thanks goes to Dr. Diego Luis Medina, without whose motivation and encouragement this project would not have been possible. He provided me with direction, technical support and, above all, friendship.

I also thank all the people from Ballabio's laboratory and TIGEM for their technical support and friendship.

I would like to thank my extraordinary parents, Francesca and Ugo, super sister, Cristina, and my beautiful grandparents, Wanda and Pasquale, for their enthusiasm that pushed me always further.

My final thanks go to Luigi for his unconditional LOVE (and unlimited patience).